| 1 |
Gao F, Zheng M, Fan J, Ding Y, Liu X, Zhang M, Zhang X, Dong J, Zhou X, Luo J, Li X. A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants. Hum Vaccin Immunother 2023;19:2186110. [PMID: 36882925 DOI: 10.1080/21645515.2023.2186110] [Reference Citation Analysis]
|
| 2 |
Pozdnyakova V, Weber B, Cheng S, Ebinger JE. Review of Immunologic Manifestations of COVID-19 Infection and Vaccination. Heart Fail Clin 2023;19:177-84. [PMID: 36863809 DOI: 10.1016/j.hfc.2022.08.006] [Reference Citation Analysis]
|
| 3 |
Kanai D, Wakui H, Hanaoka M, Haze T, Azushima K, Shinoda S, Tsukamoto S, Taguchi S, Kinguchi S, Kanaoka T, Toya Y, Hirawa N, Kato H, Watanabe F, Hanaoka K, Mitsuhashi H, Yamaguchi S, Ohnishi T, Tamura K. Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis. Clin Exp Nephrol 2023. [PMID: 36977892 DOI: 10.1007/s10157-023-02342-0] [Reference Citation Analysis]
|
| 4 |
Gutlapalli SD, Ganipineni VDP, Danda S, Fabian D, Okorie IJ, Paramsothy J, Kailayanathan T, Umyarova R, Aviles C, Garlapati SKP, Ugwendum D, Nfonoyim J. Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review. Cureus 2023. [DOI: 10.7759/cureus.36809] [Reference Citation Analysis]
|
| 5 |
William A. Werbel, Andrew H. Karaba, Teresa Po-Yu Chiang, Allan B. Massie, Diane M. Brown, Natasha Watson, Maggie Chahoud, Elizabeth A. Thompson, Aileen C. Johnson, Robin K. Avery, Willa V. Cochran, Daniel Warren, Tao Liang, Miguel Fribourg, Christopher Huerta, Hady Samaha, Sabra L. Klein, Maria P. Bettinotti, William A. Clarke, Ioannis Sitaras, Nadine Rouphael, Andrea L. Cox, Justin R. Bailey, Andrew Pekosz, Aaron A.R. Tobian, Christine M. Durand, Nancy D. Bridges, Christian P. Larsen, Peter S. Heeger, Dorry L. Segev, CPAT investigators. Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine doses. Am J Transplant 2023. [ DOI: 10.1016/j.ajt.2023.03.014] [Reference Citation Analysis]
|
| 6 |
Ryan FJ, Norton TS, McCafferty C, Blake SJ, Stevens NE, James J, Eden GL, Tee YC, Benson SC, Masavuli MG, Yeow AEL, Abayasingam A, Agapiou D, Stevens H, Zecha J, Messina NL, Curtis N, Ignjatovic V, Monagle P, Tran H, McFadyen JD, Bull RA, Grubor-Bauk B, Lynn MA, Botten R, Barry SE, Lynn DJ. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. Cell Rep Med 2023;4:100971. [PMID: 36871558 DOI: 10.1016/j.xcrm.2023.100971] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
He X, He C, Hong W, Yang J, Wei X. Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. Med Res Rev 2023. [PMID: 36929527 DOI: 10.1002/med.21941] [Reference Citation Analysis]
|
| 8 |
Swart M, van der Lubbe J, Schmit-Tillemans S, van Huizen E, Verspuij J, Gil AI, Choi Y, Daal C, Perkasa A, de Wilde A, Claassen E, de Jong R, Wiese KE, Cornelissen L, van Es M, van Heerden M, Kourkouta E, Tahiri I, Mulders M, Vreugdenhil J, Feddes-de Boer K, Muchene L, Tolboom J, Dekking L, Juraszek J, Vellinga J, Custers J, Bos R, Schuitemaker H, Wegmann F, Roozendaal R, Kuipers H, Zahn R. Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2. NPJ Vaccines 2023;8:40. [PMID: 36927774 DOI: 10.1038/s41541-023-00633-x] [Reference Citation Analysis]
|
| 9 |
Huang C, Shuai H, Qiao J, Hou Y, Zeng R, Xia A, Xie L, Fang Z, Li Y, Yoon C, Huang Q, Hu B, You J, Quan B, Zhao X, Guo N, Zhang S, Ma R, Zhang J, Wang Y, Yang R, Zhang S, Nan J, Xu H, Wang F, Lei J, Chu H, Yang S. A new generation M(pro) inhibitor with potent activity against SARS-CoV-2 Omicron variants. Signal Transduct Target Ther 2023;8:128. [PMID: 36928316 DOI: 10.1038/s41392-023-01392-w] [Reference Citation Analysis]
|
| 10 |
Ren P, Hu Y, Peng L, Yang L, Suzuki K, Fang Z, Bai M, Zhou L, Feng Y, Zou Y, Xiong Y, Chen S. Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages. bioRxiv 2023:2022. [PMID: 35982661 DOI: 10.1101/2022.08.09.503414] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Zhou P, Song G, Liu H, Yuan M, He WT, Beutler N, Zhu X, Tse LV, Martinez DR, Schäfer A, Anzanello F, Yong P, Peng L, Dueker K, Musharrafieh R, Callaghan S, Capozzola T, Limbo O, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Jardine JG, Safonova Y, Briney B, Rogers TF, Wilson IA, Baric RS, Gralinski LE, Burton DR, Andrabi R. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity 2023;56:669-686.e7. [PMID: 36889306 DOI: 10.1016/j.immuni.2023.02.005] [Reference Citation Analysis]
|
| 12 |
Nah E, Cho S, Park H, Kim S, Noh D, Kwon E, Cho H. SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers. Viruses 2023;15:751. [DOI: 10.3390/v15030751] [Reference Citation Analysis]
|
| 13 |
Korogiannou M, Vallianou K, Xagas E, Rokka E, Soukouli I, Boletis IN, Marinaki S. Disease Course, Management and Outcomes in Kidney Transplant Recipients with SARS-CoV-2 Infection during the Omicron-Variant Wave: A Single-Center Experience. Vaccines 2023;11:632. [DOI: 10.3390/vaccines11030632] [Reference Citation Analysis]
|
| 14 |
Sousa Neto ARD, Carvalho ARBD, Ferreira da Silva MD, Rêgo Neta MM, Sena IVDO, Almeida RN, Filha FSSC, Lima e Silva LL, Costa GRD, Lira IMDS, Portela DMMC, Oliveira e Silva AT, Rabêlo CBDM, Valle ARMDC, Moura MEB, Freitas DRJD. Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines. IJERPH 2023;20:4796. [DOI: 10.3390/ijerph20064796] [Reference Citation Analysis]
|
| 15 |
Bates TA, Leier HC, McBride SK, Schoen D, Lyski ZL, Lee DX, Messer WB, Curlin ME, Tafesse FG. An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants. JCI Insight 2023;8:e165265. [PMID: 36701200 DOI: 10.1172/jci.insight.165265] [Reference Citation Analysis]
|
| 16 |
Yang L, Van Beek M, Wang Z, Muecksch F, Canis M, Hatziioannou T, Bieniasz PD, Nussenzweig MC, Chakraborty AK. Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain. Cell Rep 2023;42:112256. [PMID: 36952347 DOI: 10.1016/j.celrep.2023.112256] [Reference Citation Analysis]
|
| 17 |
Anand U, Pal T, Zanoletti A, Sundaramurthy S, Varjani S, Rajapaksha AU, Barceló D, Bontempi E. The spread of the omicron variant: Identification of knowledge gaps, virus diffusion modelling, and future research needs. Environ Res 2023;225:115612. [PMID: 36871942 DOI: 10.1016/j.envres.2023.115612] [Reference Citation Analysis]
|
| 18 |
Jugler C, Sun H, Nguyen K, Palt R, Felder M, Steinkellner H, Chen Q. A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant. Plant Biotechnol J 2023;21:549-59. [PMID: 36403203 DOI: 10.1111/pbi.13970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 19 |
Wu F, Qin M, Wang H, Sun X. Nanovaccines to combat virus-related diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2023;15:e1857. [PMID: 36184873 DOI: 10.1002/wnan.1857] [Reference Citation Analysis]
|
| 20 |
Oyebanji OA, Mylonakis E, Canaday DH. Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. Infect Dis Clin North Am 2023;37:27-45. [PMID: 36805013 DOI: 10.1016/j.idc.2022.11.002] [Reference Citation Analysis]
|
| 21 |
Fryer HA, Hartley GE, Edwards ES, Varese N, Boo I, Bornheimer SJ, Hogarth PM, Drummer HE, O’hehir RE, van Zelm MC. COVID-19 adenoviral vector vaccination elicits a robust memory B cell response with the capacity to recognize Omicron BA.2 and BA.5 variants.. [DOI: 10.1101/2023.02.28.530547] [Reference Citation Analysis]
|
| 22 |
Sha J, Meng C, Sun J, Sun L, Gu R, Liu J, Zhu X, Zhu D. Clinical and upper airway characteristics of 3715 patients with the Omicron variant of SARS-Cov-2 in Changchun, China. J Infect Public Health 2023;16:422-9. [PMID: 36731245 DOI: 10.1016/j.jiph.2023.01.013] [Reference Citation Analysis]
|
| 23 |
Petrie JG, King JP, McClure DL, Rolfes MA, Meece JK, Pattinson D, Neumann G, Kawaoka Y, Belongia EA, McLean HQ. Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022. Influenza Other Respir Viruses 2023;17:e13104. [PMID: 36875208 DOI: 10.1111/irv.13104] [Reference Citation Analysis]
|
| 24 |
Qu P, Evans JP, Kurhade C, Zeng C, Zheng YM, Xu K, Shi PY, Xie X, Liu SL. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants. mBio 2023;14:e0317622. [PMID: 36625591 DOI: 10.1128/mbio.03176-22] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Hayashi N. Rapid screening methods for universal binding peptide aptamers against SARS-CoV-2 variant spikes, including omicron variants, and their application to diagnostic and therapeutic agents.. [DOI: 10.21203/rs.3.rs-2609957/v1] [Reference Citation Analysis]
|
| 26 |
Meyer C, Goffe L, Antonopoulou V, Graham F, Tang MY, Lecouturier J, Grimani A, Chadwick P, Sniehotta FF. Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England. Vaccine 2023:S0264-410X(23)00182-2. [PMID: 36933983 DOI: 10.1016/j.vaccine.2023.02.047] [Reference Citation Analysis]
|
| 27 |
Zhu Y, Zhong Q, Ma Z, Liu S, Lan Y, Peng B, Zhang X, Shi X, Qu J, Wu Z, Zhao Z, Zhang X, Zhang D. Neutralization Effect of Sera against Delta and Omicron in Patients Recovering from COVID-19 and Inactivated Vaccine Recipients. Vaccines (Basel) 2023;11. [PMID: 36851348 DOI: 10.3390/vaccines11020471] [Reference Citation Analysis]
|
| 28 |
Offersgaard A, Duarte Hernandez CR, Feng S, Marichal-Gallardo P, Holmbeck K, Pihl AF, Fernandez-Antunez C, Alzua GP, Hartmann KT, Pham LV, Zhou Y, Gammeltoft KA, Fahnøe U, Schneider UV, Pedersen GK, Jensen HE, Christensen JP, Ramirez S, Bukh J, Gottwein JM. An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. iScience 2023;26:105949. [PMID: 36644321 DOI: 10.1016/j.isci.2023.105949] [Reference Citation Analysis]
|
| 29 |
Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, Iida S, Ainai A, Ozono S, Hemmi T, Hirata Y, Moriyama S, Kotaki R, Kinoshita H, Yamada S, Shinkai M, Fukushi S, Takahashi Y, Suzuki T. Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization. iScience 2023;26:105969. [PMID: 36687316 DOI: 10.1016/j.isci.2023.105969] [Reference Citation Analysis]
|
| 30 |
Pedenko B, Sulbaran G, Guilligay D, Effantin G, Weissenhorn W. SARS-CoV-2 S Glycoprotein Stabilization Strategies. Viruses 2023;15. [PMID: 36851772 DOI: 10.3390/v15020558] [Reference Citation Analysis]
|
| 31 |
Toutoudaki K, Dimakakou M, Androutsakos T. Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review. Vaccines (Basel) 2023;11. [PMID: 36851329 DOI: 10.3390/vaccines11020452] [Reference Citation Analysis]
|
| 32 |
Zeng Q, Yang X, Lin BY, Li YZ, Huang G, Xu Y. Immunological Findings in a Group of Individuals Who Were Poor or Non-Responders to Standard Two-Dose SARS-CoV-2 Vaccines. Vaccines (Basel) 2023;11. [PMID: 36851338 DOI: 10.3390/vaccines11020461] [Reference Citation Analysis]
|
| 33 |
Song Z, Luo Q, Wan L, Zhu Q, Liu R, Yin X, Lu X, Wei L, Xiang Z, Zou Y. Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology. Vaccines (Basel) 2023;11. [PMID: 36851319 DOI: 10.3390/vaccines11020442] [Reference Citation Analysis]
|
| 34 |
Kackos CM, Surman SL, Jones BG, Sealy RE, Jeevan T, Davitt CJH, Pustylnikov S, Darling TL, Boon ACM, Hurwitz JL, Samsa MM, Webby RJ. mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19. Microbiol Spectr 2023;11:e0424022. [PMID: 36695597 DOI: 10.1128/spectrum.04240-22] [Reference Citation Analysis]
|
| 35 |
Hao L, Hsiang TY, Dalmat RR, Ireton R, Morton JF, Stokes C, Netland J, Hale M, Thouvenel C, Wald A, Franko NM, Huden K, Chu HY, Sigal A, Greninger AL, Tilles S, Barrett LK, Van Voorhis WC, Munt J, Scobey T, Baric RS, Rawlings DJ, Pepper M, Drain PK, Gale M Jr. Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron. Viruses 2023;15. [PMID: 36851745 DOI: 10.3390/v15020530] [Reference Citation Analysis]
|
| 36 |
Chinta S, Rodriguez-Guerra M, Shaban M, Pandey N, Jaquez-Duran M, Vittorio TJ. COVID-19 therapy and vaccination: a clinical narrative review. Drugs Context 2023;12. [PMID: 36793450 DOI: 10.7573/dic.2022-7-2] [Reference Citation Analysis]
|
| 37 |
Meurisse M, Catteau L, van Loenhout JAF, Braeye T, De Mot L, Serrien B, Blot K, Cauët E, Van Oyen H, Cuypers L, Belgian Collaborative Group On Covid-Hospital Surveillance, Covid-Genomics Belgium Consortium, Robert A, Van Goethem N. Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium. Vaccines (Basel) 2023;11. [PMID: 36851257 DOI: 10.3390/vaccines11020378] [Reference Citation Analysis]
|
| 38 |
Inoue T, Shinnakasu R, Kawai C, Yamamoto H, Sakakibara S, Ono C, Itoh Y, Terooatea T, Yamashita K, Okamoto T, Hashii N, Ishii-watabe A, Butler NS, Matsuura Y, Matsumoto H, Otsuka S, Hiraoka K, Teshima T, Murakami M, Kurosaki T. Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. Journal of Experimental Medicine 2023;220. [DOI: 10.1084/jem.20221786] [Reference Citation Analysis]
|
| 39 |
Ying WF, Chen Q, Jiang ZK, Hao DG, Zhang Y, Han Q. Chest computed tomography findings of the Omicron variants of SARS-CoV-2 with different cycle threshold values. World J Clin Cases 2023; 11(4): 756-763 [DOI: 10.12998/wjcc.v11.i4.756] [Reference Citation Analysis]
|
| 40 |
Wang H, Yuan Y, Wu B, Xiao M, Wang Z, Diao T, Zeng R, Chen L, Lei Y, Long P, Guo Y, Lai X, Wen Y, Li W, Cai H, Song L, Ni W, Zhao Y, Ouyang K, Wang J, Wang Q, Liu L, Wang C, Pan A, Li X, Gong R, Wu T. Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents. Front Med 2023. [PMID: 36738428 DOI: 10.1007/s11684-022-0954-x] [Reference Citation Analysis]
|
| 41 |
Freeman ML, Oyebanji OA, Moisi D, Payne M, Sheehan ML, Balazs AB, Bosch J, King CL, Gravenstein S, Lederman MM, Canaday DH. Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare Workers. Open Forum Infect Dis 2023;10:ofad063. [PMID: 36861088 DOI: 10.1093/ofid/ofad063] [Reference Citation Analysis]
|
| 42 |
Rossi MA, Cena T, Binala J, Alessi D, Scotti L, Faggiano F. Evaluation of the risk of SARS-CoV-2 infection and hospitalization in vaccinated and previously infected subjects based on real world data. Sci Rep 2023;13:2018. [PMID: 36737460 DOI: 10.1038/s41598-023-28129-7] [Reference Citation Analysis]
|
| 43 |
Han S, Yang Y, Wang T, Song R, Hu D, Peng M, Lin Z, Deng Q, Ren H, Ming J. Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer. Front Public Health 2023;11:1086872. [PMID: 36817926 DOI: 10.3389/fpubh.2023.1086872] [Reference Citation Analysis]
|
| 44 |
Alidjinou EK, Demaret J, Corroyer-Simovic B, Vuotto F, Miczek S, Labreuche J, Goffard A, Trauet J, Lupau D, Dendooven A, Huvent-Grelle D, Podvin J, Dreuil D, Faure K, Deplanque D, Bocket L, Duhamel A, Sobaszek A, Hober D, Hisbergues M, Puisieux F, Autran B, Yazdanpanah Y, Labalette M, Lefèvre G. Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination. Clin Microbiol Infect 2023;29:258.e1-4. [PMID: 36257549 DOI: 10.1016/j.cmi.2022.10.014] [Reference Citation Analysis]
|
| 45 |
Wang ML, Lin Y, Hou JF, Yang YP, Chien Y, Sun YC, Liang KH, Yang DM, Chang TJ, Wu CH, Kao SY, Hung KF. The Omicron variant wave: Where are we now and what are the prospects? J Chin Med Assoc 2023;86:135-7. [PMID: 36524941 DOI: 10.1097/JCMA.0000000000000863] [Reference Citation Analysis]
|
| 46 |
Pooley N, Abdool Karim SS, Combadière B, Ooi EE, Harris RC, El Guerche Seblain C, Kisomi M, Shaikh N. Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. Infect Dis Ther 2023;12:367-87. [PMID: 36622633 DOI: 10.1007/s40121-022-00753-2] [Reference Citation Analysis]
|
| 47 |
Obeid D, Al-Qahtani A, Almaghrabi R, Alghamdi S, Alsanea M, Alahideb B, Almutairi S, Alsuwairi F, Al-Abdulkareem M, Asiri M, Alshukairi A, Alkahtany J, Altamimi S, Mutabagani M, Althawadi S, Alanzi F, Alhamlan F. Analysis of SARS-CoV-2 genomic surveillance data during the Delta and Omicron waves at a Saudi tertiary referral hospital. J Infect Public Health 2023;16:171-81. [PMID: 36543031 DOI: 10.1016/j.jiph.2022.12.007] [Reference Citation Analysis]
|
| 48 |
Wang B, Xu H, Liang ZT, Zhao TN, Zhang X, Peng TB, Wang YC, Su XD. Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2. Int J Biol Macromol 2023;227:896-902. [PMID: 36528147 DOI: 10.1016/j.ijbiomac.2022.12.120] [Reference Citation Analysis]
|
| 49 |
Nadworny PL, Hickerson WL, Holley-Harrison HD, Bloom DC, Grams TR, Edwards TG, Schultz GS, Burrell RE. Treatment of infection and inflammation associated with COVID-19, multi-drug resistant pneumonia and fungal sinusitis by nebulizing a nanosilver solution. Nanomedicine 2023;48:102654. [PMID: 36646192 DOI: 10.1016/j.nano.2023.102654] [Reference Citation Analysis]
|
| 50 |
Liu Z, Gao X, Kan C, Li L, Zhang Y, Gao Y, Zhang S, Zhou L, Zhao H, Li M, Zhang Z, Sun Y. CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection. MedComm (2020) 2023;4:e208. [PMID: 36744219 DOI: 10.1002/mco2.208] [Reference Citation Analysis]
|
| 51 |
Du J, Su Y, Wang R, Dong E, Cao Y, Zhao W, Gong W. Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19. Front Immunol 2023;14:1118378. [PMID: 36798128 DOI: 10.3389/fimmu.2023.1118378] [Reference Citation Analysis]
|
| 52 |
Ptak K, Szymońska I, Olchawa-Czech A, Kukla K, Cisowska M, Kwinta P. Comparison of the course of multisystem inflammatory syndrome in children during different pandemic waves. Eur J Pediatr 2023;:1-10. [PMID: 36719477 DOI: 10.1007/s00431-022-04790-4] [Reference Citation Analysis]
|
| 53 |
Meng L, Zha J, Zhou B, Cao L, Jiang C, Zhu Y, Li T, Lu L, Zhang J, Yang H, Feng J, Gu Z, Tang H, Jiang L, Li D, Lavillette D, Zhang X. A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. PLoS Pathog 2023;19:e1011085. [PMID: 36706160 DOI: 10.1371/journal.ppat.1011085] [Reference Citation Analysis]
|
| 54 |
von Bülow S, Sikora M, Blanc FEC, Covino R, Hummer G. Antibody accessibility determines location of spike surface mutations in SARS-CoV-2 variants. PLoS Comput Biol 2023;19:e1010822. [PMID: 36693110 DOI: 10.1371/journal.pcbi.1010822] [Reference Citation Analysis]
|
| 55 |
Chen CS, Jian MJ, Chang CK, Chung HY, Li SY, Lin JC, Yeh KM, Yang YS, Chen CW, Hsieh SS, Tang SH, Perng CL, Chang FY, Shang HS. Monitoring algorithm of hospitalized patients in a medical center with SARS-CoV-2 (Omicron variant) infection: clinical epidemiological surveillance and immunological assessment. PeerJ 2023;11:e14666. [PMID: 36710871 DOI: 10.7717/peerj.14666] [Reference Citation Analysis]
|
| 56 |
Ai L, Li Y, Zhou L, Yao W, Zhang H, Hu Z, Han J, Wang W, Wu J, Xu P, Wang R, Li Z, Li Z, Wei C, Liang J, Chen H, Yang Z, Guo M, Huang Z, Wang X, Zhang Z, Xiang W, Sun D, Xu L, Huang M, Lv B, Peng P, Zhang S, Ji X, Luo H, Chen N, Chen J, Lan K, Hu Y. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov 2023;9:9. [PMID: 36683074 DOI: 10.1038/s41421-022-00517-9] [Reference Citation Analysis]
|
| 57 |
Taniguchi Y, Suemori K, Tanaka K, Okamoto A, Murakami A, Miyamoto H, Takasuka Y, Yamashita M, Takenaka K. Long-term transition of antibody titers in healthcare workers following the first to fourth doses of mRNA COVID-19 vaccine: Comparison of two automated SARS-CoV-2 immunoassays. J Infect Chemother 2023:S1341-321X(23)00015-6. [PMID: 36696921 DOI: 10.1016/j.jiac.2023.01.007] [Reference Citation Analysis]
|
| 58 |
Bhiman JN, Richardson SI, Lambson BE, Kgagudi P, Mzindle N, Kaldine H, Crowther C, Gray G, Bekker LG, Shinde V, Bennett C, Glenn GM, Madhi SA, Moore PL; Novavax trial clinical lead author group. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. Sci Rep 2023;13:1222. [PMID: 36681693 DOI: 10.1038/s41598-023-27698-x] [Reference Citation Analysis]
|
| 59 |
Zhou ZJ, Yang CH, Ye SB, Yu XW, Qiu Y, Ge XY. VirusRecom: an information-theory-based method for recombination detection of viral lineages and its application on SARS-CoV-2. Brief Bioinform 2023;24:bbac513. [PMID: 36567622 DOI: 10.1093/bib/bbac513] [Reference Citation Analysis]
|
| 60 |
Abebe EC, Dejenie TA. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Front Immunol 2023;14:1055457. [PMID: 36742320 DOI: 10.3389/fimmu.2023.1055457] [Reference Citation Analysis]
|
| 61 |
Khazaaleh S, Suarez ZK, Alomari M, Rashid MU, Handa A, Gonzalez AJ, Zervos XB, Kapila N. Liver transplantation amidst the COVID-19 era: Our center’s experience. World J Clin Cases 2023; 11(2): 316-321 [PMID: 36686357 DOI: 10.12998/wjcc.v11.i2.316] [Reference Citation Analysis]
|
| 62 |
Tseng HF, Ackerson BK, Bruxvoort KJ, Sy LS, Tubert JE, Lee GS, Ku JH, Florea A, Luo Y, Qiu S, Choi SK, Takhar HS, Aragones M, Paila YD, Chavers S, Talarico CA, Qian L. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat Commun 2023;14:189. [PMID: 36635284 DOI: 10.1038/s41467-023-35815-7] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 63 |
Kotaki R, Moriyama S, Takahashi Y. Humoral immunity for durable control of SARS-CoV-2 and its variants. Inflamm Regen 2023;43:4. [PMID: 36631890 DOI: 10.1186/s41232-023-00255-9] [Reference Citation Analysis]
|
| 64 |
Qin S, Huang H, Xiao W, Chen K, He X, Tang X, Huang Z, Zhang Y, Duan X, Fan N, Zheng Q, Wu M, Lu G, Wei Y, Wei X, Song X. A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants. Acta Pharm Sin B 2023. [PMID: 36647424 DOI: 10.1016/j.apsb.2023.01.010] [Reference Citation Analysis]
|
| 65 |
Kling KD, Janulis P, Demonbreun AR, Sancilio A, Berzins B, Krueger K, Achenbach C, Price R, Sullivan M, Caputo M, Hockney S, Zembower T, McDade TW, Taiwo B. No difference in anti-spike antibody and surrogate viral neutralization following SARS-CoV-2 booster vaccination in persons with HIV compared to controls (CO-HIV Study). Front Immunol 2022;13:1048776. [PMID: 36700200 DOI: 10.3389/fimmu.2022.1048776] [Reference Citation Analysis]
|
| 66 |
Kato Y, Morita T, Kumanogoh A. Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases. Inflamm Regen 2023;43:1. [PMID: 36609472 DOI: 10.1186/s41232-022-00247-1] [Reference Citation Analysis]
|
| 67 |
Xu K, Lei W, Kang B, Yang H, Wang Y, Lu Y, Lv L, Sun Y, Zhang J, Wang X, Yang M, Dan M, Wu G. A novel mRNA vaccine, SYS6006, against SARS-CoV-2. Front Immunol 2022;13:1051576. [PMID: 36685587 DOI: 10.3389/fimmu.2022.1051576] [Reference Citation Analysis]
|
| 68 |
Bates TA, Leier HC, McBride SK, Schoen D, Lyski ZL, Lee DX, Messer WB, Curlin ME, Tafesse FG. The time between vaccination and infection impacts immunity against SARS-CoV-2 variants. medRxiv 2023:2023. [PMID: 36656773 DOI: 10.1101/2023.01.02.23284120] [Reference Citation Analysis]
|
| 69 |
Kim YC, Kim B, Son NH, Heo N, Nam Y, Shin A, Yang AJ, Kim MH, Kyong T, Kang E, Park YS, Kim H. Vaccine Effect on Household Transmission of Omicron and Delta SARS-CoV-2 Variants. J Korean Med Sci 2023;38:e9. [PMID: 36593690 DOI: 10.3346/jkms.2023.38.e9] [Reference Citation Analysis]
|
| 70 |
Yang H, Xie Y, Li C. Understanding the mechanisms for COVID-19 vaccine's protection against infection and severe disease. Expert Rev Vaccines 2023;22:186-92. [PMID: 36715150 DOI: 10.1080/14760584.2023.2174529] [Reference Citation Analysis]
|
| 71 |
Camacho J, Giménez E, Albert E, Zulaica J, Álvarez-Rodríguez B, Torres I, Rusu L, Burgos JS, Peiró S, Vanaclocha H, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Comas I, Gonzáles-Candelas F, Geller R, Navarro D; Valencian Vaccine Research Program (ProVaVac) study group. Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant. J Med Virol 2023;95:e28284. [PMID: 36333837 DOI: 10.1002/jmv.28284] [Reference Citation Analysis]
|
| 72 |
Jiang C, Jiang K, Li X, Zhang N, Zhu W, Meng L, Zhang Y, Lu S. Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. J Pharm Anal 2023;13:1-10. [PMID: 36317070 DOI: 10.1016/j.jpha.2022.10.003] [Reference Citation Analysis]
|
| 73 |
Kirste I, Hortsch S, Grunert VP, Legault H, Maglinao M, Eichenlaub U, Kashlan B, Pajon R, Jochum S. Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19. Infect Dis Ther 2023;12:177-91. [PMID: 36376733 DOI: 10.1007/s40121-022-00711-y] [Reference Citation Analysis]
|
| 74 |
Wand O, Einbinder Y, Nacasch N, Halperin T, Erez D, Grupper A, Benchetrit S, Lishner M, Bar-Shai A, Shashar M, Cohen-Hagai K. Kinetics of the humoral response 1-year following vaccination with BNT162b2 SARS-CoV-2 vaccine among maintenance hemodialysis patients. J Nephrol 2023;36:213-6. [PMID: 35809158 DOI: 10.1007/s40620-022-01377-y] [Reference Citation Analysis]
|
| 75 |
Belik M, Liedes O, Vara S, Haveri A, Pöysti S, Kolehmainen P, Maljanen S, Huttunen M, Reinholm A, Lundberg R, Skön M, Österlund P, Melin M, Hänninen A, Hurme A, Ivaska L, Tähtinen PA, Lempainen J, Kakkola L, Jalkanen P, Julkunen I. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose. Front Immunol 2023;14:1099246. [PMID: 36756112 DOI: 10.3389/fimmu.2023.1099246] [Reference Citation Analysis]
|
| 76 |
Zheng P, Ma J, Yang J, Liao B, Cheng ZJ, Xue M, Li S, Fang Y, Lin R, Zhang G, Huang H, Hu F, Ma H, Sun B. Evaluating SARS-CoV-2 antibody reactivity to natural exposure and inactivated vaccination with peptide microarrays. Front Immunol 2023;14:1079960. [PMID: 36891316 DOI: 10.3389/fimmu.2023.1079960] [Reference Citation Analysis]
|
| 77 |
Bjørlykke KH, Ørbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, Christensen IE, Kro GB, Kvien TK, Jahnsen J, Munthe LA, Chopra A, Warren DJ, Mjaaland S, Haavardsholm EA, Grødeland G, Provan SA, Vaage JT, Syversen SW, Goll GL, Jørgensen KK. Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study. Lancet Rheumatol 2023;5:e36-46. [PMID: 36415604 DOI: 10.1016/S2665-9913(22)00330-7] [Reference Citation Analysis]
|
| 78 |
Vogrig M, Berger AE, Bourlet T, Waeckel L, Haccourt A, Chanavat A, Hupin D, Roche F, Botelho-Nevers E, Pozzetto B, Paul S. Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. J Clin Immunol 2023;43:31-45. [PMID: 36006568 DOI: 10.1007/s10875-022-01354-x] [Reference Citation Analysis]
|
| 79 |
Wan J, Cazer CL, Clarkberg ME, Henderson SG, Lee SE, Meredith GR, Osman M, Shmoys DB, Frazier PI. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study. PLoS Med 2023;20:e1004153. [PMID: 36626376 DOI: 10.1371/journal.pmed.1004153] [Reference Citation Analysis]
|
| 80 |
Dehgani-Mobaraki P, Wang C, Floridi A, Floridi E, Dawoodi S, Zaidi AK. Long-term persistence of IgG antibodies in recovered COVID-19 individuals at 18 months post-infection and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response: Analysis using fixed-effects linear regression model. Virology 2023;578:111-6. [PMID: 36516688 DOI: 10.1016/j.virol.2022.12.003] [Reference Citation Analysis]
|
| 81 |
Silva SJRD, Kohl A, Pena L, Pardee K. Recent insights into SARS-CoV-2 omicron variant. Rev Med Virol 2023;33:e2373. [PMID: 35662313 DOI: 10.1002/rmv.2373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 82 |
Bordat J, Maury S, Leclerc M. Allogeneic hematopoietic stem cell transplantation in the COVID-19 era. Front Immunol 2023;14:1100468. [PMID: 36911678 DOI: 10.3389/fimmu.2023.1100468] [Reference Citation Analysis]
|
| 83 |
Dickerman BA, Gerlovin H, Madenci AL, Figueroa Muñiz MJ, Wise JK, Adhikari N, Ferolito BR, Kurgansky KE, Gagnon DR, Cho K, Casas JP, Hernán MA. Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans. Nat Microbiol 2023;8:55-63. [PMID: 36593297 DOI: 10.1038/s41564-022-01272-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 84 |
Zhang M, Hussain A, Yang H, Zhang J, Liang XJ, Huang Y. mRNA-based modalities for infectious disease management. Nano Res 2023;16:672-91. [PMID: 35818566 DOI: 10.1007/s12274-022-4627-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 85 |
Trombetta CM, Marchi S, Leonardi M, Stufano A, Lorusso E, Montomoli E, Decaro N, Buonvino N, Lovreglio P. Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility. Hum Vaccin Immunother 2022;18:2153537. [PMID: 36503363 DOI: 10.1080/21645515.2022.2153537] [Reference Citation Analysis]
|
| 86 |
Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K, Thomassen KS, Kro GB, Cox RJ, Zhou F, Langeland N, Aukrust P, Melum E, Åvitsland TL, Wiencke K, Holter JC, Munthe LA, Grødeland G, Andersen JT, Vaage JT, Lund-Johansen F. Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. NPJ Vaccines 2022;7:174. [PMID: 36585405 DOI: 10.1038/s41541-022-00586-7] [Reference Citation Analysis]
|
| 87 |
Wang XJ, Yao L, Zhang HY, Zhu KL, Zhao J, Zhan BD, Li YK, He XJ, Huang C, Wang ZY, Jiang MD, Yang P, Yang Y, Wang GL, Wang SQ, Dai EH, Gao HX, Ma MJ. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. Genome Med 2022;14:146. [PMID: 36581867 DOI: 10.1186/s13073-022-01151-6] [Reference Citation Analysis]
|
| 88 |
Emmelot ME, Vos M, Boer MC, Rots NY, van Els CACM, Kaaijk P. SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals. Viruses 2022;15. [PMID: 36680141 DOI: 10.3390/v15010101] [Reference Citation Analysis]
|
| 89 |
Hernandez A, Boigues M, Felip E, Cucurull M, Notario L, Pous A, Torres P, Benitez M, Rodriguez M, Quirant B, Romeo M, Fuster D, Moran T. Immune Response and Effects of COVID-19 Vaccination in Patients with Lung Cancer-COVID Lung Vaccine Study. Cancers (Basel) 2022;15. [PMID: 36612134 DOI: 10.3390/cancers15010137] [Reference Citation Analysis]
|
| 90 |
Chen Y, Tong P, Whiteman N, Sanjari Moghaddam A, Zarghami M, Zuiani A, Habibi S, Gautam A, Keerti, Bi C, Xiao T, Cai Y, Chen B, Neuberg D, Wesemann DR. Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Sci Immunol 2022;7:eabp8328. [PMID: 35549298 DOI: 10.1126/sciimmunol.abp8328] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 91 |
Keeton R, Tincho MB, Suzuki A, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Skelem S, Adriaanse M, Grifoni A, Weiskopf D, Sette A, Bekker LG, Gray G, Ntusi NAB, Burgers WA, Riou C. Impact of SARS-CoV-2 exposure history on the T cell and IgG response. Cell Rep Med 2023;4:100898. [PMID: 36584684 DOI: 10.1016/j.xcrm.2022.100898] [Reference Citation Analysis]
|
| 92 |
Lin FJ, Doss AMA, Davis-Adams HG, Adams LJ, Hanson CH, VanBlargan LA, Liang CY, Chen RE, Monroy JM, Wedner HJ, Kulczycki A, Mantia TL, O'Shaughnessy CC, Raju S, Zhao FR, Rizzi E, Rigell CJ, Dy TB, Kau AL, Ren Z, Turner JS, O'Halloran JA, Presti RM, Fremont DH, Kendall PL, Ellebedy AH, Mudd PA, Diamond MS, Zimmerman O, Laidlaw BJ. SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients. Front Immunol 2022;13:1033770. [PMID: 36618402 DOI: 10.3389/fimmu.2022.1033770] [Reference Citation Analysis]
|
| 93 |
Vangeti S, Periasamy S, Sun P, Balinsky CA, Mahajan AS, Kuzmina NA, Soares-Schanoski A, Cooper E, Beckett C, Marayag J, Marrone A, Nunez E, Ge Y, Porter CK, Goforth CW, Lizewski SE, Lizewski R, Jani V, Sugiharto VA, Schilling M, Yu XB, Marjanovic N, George MC, Bukreyev A, Sealfon SC, Letizia AG, Ramos I. Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection. Microbiol Spectr 2022;10:e0183722. [PMID: 36374040 DOI: 10.1128/spectrum.01837-22] [Reference Citation Analysis]
|
| 94 |
Lee B, Ko JH, Lee KH, Kim YC, Song YG, Park YS, Baek YJ, Ahn JY, Choi JY, Song KH, Kim ES, Bae S, Kim SH, Jeong HW, Kim SW, Kwon KT, Kim SH, Jeong H, Kim B, Kim SS, Choi WS, Peck KR, Kang ES. Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding Domain. Microbiol Spectr 2022;10:e0266922. [PMID: 36250875 DOI: 10.1128/spectrum.02669-22] [Reference Citation Analysis]
|
| 95 |
Zapata-Cardona MI, Flórez-Álvarez L, Lopera TJ, Chvatal-Medina M, Zapata-Builes W, Diaz FJ, Aguilar-Jimenez W, Taborda N, Hernandez JC, Rugeles MT. Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia. Front Immunol 2022;13:1102384. [PMID: 36618393 DOI: 10.3389/fimmu.2022.1102384] [Reference Citation Analysis]
|
| 96 |
Hsiao Y, Taddese T, Jiménez-serratos G, Bray DJ, Crain J. Structure adaptation in Omicron SARS-CoV-2/hACE2: Biophysical origins of evolutionary driving forces.. [DOI: 10.1101/2022.12.20.521221] [Reference Citation Analysis]
|
| 97 |
Yamaguchi Y, Nameki S, Kato Y, Saita R, Sato T, Nagao S, Murakami T, Yoshimine Y, Amiya S, Morita T, Okita Y, Kawasaki T, Fujimoto J, Ueda Y, Maeda Y, Watanabe A, Takamatsu H, Nishida S, Shima Y, Narazaki M, Kumanogoh A. Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: an explanatory study in Japan. Lancet Reg Health West Pac 2023;32:100661. [PMID: 36569794 DOI: 10.1016/j.lanwpc.2022.100661] [Reference Citation Analysis]
|
| 98 |
Pratama NR, Wafa IA, Budi DS, Sutanto H, Asmarawati TP, Barlian Effendi G, Wungu CDK. Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression. Vaccines (Basel) 2022;10. [PMID: 36560590 DOI: 10.3390/vaccines10122180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 99 |
Assantachai P, Niyomnaitham S, Chatthanawaree W, Intalapaporn S, Muangpaisan W, Phannarus H, Saichompoo RB, Sura-amonrattana U, Wongprompitak P, Toh ZQ, Licciardi PV, Srisutthisamphan K, Chokephaibulkit K. Immunogenicity and reactogenicity of mRNA COVID-19 vaccine booster administered by intradermal or intramuscular route in Thai Older adults.. [DOI: 10.1101/2022.12.16.22283601] [Reference Citation Analysis]
|
| 100 |
Cinicola BL, Piano Mortari E, Zicari AM, Agrati C, Bordoni V, Albano C, Fedele G, Schiavoni I, Leone P, Fiore S, Capponi M, Conti MG, Petrarca L, Stefanelli P, Spalice A, Midulla F, Palamara AT, Quinti I, Locatelli F, Carsetti R. The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age. Front Immunol 2022;13:1094727. [PMID: 36591287 DOI: 10.3389/fimmu.2022.1094727] [Reference Citation Analysis]
|
| 101 |
Pizzo H, Soni PR, Nadipuram S, Garrison J, Jordan SC, Puliyanda D. Utilization of SARS-CoV-2-Positive donors in pediatric renal transplantation. Pediatr Transplant 2022;:e14451. [PMID: 36518031 DOI: 10.1111/petr.14451] [Reference Citation Analysis]
|
| 102 |
Narita K, Ikeda D, Seki M, Fukumoto A, Tabata R, Uesugi Y, Miura D, Takeuchi M, Doi M, Umezawa Y, Otsuka Y, Matsue K. Prevalence and clinical outcome of Omicron breakthrough infection in patients with hematologic disease: a prospective observational cohort study.. [DOI: 10.21203/rs.3.rs-2353891/v1] [Reference Citation Analysis]
|
| 103 |
Wu Y, Wang S, Zhang Y, Yuan L, Zheng Q, Wei M, Shi Y, Wang Z, Ma J, Wang K, Nie M, Xiao J, Huang Z, Chen P, Guo H, Lan M, Xu J, Hou W, Hong Y, Chen D, Sun H, Xiong H, Zhou M, Liu C, Guo W, Guo H, Gao J, Gan C, Li Z, Zhang H, Wang X, Li S, Cheng T, Zhao Q, Chen Y, Wu T, Zhang T, Zhang J, Cao H, Zhu H, Yuan Q, Guan Y, Xia N. Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine. Cell Host Microbe 2022;30:1732-1744.e7. [PMID: 36323313 DOI: 10.1016/j.chom.2022.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 104 |
Wang W, Lusvarghi S, Subramanian R, Epsi NJ, Wang R, Goguet E, Fries AC, Echegaray F, Vassell R, Coggins SA, Richard SA, Lindholm DA, Mende K, Ewers EC, Larson DT, Colombo RE, Colombo CJ, Joseph JO, Rozman JS, Smith A, Lalani T, Berjohn CM, Maves RC, Jones MU, Mody R, Huprikar N, Livezey J, Saunders D, Hollis-Perry M, Wang G, Ganesan A, Simons MP, Broder CC, Tribble DR, Laing ED, Agan BK, Burgess TH, Mitre E, Pollett SD, Katzelnick LC, Weiss CD. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history. Cell Host Microbe 2022;30:1745-1758.e7. [PMID: 36356586 DOI: 10.1016/j.chom.2022.10.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 105 |
Sriphoosanaphan S, Suksawatamnuay S, Srisoonthorn N, Siripon N, Thaimai P, Ananchuensook P, Thanapirom K, Nonthasoot B, Hansasuta P, Komolmit P. Immunogenicity, Immune Dynamics, and Subsequent Response to the Booster Dose of Heterologous versus Homologous Prime-Boost Regimens with Adenoviral Vector and mRNA SARS-CoV-2 Vaccine among Liver Transplant Recipients: A Prospective Study. Vaccines (Basel) 2022;10. [PMID: 36560535 DOI: 10.3390/vaccines10122126] [Reference Citation Analysis]
|
| 106 |
Planas D, Staropoli I, Porot F, Guivel-Benhassine F, Handala L, Prot M, Bolland WH, Puech J, Péré H, Veyer D, Sève A, Simon-Lorière E, Bruel T, Prazuck T, Stefic K, Hocqueloux L, Schwartz O. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. Med (N Y) 2022;3:838-847.e3. [PMID: 36228619 DOI: 10.1016/j.medj.2022.09.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 107 |
Curlin ME, Bates TA, Guzman G, Schoen D, McBride SK, Carpenter SD, Tafesse FG. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection. Med (N Y) 2022;3:827-837.e3. [PMID: 36198311 DOI: 10.1016/j.medj.2022.09.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 108 |
Li J, Li X, Wang E, Yang J, Li J, Huang C, Zhang Y, Chen K. Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. Vaccines (Basel) 2022;10. [PMID: 36560521 DOI: 10.3390/vaccines10122111] [Reference Citation Analysis]
|
| 109 |
Li Y, Kim H, Ju Y, Park Y, Kang T, Yong D, Park HG. Ultrasensitive Isothermal Detection of SARS-CoV-2 Based on Self-Priming Hairpin-Utilized Amplification of the G-Rich Sequence. Anal Chem 2022;94:17448-55. [PMID: 36480911 DOI: 10.1021/acs.analchem.2c03442] [Reference Citation Analysis]
|
| 110 |
Zhu FF, Gu BB, Jin YJ, Yao L, Zhou L, Zou D, Ding J, Zhou T, Shen XH, Chen C. Risk Factors for Radiological Progression Within Admissive One Week in the Hospitalized COVID-19 Omicron Variant-Infected Patients. Infect Drug Resist 2022;15:7127-37. [PMID: 36510589 DOI: 10.2147/IDR.S388696] [Reference Citation Analysis]
|
| 111 |
Toptygina A, Afridonova Z, Zakirov R, Semikina E. Maintaining immunological memory to the SARS-CoV-2 virus during a pandemic. Russian Journal of Infection and Immunity 2022. [DOI: 10.15789/2220-7619-mim-2009] [Reference Citation Analysis]
|
| 112 |
Xu Y, Li H, Kirui B, Santosa A, Gisslén M, Leach S, Wettermark B, Vanfleteren LEGW, Nyberg F. Effectiveness of COVID-19 Vaccines over 13 Months Covering the Period of the Emergence of the Omicron Variant in the Swedish Population. Vaccines (Basel) 2022;10. [PMID: 36560484 DOI: 10.3390/vaccines10122074] [Reference Citation Analysis]
|
| 113 |
Arunachalam PS, Lai L, Samaha H, Feng Y, Hu M, Hui HS, Wali B, Ellis M, Huerta C, Bechnack K, Bechnack S, Lee M, Litvack M, Losada C, Grifoni A, Sette A, Zarnitsyna VI, Rouphael N, Suthar MS, Pulendran B. Durability of immune responses to the booster mRNA vaccination against COVID-19. medRxiv 2022:2022. [PMID: 36482977 DOI: 10.1101/2022.12.02.22282921] [Reference Citation Analysis]
|
| 114 |
Bessen C, Plaza-Sirvent C, Simsek A, Bhat J, Marheinecke C, Urlaub D, Bonowitz P, Busse S, Schumann S, Blanco EV, Skaletz-Rorowski A, Brockmeyer NH, Overheu O, Reinacher-Schick A, Faissner S, Watzl C, Pfaender S, Potthoff A, Schmitz I. Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV. Front Immunol 2022;13:1049070. [PMID: 36532034 DOI: 10.3389/fimmu.2022.1049070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 115 |
Homma T, Nagata N, Hashimoto M, Iwata-Yoshikawa N, Seki NM, Shiwa-Sudo N, Ainai A, Dohi K, Nikaido E, Mukai A, Ukai Y, Nakagawa T, Shimo Y, Maeda H, Shirai S, Aoki M, Sonoyama T, Sato M, Fumoto M, Nagira M, Nakata F, Hashiguchi T, Suzuki T, Omoto S, Hasegawa H. Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice. Sci Rep 2022;12:20861. [PMID: 36460696 DOI: 10.1038/s41598-022-25418-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 116 |
Notario GR, Kwak K. Increased B Cell Understanding Puts Improved Vaccine Platforms Just Over the Horizon. Immune Netw 2022;22:e47. [PMID: 36627934 DOI: 10.4110/in.2022.22.e47] [Reference Citation Analysis]
|
| 117 |
Chuang CH, Huang CG, Huang CT, Chen YC, Kung YA, Chen CJ, Chuang TC, Liu CC, Huang PW, Yang SL, Gu PW, Shih SR, Chiu CH. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial. J Clin Virol 2022;157:105328. [PMID: 36399969 DOI: 10.1016/j.jcv.2022.105328] [Reference Citation Analysis]
|
| 118 |
Chen X, Li H, Song H, Wang J, Zhang X, Han P, Wang X. Meet changes with constancy: Defence, antagonism, recovery, and immunity roles of extracellular vesicles in confronting SARS-CoV-2. J Extracell Vesicles 2022;11:e12288. [PMID: 36450704 DOI: 10.1002/jev2.12288] [Reference Citation Analysis]
|
| 119 |
Ling KM, Dougan M. Monoclonal antibodies for the treatment of COVID-19 infection in children. Expert Rev Anti Infect Ther 2022;20:1529-35. [PMID: 36225144 DOI: 10.1080/14787210.2022.2134117] [Reference Citation Analysis]
|
| 120 |
Poland GA, Issa M, Sundsted K. Year 3 of COVID-19: Harsh Truths, Brutal Realities, and Glimmers of Hope. Mayo Clin Proc 2022;97:2324-32. [PMID: 36464465 DOI: 10.1016/j.mayocp.2022.10.022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 121 |
Hansen C, Perofsky AC, Burstein R, Famulare M, Boyle S, Prentice R, Marshall C, McCormick BJJ, Reinhart D, Capodanno B, Truong M, Schwabe-Fry K, Kuchta K, Pfau B, Acker Z, Lee J, Sibley TR, McDermot E, Rodriguez-Salas L, Stone J, Gamboa L, Han PD, Duchin JS, Waghmare A, Englund JA, Shendure J, Bedford T, Chu HY, Starita LM, Viboud C. Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022. JAMA Netw Open 2022;5:e2245861. [PMID: 36484987 DOI: 10.1001/jamanetworkopen.2022.45861] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 122 |
Zhu Y, Yang X, Xun J, Liu J, Wen Q, Lin Y, Shen X, Chen J, Yuan S, Zhao X, Wang J, Pan H, Yang J, Liang Z, Liang Y, Lin Q, Liang H, Li M, Liu J, Shen Y, Zhang X, Wang P, Lu D, Yin C, Xu J, Jiang S, Lu H, Zhu H. Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum. Virol Sin 2022;37:831-41. [PMID: 36309305 DOI: 10.1016/j.virs.2022.10.006] [Reference Citation Analysis]
|
| 123 |
Chen Y, Chen L, Yin S, Tao Y, Zhu L, Tong X, Mao M, Li M, Wan Y, Ni J, Ji X, Dong X, Li J, Huang R, Shen Y, Shen H, Bao C, Wu C. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. Emerg Microbes Infect 2022;11:1524-36. [PMID: 35608053 DOI: 10.1080/22221751.2022.2081614] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 124 |
Meggiolaro A, Sane Schepisi M, Farina S, Castagna C, Mammone A, Siddu A, Stefanelli P, Boccia S, Rezza G. Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis. Expert Rev Vaccines 2022;21:1831-41. [PMID: 36242513 DOI: 10.1080/14760584.2022.2130773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 125 |
Ward V, Wei J, Gordon W, Barnes E, Dunachie S, Jeffery K, Eyre D, O'Donnell AM. SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study. BMJ Open 2022;12:e066766. [PMID: 36456004 DOI: 10.1136/bmjopen-2022-066766] [Reference Citation Analysis]
|
| 126 |
Pavan M, Bassani D, Sturlese M, Moro S. From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? J Enzyme Inhib Med Chem 2022;37:1704-14. [PMID: 35695095 DOI: 10.1080/14756366.2022.2081847] [Reference Citation Analysis]
|
| 127 |
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis 2022;22:1703-15. [PMID: 36113538 DOI: 10.1016/S1473-3099(22)00506-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 128 |
Nanishi E, Levy O, Ozonoff A. Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. Hum Vaccin Immunother 2022;18:2045857. [PMID: 35240940 DOI: 10.1080/21645515.2022.2045857] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 129 |
Gan P, Pan X, Huang S, Xia H, Zhou X, Tang X. Current status of coronavirus disease 2019 vaccine research based on bibliometric analysis. Hum Vaccin Immunother 2022;18:2119766. [PMID: 36494998 DOI: 10.1080/21645515.2022.2119766] [Reference Citation Analysis]
|
| 130 |
Wei J, Matthews PC, Stoesser N, Newton JN, Diamond I, Studley R, Taylor N, Bell JI, Farrar J, Kolenchery J, Marsden BD, Hoosdally S, Jones EY, Stuart DI, Crook DW, Peto TEA, Walker AS, Pouwels KB, Eyre DW, the COVID-19 Infection Survey team. Correlates of protection against SARS-CoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or breakthrough infection in the UK general population.. [DOI: 10.1101/2022.11.29.22282916] [Reference Citation Analysis]
|
| 131 |
Li SC, Kabeer MH. Caveolae-Mediated Extracellular Vesicle (CMEV) Signaling of Polyvalent Polysaccharide Vaccination: A Host-Pathogen Interface Hypothesis. Pharmaceutics 2022;14. [PMID: 36559147 DOI: 10.3390/pharmaceutics14122653] [Reference Citation Analysis]
|
| 132 |
Gao X, Fan L, Zheng B, Li H, Wang J, Zhang L, Li J, Zhu F. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain. Hum Vaccin Immunother 2022;18:2055373. [PMID: 35417303 DOI: 10.1080/21645515.2022.2055373] [Reference Citation Analysis]
|
| 133 |
Du Y, Chen L, Shi Y. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review. Hum Vaccin Immunother 2022;18:2062983. [PMID: 35499517 DOI: 10.1080/21645515.2022.2062983] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 134 |
Mohapatra RK, El-Shall NA, Tiwari R, Nainu F, Kandi V, Sarangi AK, Mohammed TA, Desingu PA, Chakraborty C, Dhama K. Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update. Hum Vaccin Immunother 2022;18:2065824. [PMID: 35594528 DOI: 10.1080/21645515.2022.2065824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 135 |
Lovell JF, Baik YO, Choi SK, Lee C, Lee JY, Miura K, Huang WC, Park YS, Woo SJ, Seo SH, Kim JO, Song M, Kim CJ, Choi JK, Kim J, Choo EJ, Choi JH. Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine. BMC Med 2022;20:462. [PMID: 36447243 DOI: 10.1186/s12916-022-02661-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 136 |
Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K, Sapsutthipas S, Jantraphakorn Y, Mingngamsup N, Licciardi PV, Chokephaibulkit K. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults. Hum Vaccin Immunother 2022;18:2091865. [PMID: 35816053 DOI: 10.1080/21645515.2022.2091865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 137 |
Kang L, Wang Y, Xing S, Li H, Chien CW, Tung TH. Group-based trajectory modeling to identify health beliefs of COVID-19 vaccination and its predictors: A cohort study in China. Hum Vaccin Immunother 2022;18:2091899. [PMID: 35977916 DOI: 10.1080/21645515.2022.2091899] [Reference Citation Analysis]
|
| 138 |
Durier C, Ninove L, Lefebvre M, Radenne A, Desaint C, Ropers J, Bauer R, Lebbah S, Carette D, Lachatre M, Lecompte AS, Deplanque D, Botelho-Nevers E, Conrad A, Dussol B, Maakaroun-Vermesse Z, Melica G, Nicolas JF, Verdon R, Kiladjian J, Loubet P, Schmidt-Mutter C, Dualé C, Ansart S, Priet S, Levier A, Molino D, Vieillard LV, Parfait B, Lelièvre JD, Tartour E, de Lamballerie X, Launay O; ANRS0002S CoviCompareP Group, AP-HP CoviCompareM Group, Biological resource centers, Laboratories, Trial coordination, Sponsor, Scientific Committee. Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years. Sci Rep 2022;12:20373. [PMID: 36437298 DOI: 10.1038/s41598-022-24409-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 139 |
Roohani J, Keikha M. Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned? World J Virol 2022; 11(6): 496-501 [DOI: 10.5501/wjv.v11.i6.496] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 140 |
Fryer HA, Hartley GE, Edwards ES, O'hehir RE, van Zelm MC. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochemical Society Transactions 2022. [DOI: 10.1042/bst20220415] [Reference Citation Analysis]
|
| 141 |
Yen AM, Chen SL, Hsu CY, Chen TH. The Preventive Role of mRNA Vaccines in Reducing Death among Moderate Omicron-Infected Patients: A Follow-Up Study. Viruses 2022;14. [PMID: 36560626 DOI: 10.3390/v14122622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 142 |
Xiang T, Wang J, Zheng X. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. Virol Sin 2022:S1995-820X(22)00191-2. [PMID: 36427646 DOI: 10.1016/j.virs.2022.11.007] [Reference Citation Analysis]
|
| 143 |
Mollura M, Sarti R, Levi R, Pozzi C, Azzolini E, Politi LS, Mantovani A, Barbieri R, Rescigno M. Antibody Titer Correlates with Omicron Infection in Vaccinated Healthcare Workers. Viruses 2022;14. [PMID: 36560609 DOI: 10.3390/v14122605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 144 |
Abed M, Al Omari S, Mourad R, Al Faraj A. Cross-sectional study of the knowledge, perception and attitude of first-year university students in Iraq towards SARS-CoV-2 Omicron variant and COVID-19 vaccines. BMJ Open 2022;12:e064301. [PMID: 36410839 DOI: 10.1136/bmjopen-2022-064301] [Reference Citation Analysis]
|
| 145 |
Harada D, Tamura T, Ninomiya K, Kubo T, Kuyama S, Tachibana S, Inoue K, Chikamori K, Kudo K, Ochi N, Maeda Y, Kiura K. Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study. Thorac Cancer 2023;14:231-6. [PMID: 36404396 DOI: 10.1111/1759-7714.14737] [Reference Citation Analysis]
|
| 146 |
Jacobsen H, Strengert M, Maaß H, Ynga Durand MA, Katzmarzyk M, Kessel B, Harries M, Rand U, Abassi L, Kim Y, Lüddecke T, Metzdorf K, Hernandez P, Ortmann J, Heise JK, Castell S, Gornyk D, Glöckner S, Melhorn V, Kemmling Y, Lange B, Dulovic A, Marsall P, Häring J, Junker D, Schneiderhan-Marra N, Hoffmann M, Pöhlmann S, Krause G, Cicin-Sain L. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. Sci Rep 2022;12:19858. [PMID: 36400804 DOI: 10.1038/s41598-022-22552-y] [Reference Citation Analysis]
|
| 147 |
Chattopadhyay P, Mishra P, Mehta P, Soni J, Gupta R, Tarai B, Budhiraja S, Pandey R. Transcriptomic study reveals lncRNA-mediated downregulation of innate immune and inflammatory response in the SARS-CoV-2 vaccination breakthrough infections. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1035111] [Reference Citation Analysis]
|
| 148 |
Fericean RM, Rosca O, Citu C, Manolescu D, Bloanca V, Toma AO, Boeriu E, Dumitru C, Ravulapalli M, Barbos V, Oancea C. COVID-19 Clinical Features and Outcomes in Elderly Patients during Six Pandemic Waves. J Clin Med 2022;11. [PMID: 36431282 DOI: 10.3390/jcm11226803] [Reference Citation Analysis]
|
| 149 |
Bruel T, Stéfic K, Nguyen Y, Toniutti D, Staropoli I, Porrot F, Guivel-Benhassine F, Bolland WH, Planas D, Hadjadj J, Handala L, Planchais C, Prot M, Simon-Lorière E, André E, Baele G, Cuypers L, Mouthon L, Mouquet H, Buchrieser J, Sève A, Prazuck T, Maes P, Terrier B, Hocqueloux L, Schwartz O. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies. Cell Rep Med 2022;3:100850. [PMID: 36450283 DOI: 10.1016/j.xcrm.2022.100850] [Reference Citation Analysis]
|
| 150 |
Aralis Z, Comer S, Ansorg H, Palmer C, Smith J, Feinstein SC, Fitzgibbons LN, Arias C. Efficient Tracing of the SARS-CoV-2 Omicron Variants in Santa Barbara County Using a Rapid Quantitative Reverse Transcription PCR Assay. Diagnostics (Basel) 2022;12. [PMID: 36428863 DOI: 10.3390/diagnostics12112805] [Reference Citation Analysis]
|
| 151 |
Byazrova MG, Astakhova EA, Minnegalieva AR, Sukhova MM, Mikhailov AA, Prilipov AG, Gorchakov AA, Filatov AV. Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination. npj Vaccines 2022;7:145. [DOI: 10.1038/s41541-022-00566-x] [Reference Citation Analysis]
|
| 152 |
Hauser BM, Feldman J, Sangesland M, Ronsard L, St Denis KJ, Sheehan ML, Cao Y, Boucau J, Windsor IW, Cheng AH, Vu ML, Cardoso MR, Kannegieter T, Balazs AB, Lingwood D, Garcia-Beltran WF, Schmidt AG. Cross-reactive SARS-CoV-2 epitope targeted across donors informs immunogen design. Cell Rep Med 2022;3:100834. [PMID: 36423634 DOI: 10.1016/j.xcrm.2022.100834] [Reference Citation Analysis]
|
| 153 |
Khong K, Zhang R, Hung IF. The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. Vaccines 2022;10:1924. [DOI: 10.3390/vaccines10111924] [Reference Citation Analysis]
|
| 154 |
Arora P, Zhang L, Rocha C, Graichen L, Nehlmeier I, Kempf A, Cossmann A, Ramos GM, Baier E, Tampe B, Moerer O, Dickel S, Winkler MS, Behrens GMN, Pöhlmann S, Hoffmann M. The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant. Int J Mol Sci 2022;23. [PMID: 36430535 DOI: 10.3390/ijms232214057] [Reference Citation Analysis]
|
| 155 |
Gobeil P, Pillet S, Boulay I, Charland N, Lorin A, Cheng MP, Vinh DC, Boutet P, Van Der Most R, Roman F, Ceregido MA, Landry N, D'Aoust MA, Ward BJ. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19. Nat Commun 2022;13:6905. [PMID: 36371408 DOI: 10.1038/s41467-022-34728-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 156 |
Wang Z, An J, Liu K, Yu P, Fang X, Li J, Zhu H, Zhu Q, Huang C, Zhang C, Zhao B, Bao L, Song Y, Cao X, Hu D, Jiang Y, Shi L, Zhou L, Fan J, Guan W, Zhou C, Hu Z, Yuan Z, Liu J, Shan C, Liu G. A potent, broadly protective vaccine against SARS-CoV-2 variants of concern. npj Vaccines 2022;7:144. [DOI: 10.1038/s41541-022-00571-0] [Reference Citation Analysis]
|
| 157 |
Seegers V, Rousseau G, Zhou K, Blanc-Lapierre A, Bigot F, Mahammedi H, Lambert A, Moreau-Bachelard C, Campone M, Conroy T, Penault-Llorca F, Boisdron-Celle M, Bellanger M, Raoul JL. COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19). Cancers (Basel) 2022;14. [PMID: 36428640 DOI: 10.3390/cancers14225547] [Reference Citation Analysis]
|
| 158 |
Wang J, Deng C, Liu M, Liu Y, Li L, Huang Z, Shang L, Jiang J, Li Y, Mo R, Zhang H, Liu M, Peng S, Xiao H. A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain. Nat Commun 2022;13:6866. [PMID: 36369243 DOI: 10.1038/s41467-022-34633-7] [Reference Citation Analysis]
|
| 159 |
Yu C, Fengzhao Z, Hongmei W, Zeyuan L, Yu L, Yuhang G, Rufei S, Qingzhu J, Xiaorong S, Xia W, Caiping S, Zhi X, Chunmei L. The impact of vaccination on patients with COVID-19 during the wave of Omicron in Shanghai. Front Public Health 2022;10:1054313. [PMID: 36438303 DOI: 10.3389/fpubh.2022.1054313] [Reference Citation Analysis]
|
| 160 |
Khamadi SA, Opanda S, Symekher SL, Limbaso SK, Langat S, Cirindi JK, Mwangi M, Mwikwabe N, Okeyo S, Koskei E, Mutisya J, Owaka S, Nyunja A, Koka H, Wadegu M, Chitechi E, Achilla R, Majanja JM, Kanyara L, Amukoye E, Bulimo W. Whole-genome sequence analysis reveals the circulation of multiple SARS-CoV-2 variants of concern in Nairobi and neighboring counties, Kenya between March and July 2021. Virol J 2022;19:178. [DOI: 10.1186/s12985-022-01895-y] [Reference Citation Analysis]
|
| 161 |
Lau DK, Aresu M, Planche T, Tran A, Lazaro-Alcausi R, Duncan J, Kidd S, Cromarty S, Begum R, Rana I, Li S, Mohamed AA, Monahan I, Clark DJ, Eckersley N, Staines HM, Groppelli E, Krishna S, Mayora-Neto M, Temperton N, Fribbens C, Watkins D, Starling N, Chau I, Cunningham D, Rao S. SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy. Oncologist 2023;28:e1-8. [PMID: 36342104 DOI: 10.1093/oncolo/oyac230] [Reference Citation Analysis]
|
| 162 |
Eberhardt AT, Simoncini M, Piña C, Galoppo G, Parachú-Marco V, Racca A, Arce S, Viotto E, Facelli F, Valli F, Botto C, Scarpa L, Junges C, Palavecino C, Beccaria C, Sklar D, Mingo G, Genolet A, Muñoz de Toro M, Aimar H, Marignac V, Bossio JC, Armando G, Fernández H, Beldomenico PM. Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina. Epidemiol Infect 2022;150:e187. [PMID: 36325837 DOI: 10.1017/S0950268822001716] [Reference Citation Analysis]
|
| 163 |
Powis M, Sutradhar R, Patrikar A, Cheung M, Gong I, Vijenthira A, Hicks LK, Wilton D, Krzyzanowska MK, Singh S. Factors associated with timely COVID-19 vaccination in a population-based cohort of patients with cancer. J Natl Cancer Inst 2023;115:146-54. [PMID: 36321960 DOI: 10.1093/jnci/djac204] [Reference Citation Analysis]
|
| 164 |
Kim YY, Choe YJ, Kim J, Kim RK, Jang EJ, Park SK, Lim DS, Yi S, Lee S, Kwon GY, Shin JY, Choi SY, Jeong MJ, Park YJ. Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents. Emerg Infect Dis 2022;28:2165-70. [PMID: 36191615 DOI: 10.3201/eid2811.220918] [Reference Citation Analysis]
|
| 165 |
Yu J, Thomas PV, McMahan K, Jacob-Dolan C, Liu J, He X, Hope D, Martinez EJ, Chen WH, Sciacca M, Hachmann NP, Lifton M, Miller J, Powers OC, Hall K, Wu C, Barrett J, Swafford I, Currier JR, King J, Corbitt C, Chang WC, Golub E, Rees PA, Peterson CE, Hajduczki A, Hussin E, Lange C, Gong H, Matyas GR, Rao M, Paquin-Proulx D, Gromowski GD, Lewis MG, Andersen H, Davis-Gardner M, Suthar MS, Michael NL, Bolton DL, Joyce MG, Modjarrad K, Barouch DH. Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN. Sci Adv 2022;8:eade4433. [PMID: 36417525 DOI: 10.1126/sciadv.ade4433] [Reference Citation Analysis]
|
| 166 |
Almufty HB, Mamani MMA, Ali AH, Merza MA. COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan: A retrospective cohort study. J Med Virol 2022;94:5244-50. [PMID: 35811398 DOI: 10.1002/jmv.27985] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 167 |
Ho HPT, Vo DNK, Lin TY, Hung JN, Chiu YH, Tsai MH. Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. Biomed Pharmacother 2022;155:113766. [PMID: 36271550 DOI: 10.1016/j.biopha.2022.113766] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 168 |
Zhao J, Zhu J, Huang C, Zhu X, Zhu Z, Wu Q, Yuan R. Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1035151] [Reference Citation Analysis]
|
| 169 |
Ferrari A, Cassaniti I, Sarasini A, Lilleri D, Sammartino JC, Del Fante C, Baldanti F, Percivalle E, Perotti C. Characterization of CCP: Can We Use Past Convalescent Plasma from COVID-19 Patients for Treatment of New Emerging Variants? COVID 2022;2:1564-1574. [DOI: 10.3390/covid2110112] [Reference Citation Analysis]
|
| 170 |
Rossi MA, Cena T, Binala J, Alessi D, Scotti L, Faggiano F. Evaluation of the risk of SARS-CoV-2 Infection and Hospitalization in Vaccinated and Previously Infected Subjects Based on Real World Data.. [DOI: 10.21203/rs.3.rs-2082030/v1] [Reference Citation Analysis]
|
| 171 |
Chiu CH, Chang YH, Tao CW, Chang FY, Chiu KC, Chang TW, Yen LC. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. Microbiol Spectr 2022;10:e0060922. [PMID: 36005765 DOI: 10.1128/spectrum.00609-22] [Reference Citation Analysis]
|
| 172 |
Panahi Y, Einollahi B, Beiraghdar F, Darvishi M, Fathi S, Javanbakht M, Shafiee S, Akhavan-sigari R. Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.947602] [Reference Citation Analysis]
|
| 173 |
Sarkar MS, Madabhavi I. SARS-CoV-2 variants of concern: a review. Monaldi Arch Chest Dis 2022. [DOI: 10.4081/monaldi.2022.2337] [Reference Citation Analysis]
|
| 174 |
Bates TA, Lu P, Kang YJ, Schoen D, Thornton M, McBride SK, Park C, Kim D, Messer WB, Curlin ME, Tafesse FG, Lu LL. BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. Cell Rep 2022;41:111544. [PMID: 36252569 DOI: 10.1016/j.celrep.2022.111544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 175 |
Sun Y, Zou Y, Wang H, Cui G, Yu Z, Ren Z. Immune response induced by novel coronavirus infection. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.988604] [Reference Citation Analysis]
|
| 176 |
Jalloh S, Olejnik J, Berrigan J, Nisa A, Suder EL, Akiyama H, Lei M, Ramaswamy S, Tyagi S, Bushkin Y, Mühlberger E, Gummuluru S. CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. PLoS Pathog 2022;18:e1010479. [PMID: 36279285 DOI: 10.1371/journal.ppat.1010479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 177 |
Maio N, Cherry S, Schultz DC, Hurst BL, Linehan WM, Rouault TA. TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model. iScience 2022;25:105074. [PMID: 36093377 DOI: 10.1016/j.isci.2022.105074] [Reference Citation Analysis]
|
| 178 |
Park YJ, Pinto D, Walls AC, Liu Z, De Marco A, Benigni F, Zatta F, Silacci-Fregni C, Bassi J, Sprouse KR, Addetia A, Bowen JE, Stewart C, Giurdanella M, Saliba C, Guarino B, Schmid MA, Franko NM, Logue JK, Dang HV, Hauser K, di Iulio J, Rivera W, Schnell G, Rajesh A, Zhou J, Farhat N, Kaiser H, Montiel-Ruiz M, Noack J, Lempp FA, Janer J, Abdelnabi R, Maes P, Ferrari P, Ceschi A, Giannini O, de Melo GD, Kergoat L, Bourhy H, Neyts J, Soriaga L, Purcell LA, Snell G, Whelan SPJ, Lanzavecchia A, Virgin HW, Piccoli L, Chu HY, Pizzuto MS, Corti D, Veesler D. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 2022;:eadc9127. [PMID: 36264829 DOI: 10.1126/science.adc9127] [Reference Citation Analysis]
|
| 179 |
Burke MJ, Scott JNF, Minshull TC, Gao Z, Manfield I, Savic S, Stockley PG, Calabrese AN, Boyes J. A bovine antibody possessing an ultralong complementarity-determining region CDRH3 targets a highly conserved epitope in sarbecovirus spike proteins. J Biol Chem 2022;298:102624. [PMID: 36272646 DOI: 10.1016/j.jbc.2022.102624] [Reference Citation Analysis]
|
| 180 |
Hussein K, Dabaja-Younis H, Szwarcwort-Cohen M, Almog R, Leiba R, Weissman A, Mekel M, Hyams G, Horowitz NA, Gepstein V, Cohen Saban H, Tarabeia J, Halberthal M, Shachor-Meyouhas Y. Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers. Vaccines (Basel) 2022;10. [PMID: 36298606 DOI: 10.3390/vaccines10101741] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 181 |
Nickel O, Rockstroh A, Wolf J, Landgraf S, Kalbitz S, Kellner N, Borte M, Pietsch C, Fertey J, Lübbert C, Ulbert S, Borte S. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. PLoS One 2022;17:e0263861. [PMID: 36256664 DOI: 10.1371/journal.pone.0263861] [Reference Citation Analysis]
|
| 182 |
Liu Q, Zhou W, Jiang W, Jia X. Observational study of antibody levels after second and third SARS-CoV-2 vaccinations in medical workers. J Clin Lab Anal 2022;:e24731. [PMID: 36250228 DOI: 10.1002/jcla.24731] [Reference Citation Analysis]
|
| 183 |
Qu P, Evans JP, Kurhade C, Zeng C, Zheng YM, Xu K, Shi PY, Xie X, Liu SL. Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants. bioRxiv 2022:2022. [PMID: 36299433 DOI: 10.1101/2022.10.15.512322] [Reference Citation Analysis]
|
| 184 |
Kaunang ED, Kristanto EG, Panelewen J, Rotty IE. Clinical Characteristics of COVID-19 Deaths: An Electronic Medical Records-based Study. Open Access Maced J Med Sci 2022;10:2509-2512. [DOI: 10.3889/oamjms.2022.10959] [Reference Citation Analysis]
|
| 185 |
Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, Ferrall L, Hung CF, Wu TC. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci 2022;29:82. [PMID: 36243868 DOI: 10.1186/s12929-022-00853-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 186 |
Müller L, Andrée M, Moskorz W, Drexler I, Hauka S, Ptok J, Walotka L, Grothmann R, Hillebrandt J, Ritchie A, Peter L, Walker A, Timm J, Adams O, Schaal H. Adjusted COVID-19 booster schedules balance age-dependent differences in antibody titers benefitting risk populations. Front Aging 2022;3:1027885. [PMID: 36313184 DOI: 10.3389/fragi.2022.1027885] [Reference Citation Analysis]
|
| 187 |
Lam JH, Shivhare D, Chia TW, Chew SL, Sinsinbar G, Aw TY, Wong S, Venkataraman S, Lim FWI, Vandepapeliere P, Nallani M. Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine. ACS Nano 2022;16:16757-75. [PMID: 36223228 DOI: 10.1021/acsnano.2c06350] [Reference Citation Analysis]
|
| 188 |
Sang Y, Zhang Z, Li E, Lu H, Long J, Cao Y, Yu C, Wang T, Yang J, Wang S. An mRNA vaccine with broad-spectrum neutralizing protection against Omicron variant sublineages BA.4/5 -included SARS-CoV-2. Signal Transduct Target Ther 2022;7:362. [PMID: 36220820 DOI: 10.1038/s41392-022-01207-4] [Reference Citation Analysis]
|
| 189 |
Seaman MS, Siedner MJ, Boucau J, Lavine CL, Ghantous F, Liew MY, Mathews JI, Singh A, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, Chen G, Stuckwisch AM, Lipiner T, Kittilson A, Melberg M, Gilbert RF, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Goldberg MB, Luban J, Li JZ, Barczak AK, Lemieux JE. Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant. JCI Insight 2022;7:e159944. [DOI: 10.1172/jci.insight.159944] [Reference Citation Analysis]
|
| 190 |
da Silva SJR. The emergence of new SARS-CoV-2 omicron subvariants introduces uncertainty about the end of the COVID-19 pandemic. Front Med (Lausanne) 2022;9:1010489. [PMID: 36300185 DOI: 10.3389/fmed.2022.1010489] [Reference Citation Analysis]
|
| 191 |
Wang Y, Zhang X, Ma Y, Wang Y, Zhan W, Zheng Q, Zhang M, Ji P, Liu M, Liu Q, Sun T, Zhu T, Wen Y, Sun L, Zhao J, Wu F, Chen Z, Huang J. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. Cell Discov 2022;8:104. [PMID: 36207299 DOI: 10.1038/s41421-022-00463-6] [Reference Citation Analysis]
|
| 192 |
Lenart K, Hellgren F, Ols S, Yan X, Cagigi A, Cerveira RA, Winge I, Hanczak J, Mueller SO, Jasny E, Schwendt K, Rauch S, Petsch B, Loré K. A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. Mol Ther Methods Clin Dev 2022. [PMID: 36217434 DOI: 10.1016/j.omtm.2022.10.001] [Reference Citation Analysis]
|
| 193 |
Hvidt AK, Baerends EAM, Søgaard OS, Stærke NB, Raben D, Reekie J, Nielsen H, Johansen IS, Wiese L, Benfield TL, Iversen KK, Mustafa AB, Juhl MR, Petersen KT, Ostrowski SR, Lindvig SO, Rasmussen LD, Schleimann MH, Andersen SD, Juhl AK, Dietz LL, Andreasen SR, Lundgren J, Østergaard L, Tolstrup M; ENFORCE Study Group. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines. Front Med (Lausanne) 2022;9:994160. [PMID: 36262278 DOI: 10.3389/fmed.2022.994160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 194 |
Delshad M, Sanaei MJ, Pourbagheri-Sigaroodi A, Bashash D. Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. Int Immunopharmacol 2022;111:109128. [PMID: 35963158 DOI: 10.1016/j.intimp.2022.109128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 195 |
Yin Y, Li X, Qian C, Cheng B, Lu F, Shen T. Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study. J Infect 2022;85:e119-21. [PMID: 35760302 DOI: 10.1016/j.jinf.2022.06.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 196 |
Shi J, Zheng J, Zhang X, Tai W, Odle AE, Perlman S, Du L. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. Transl Res 2022;248:11-21. [PMID: 35489692 DOI: 10.1016/j.trsl.2022.04.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 197 |
Tseng HF, Ackerson BK, Bruxvoort KJ, Sy LS, Tubert JE, Lee GS, Ku JH, Florea A, Luo Y, Qiu S, Choi SK, Takhar HS, Aragones M, Paila YD, Chavers S, Qian L. Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5.. [DOI: 10.1101/2022.09.30.22280573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 198 |
Kaya G, Altindiş M. Virological, Epidemiological Features and Prevention of SARS-CoV-2 Omicron (B.1.1.529) Variant: A Rewiev. KOU Sag Bil Derg 2022. [DOI: 10.30934/kusbed.1060956] [Reference Citation Analysis]
|
| 199 |
Gamage SST, Pahattuge TN, Wijerathne H, Childers K, Vaidyanathan S, Athapattu US, Zhang L, Zhao Z, Hupert ML, Muller RM, Muller-Cohn J, Dickerson J, Dufek D, Geisbrecht BV, Pathak H, Pessetto Z, Gan GN, Choi J, Park S, Godwin AK, Witek MA, Soper SA. Microfluidic affinity selection of active SARS-CoV-2 virus particles. Sci Adv 2022;8:eabn9665. [PMID: 36170362 DOI: 10.1126/sciadv.abn9665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 200 |
Xie Y, Liu L, Wang J, Zheng Y, Luo C, Ni W, He Z, Zhao X, Liu Y, He Y, Zheng S, Li L, Liu Z. Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants. Front Immunol 2022;13:975533. [DOI: 10.3389/fimmu.2022.975533] [Reference Citation Analysis]
|
| 201 |
Norddahl GL, Melsted P, Gunnarsdottir K, Halldorsson GH, Olafsdottir TA, Gylfason A, Kristjansson M, Magnusson OT, Sulem P, Gudbjartsson DF, Thorsteinsdottir U, Jonsdottir I, Stefansson K. Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland. Nat Commun 2022;13:5701. [PMID: 36171188 DOI: 10.1038/s41467-022-33076-4] [Reference Citation Analysis]
|
| 202 |
Huang Y, Shin JE, Xu AM, Yao C, Joung S, Wu M, Zhang R, Shin B, Foley J, Mahov SB, Modes ME, Ebinger JE, Driver M, Braun JG, Jefferies CA, Parimon T, Hayes C, Sobhani K, Merchant A, Gharib SA, Jordan SC, Cheng S, Goodridge HS, Chen P. Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination. iScience 2022;25:105209. [PMID: 36188190 DOI: 10.1016/j.isci.2022.105209] [Reference Citation Analysis]
|
| 203 |
González S, Olszevicki S, Gaiano A, Salazar M, Regairaz L, Varela Baino AN, Barkel E, Varela T, González Martínez VV, Pesci S, Marín L, Irassar JI, Ceriani L, Garcia E, Kreplak N, Estenssoro E, Marsico F. Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the Omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study.. [DOI: 10.1101/2022.09.25.22280341] [Reference Citation Analysis]
|
| 204 |
Negroni D, Carriero S, Passarella I, Siani A, Biondetti P, Pizzolante A, Saba L, Guzzardi G. Preliminary Analysis of the Effects of Ad26.COV2.S Vaccination on CT Findings and High Intensive Care Admission Rates of COVID-19 Patients. Tomography 2022;8:2403-2410. [DOI: 10.3390/tomography8050199] [Reference Citation Analysis]
|
| 205 |
Le TTB, Vasanthakumaran T, Thi Hien HN, Hung IC, Luu MN, Khan ZA, An NT, Tran VP, Lee WJ, Abdul Aziz JM, Ali T, Dumre SP, Huy NT. SARS-CoV-2 Omicron and its current known unknowns: A narrative review. Rev Med Virol 2023;33:e2398. [PMID: 36150052 DOI: 10.1002/rmv.2398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 206 |
Kaku CI, Starr TN, Zhou P, Dugan HL, Khalifé P, Song G, Champney ER, Mielcarz DW, Geoghegan JC, Burton DR, Andrabi R, Bloom JD, Walker LM. Evolution of antibody immunity following Omicron BA.1 breakthrough infection. bioRxiv 2022:2022. [PMID: 36172124 DOI: 10.1101/2022.09.21.508922] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 207 |
Arriaga-canon C, Contreras-espinosa L, Rebollar-vega R, Montiel-manríquez R, Cedro-tanda A, García-gordillo JA, Álvarez-gómez RM, Jiménez-trejo F, Castro-hernández C, Herrera LA. Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection. IJMS 2022;23:11058. [DOI: 10.3390/ijms231911058] [Reference Citation Analysis]
|
| 208 |
Zhang L, Chen H, Yang S, Zhao Y, Shen X, He X, Ye H, Wang D, Lou J, Wang Y, Wu S. The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses. Front Immunol 2022;13:990071. [DOI: 10.3389/fimmu.2022.990071] [Reference Citation Analysis]
|
| 209 |
Mai F, Volzke J, Reisinger EC, Müller-Hilke B. Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition. Vaccines (Basel) 2022;10:1563. [PMID: 36146641 DOI: 10.3390/vaccines10091563] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 210 |
Duan LJ, Jiang WG, Wang ZY, Yao L, Zhu KL, Meng QC, Wang BS, Li LB, Wang GL, Ma MJ. Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. iScience 2022;25:104886. [PMID: 35966041 DOI: 10.1016/j.isci.2022.104886] [Reference Citation Analysis]
|
| 211 |
Wagner A, Ohradanova-Repic A, Gebetsberger L, Tajti G, Kundi M, Stockinger H, Wiedermann U, Grabmeier-Pfistershammer K. Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule. Immunol Lett 2022;250:1-6. [PMID: 36108774 DOI: 10.1016/j.imlet.2022.09.001] [Reference Citation Analysis]
|
| 212 |
Savinkina A, Bilinski A, Fitzpatrick M, Paltiel AD, Rizvi Z, Salomon J, Thornhill T, Gonsalves G. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. BMJ Open 2022;12:e061752. [PMID: 36100306 DOI: 10.1136/bmjopen-2022-061752] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 213 |
Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, Ke FY, Su SC, Liang KH, Yuan JP, Chiang HL, Sun CP, Lee IJ, Li WS, Hsieh HP, Tao MH, Wu HC. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. J Biomed Sci 2022;29:68. [PMID: 36096815 DOI: 10.1186/s12929-022-00852-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 214 |
Venkatakrishnan AJ, Anand P, Lenehan PJ, Suratekar R, Raghunathan B, Niesen MJM, Soundararajan V. On the Origins of Omicron's Unique Spike Gene Insertion. Vaccines (Basel) 2022;10. [PMID: 36146586 DOI: 10.3390/vaccines10091509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 215 |
da Silva SJR, do Nascimento JCF, Germano Mendes RP, Guarines KM, Targino Alves da Silva C, da Silva PG, de Magalhães JJF, Vigar JRJ, Silva-Júnior A, Kohl A, Pardee K, Pena L. Two Years into the COVID-19 Pandemic: Lessons Learned. ACS Infect Dis 2022;8:1758-814. [PMID: 35940589 DOI: 10.1021/acsinfecdis.2c00204] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 216 |
Kuse N, Zhang Y, Chikata T, Nguyen HT, Oka S, Gatanaga H, Takiguchi M. Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. Nat Commun 2022;13:5251. [PMID: 36068240 DOI: 10.1038/s41467-022-32989-4] [Reference Citation Analysis]
|
| 217 |
Trombetta CM, Piccini G, Pierleoni G, Leonardi M, Dapporto F, Marchi S, Andreano E, Paciello I, Benincasa L, Lovreglio P, Buonvino N, Decaro N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Rappuoli R, Molesti E, Manenti A, Montomoli E. Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations. Commun Biol 2022;5:903. [PMID: 36056181 DOI: 10.1038/s42003-022-03849-0] [Reference Citation Analysis]
|
| 218 |
Bordi L, Sberna G, Piscioneri CN, Cocchiara RA, Miani A, Grammatico P, Mariani B, Parisi G. Longitudinal dynamics of SARS-CoV-2 anti-receptor binding domain IgG antibodies in a wide population of health care workers after BNT162b2 vaccination. Int J Infect Dis 2022;122:174-7. [PMID: 35661687 DOI: 10.1016/j.ijid.2022.05.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 219 |
Bruel T, Pinaud L, Tondeur L, Planas D, Staropoli I, Porrot F, Guivel-Benhassine F, Attia M, Pelleau S, Woudenberg T, Duru C, Koffi AD, Castelain S, Fernandes-Pellerin S, Jolly N, De Facci LP, Roux E, Ungeheuer MN, Van Der Werf S, White M, Schwartz O, Fontanet A. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study. EClinicalMedicine 2022;51:101576. [PMID: 35891947 DOI: 10.1016/j.eclinm.2022.101576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 220 |
Monge S, Rojas-benedicto A, Olmedo C, Mazagatos C, José Sierra M, Limia A, Martín-merino E, Larrauri A, Hernán MA, Moreno D, Méndez Díaz M, Huerta González I, Galmés Truyols A, Barreno Estévez A, García Velasco V, Rodríguez Recio MJ, Sacristán J, Martínez Marcos M, Pastor Villalba E, Macías Ortiz MJ, García Vallejo A, Sánchez Gómez A, García Pina R, Barricarte Gurea A, Sancho Martínez R, Ochoa EM, Vázquez Cantero M, Gómez Anés A, Pareja Megía MJ, Castán Y, Fonseca Álvarez MR, Salvà Fiol A, Sánchez Janáriz H, López Arce L, Cisneros Martín MÁ, Gibernau FJ, Fernandez Buey C, Villatoro Bongiorno K, Rubio García FJ, Santos Guerra F, Astray Mochales J, Francisco Verdu FJ, García Romero I, Oriza Bernal R, Gómez Pérez T, Hijano Villegas S, Román Soto S, Gómez-barroso D, Lapeña MF, Yagüe Galaup V, Alfaro Latorre M, Aguilera Guzmán M, Crespo Sánchez-eznarriaga B, Neira León M, Cívicos Villa N. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. The Lancet Infectious Diseases 2022;22:1313-20. [DOI: 10.1016/s1473-3099(22)00292-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 221 |
Gu Y, Duan J, Yang N, Yang Y, Zhao X. mRNA vaccines in the prevention and treatment of diseases. MedComm 2022;3. [DOI: 10.1002/mco2.167] [Reference Citation Analysis]
|
| 222 |
Xu A, Hong B, Lou F, Wang S, Li W, Shafqat A, An X, Zhao Y, Song L, Tong Y, Fan H. Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention. MedComm 2022;3. [DOI: 10.1002/mco2.172] [Reference Citation Analysis]
|
| 223 |
Mitra J, Kodavati M, Provasek VE, Rao KS, Mitra S, Hamilton DJ, Horner PJ, Vahidy FS, Britz GW, Kent TA, Hegde ML. SARS-CoV-2 and the central nervous system: Emerging insights into hemorrhage-associated neurological consequences and therapeutic considerations. Ageing Res Rev 2022;80:101687. [PMID: 35843590 DOI: 10.1016/j.arr.2022.101687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 224 |
Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Mongkolsapaya J, Wanlapakorn N, Honsawek S, Poovorawan Y. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. Int J Infect Dis 2022;122:793-801. [PMID: 35863731 DOI: 10.1016/j.ijid.2022.07.038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 225 |
Shi W, Wang L, Zhou T, Sastry M, Yang ES, Zhang Y, Chen M, Chen X, Choe M, Creanga A, Leung K, Olia AS, Pegu A, Rawi R, Schön A, Shen CH, Stancofski ED, Talana CA, Teng IT, Wang S, Corbett KS, Tsybovsky Y, Mascola JR, Kwong PD. Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. Structure 2022;30:1233-1244.e7. [PMID: 35841885 DOI: 10.1016/j.str.2022.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 226 |
Ghazvini K, Karbalaei M, Keikha M. Third booster vaccination and stopping the Omicron, a new variant of concern. Vacunas (English Edition) 2022;23:S103-S110. [DOI: 10.1016/j.vacune.2022.10.020] [Reference Citation Analysis]
|
| 227 |
Dias VMDCH, Oliveira AF, Marinho AKBB, Santos Ferreira CED, Domingues CEF, Fortaleza CMCB, Vidal CFDL, Carrilho CMDDM, Pinheiro DOBP, de Assis DB, Medeiros EA, Morejón KML, Weissmann L, Michelin L, Carneiro M, Nogueira MDSDP, de Oliveira PRD, Buralli RJ, Stucchi RSB, Lins RS, Costa SF, Chebabo A. COVID-19 and isolation: Risks and implications in the scenario of new variants. The Brazilian Journal of Infectious Diseases 2022;26:102703. [DOI: 10.1016/j.bjid.2022.102703] [Reference Citation Analysis]
|
| 228 |
Shukri AMA, Wang SM, Chia SL, Nawi SFAM. The SARS-CoV-2 Variants and their Impacts. J Pure Appl Microbiol 2022;16:1409-1424. [DOI: 10.22207/jpam.16.3.45] [Reference Citation Analysis]
|
| 229 |
Chantasrisawad N, Puthanakit T, Kornsitthikul K, Jaru-ampornpan P, Tawan M, Matapituk P, Sophonphan J, Anugulruengkitt S, Tangsathapornpong A, Katanyutanon A. Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster. Vaccine: X 2022. [DOI: 10.1016/j.jvacx.2022.100221] [Reference Citation Analysis]
|
| 230 |
Mirghaderi SP, Salimi M, Moharrami A, Hosseini-dolama R, Mirghaderi SR, Ghaderi M, Motififard M, Mortazavi SMJ. COVID-19 Infection Risk Following Elective Arthroplasty and Surgical Complications in COVID-19 Vaccinated Patients: A Multicenter Comparative Cohort Study. Arthroplasty Today 2022. [DOI: 10.1016/j.artd.2022.09.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 231 |
Stoddard M, Yuan L, Sarkar S, Mangalaganesh S, Nolan RP, Bottino D, Hather G, Hochberg NS, White LF, Chakravarty A. Heterogeneity in vaccinal immunity to SARS-CoV-2 can be addressed by a personalized booster strategy.. [DOI: 10.1101/2022.08.30.22279397] [Reference Citation Analysis]
|
| 232 |
Dapporto F, Marchi S, Leonardi M, Piu P, Lovreglio P, Decaro N, Buonvino N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Molesti E, Trombetta CM, Manenti A, Montomoli E, Passero LF. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. Journal of Immunology Research 2022;2022:1-9. [DOI: 10.1155/2022/4813199] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 233 |
Goh YS, Fong SW, Rouers A, Chang ZW, Tay MZ, Chavatte JM, Zhuo NZ, Hor PX, Loh CY, Huang Y, Wong JXE, Tan YJ, Lim DRX, Wang B, Ngoh EZX, Salleh SNM, Lee RTC, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES, Maurer-Stroh S, Wang CI, Leo YS, Lin RT, Ren EC, Lye DC, Young BE, Lim PL, Ng LF, Renia L; NCID Study Group., COVID‐19 Study Group. Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine. Clin Transl Immunology 2022;11:e1403. [PMID: 36016852 DOI: 10.1002/cti2.1403] [Reference Citation Analysis]
|
| 234 |
Yang L, Van Beek M, Wang Z, Muecksch F, Canis M, Hatziioannou T, Bieniasz PD, Nussenzweig MC, Chakraborty AK. Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain.. [DOI: 10.1101/2022.08.24.505127] [Reference Citation Analysis]
|
| 235 |
Neerukonda SN, Wang R, Vassell R, Baha H, Lusvarghi S, Liu S, Wang T, Weiss CD, Wang W. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. J Virol 2022;:e0114022. [PMID: 36000843 DOI: 10.1128/jvi.01140-22] [Reference Citation Analysis]
|
| 236 |
Walker MR, Podlekareva D, Johnsen S, Leerhøy B, Fougeroux C, Søgaard M, Salanti A, Ditlev SB, Barfod L. SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition. Viruses 2022;14:1861. [DOI: 10.3390/v14091861] [Reference Citation Analysis]
|
| 237 |
Babel N, Hugo C, Westhoff TH. Vaccination in patients with kidney failure: lessons from COVID-19. Nat Rev Nephrol 2022. [PMID: 35999285 DOI: 10.1038/s41581-022-00617-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 238 |
Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, Meschi S, Iannazzo R, Mazzotta V, Colavita F, Mastrorosa I, Cimini E, Mariotti D, De Pascale L, Marani A, Gallì P, Garbuglia A, Castilletti C, Puro V, Agrati C, Girardi E, Vaia F, Antinori A; HIV-VAC study group. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. Nat Commun 2022;13:4922. [PMID: 35995780 DOI: 10.1038/s41467-022-32263-7] [Reference Citation Analysis]
|
| 239 |
Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Mongkolsapaya J, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y. Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. Vaccine 2022:S0264-410X(22)01011-8. [PMID: 36031500 DOI: 10.1016/j.vaccine.2022.08.033] [Reference Citation Analysis]
|
| 240 |
Bowen JE, Addetia A, Dang HV, Stewart C, Brown JT, Sharkey WK, Sprouse KR, Walls AC, Mazzitelli IG, Logue JK, Franko NM, Czudnochowski N, Powell AE, Dellota E Jr, Ahmed K, Ansari AS, Cameroni E, Gori A, Bandera A, Posavad CM, Dan JM, Zhang Z, Weiskopf D, Sette A, Crotty S, Iqbal NT, Corti D, Geffner J, Snell G, Grifantini R, Chu HY, Veesler D. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science 2022;377:890-4. [PMID: 35857529 DOI: 10.1126/science.abq0203] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 68.0] [Reference Citation Analysis]
|
| 241 |
Campos DMO, Silva MKD, Barbosa ED, Leow CY, Fulco UL, Oliveira JIN. Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants. Comput Biol Chem 2022;101:107754. [PMID: 36037724 DOI: 10.1016/j.compbiolchem.2022.107754] [Reference Citation Analysis]
|
| 242 |
Hansen CL, Perofsky A, Burstein R, Famulare M, Boyle S, Prentice R, Marshall C, Mccormick BJ, Reinhart D, Capodanno B, Truong M, Schwabe-fry K, Kuchta K, Pfau B, Acker Z, Lee J, Sibley TR, Mcdermot E, Rodriguez-salas L, Stone J, Gamboa L, Han PD, Duchin JS, Waghmare A, Englund JA, Shendure J, Bedford T, Chu HY, Starita LM, Viboud C. Trends in risk factors and symptoms associated with SARS-CoV-2 and Rhinovirus test positivity in King County, Washington: A Test-Negative Design Study of the Greater Seattle Coronavirus Assessment Network.. [DOI: 10.1101/2022.08.12.22278203] [Reference Citation Analysis]
|
| 243 |
Castro JT, Azevedo P, Fumagalli MJ, Hojo-Souza NS, Salazar N, Almeida GG, Oliveira LI, Faustino L, Antonelli LR, Marçal TG, Augusto M, Valiate B, Fiorini A, Rattis B, Ramos SG, Piccin M, Nonato OC, Benevides L, Magalhães R, Cassaro B, Burle G, Doro D, Kalil J, Durigon E, Salazar A, Caballero O, Santiago H, Machado A, Silva JS, da Fonseca F, Fernandes AP, Teixeira SR, Gazzinelli RT. Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. Nat Commun 2022;13:4831. [PMID: 35977933 DOI: 10.1038/s41467-022-32547-y] [Reference Citation Analysis]
|
| 244 |
Arunachalam PS, Feng Y, Ashraf U, Hu M, Walls AC, Edara VV, Zarnitsyna VI, Aye PP, Golden N, Miranda MC, Green KWM, Threeton BM, Maness NJ, Beddingfield BJ, Bohm RP, Scheuermann SE, Goff K, Dufour J, Russell-Lodrigue K, Kepl E, Fiala B, Wrenn S, Ravichandran R, Ellis D, Carter L, Rogers K, Shirreff LM, Ferrell DE, Deb Adhikary NR, Fontenot J, Hammond HL, Frieman M, Grifoni A, Sette A, O'Hagan DT, Van Der Most R, Rappuoli R, Villinger F, Kleanthous H, Rappaport J, Suthar MS, Veesler D, Wang TT, King NP, Pulendran B. Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine. Sci Transl Med 2022;14:eabq4130. [PMID: 35976993 DOI: 10.1126/scitranslmed.abq4130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 245 |
Pascuale CA, Varese A, Ojeda DS, Pasinovich ME, Lopez L, Rossi AH, Rodriguez PE, Miglietta EA, Mazzitelli I, Di Diego Garcia F, Sanchez L, Rouco SO, Gonzalez Lopez Ledesma MM, Zurano JP, Mazzitelli B, Scruzzi G, Barbero P, Cardozo D, Gallego S, Borda M, Diaz M, Ridao F, Rosales AB, Bhon J, Talia JM, Diangelo ME, Lacaze MA, Aime B, Gutierrez SI, Ercole R, Toro R, Tau L, Delaplace L, Compagnucci MF, Sartori C, Desimone I, Echegoyen C, Velazquez P, Testa C, Hozbor D, Docena G, Laino CH, Kreplak N, Pifano M, Barbas G, Rearte A, Vizzotti C, Castelli JM, Geffner J, Gamarnik AV; Laboratorio SeVa Group., Ministerio de Salud de la Provincia de Córdoba Group., UNC-Fac. Cs. Médicas-InViV Group., Ministerio de Salud de la Provincia de La Rioja Group., Ministerio de Salud de la Provincia de San Luis Group., Universidad Nacional de La Plata Group., Ministerio de Salud de la Provincia de Buenos Aires Group. Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273. Cell Rep Med 2022;3:100706. [PMID: 35926505 DOI: 10.1016/j.xcrm.2022.100706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 246 |
Bates TA, Lu P, Kang YJ, Schoen D, Thornton M, Mcbride SK, Park C, Kim D, Messer WB, Curlin ME, Tafesse FG, Lu LL. BNT162b2 induced neutralizing and non-neutralizing antibody functions against SARSCoV-2 diminish with age.. [DOI: 10.1101/2022.08.12.22278726] [Reference Citation Analysis]
|
| 247 |
Shi J, Zheng J, Tai W, Verma AK, Zhang X, Geng Q, Wang G, Guan X, Malisheni MM, Odle AE, Zhang W, Li F, Perlman S, Du L. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. J Virol 2022;:e0011822. [PMID: 35972290 DOI: 10.1128/jvi.00118-22] [Reference Citation Analysis]
|
| 248 |
Cheng CC, Platen L, Christa C, Tellenbach M, Kappler V, Bester R, Liao BH, Holzmann-Littig C, Werz M, Schönhals E, Platen E, Eggerer P, Tréguer L, Küchle C, Schmaderer C, Heemann U, Renders L, Protzer U, Braunisch MC. Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients. Vaccines (Basel) 2022;10. [PMID: 36016216 DOI: 10.3390/vaccines10081328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 249 |
Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed Pharmacother 2022;154:113522. [PMID: 36030585 DOI: 10.1016/j.biopha.2022.113522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 250 |
Bruel T, Stéfic K, Nguyen Y, Toniutti D, Staropoli I, Porrot F, Guivel-benhassine F, Bolland W, Planas D, Hadjadj J, Handala L, Planchais C, Prot M, Simon-lorière E, André E, Baele G, Cuypers L, Mouthon L, Mouquet H, Buchrieser J, Sève A, Prazuck T, Maes P, Terrier B, Hocqueloux L, Schwartz O. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies.. [DOI: 10.1101/2022.08.12.22278699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 251 |
Karsten H, Cords L, Westphal T, Knapp M, Brehm TT, Hermanussen L, Omansen TF, Schmiedel S, Woost R, Ditt V, Peine S, Lütgehetmann M, Huber S, Ackermann C, Wittner M, Addo MM, Sette A, Sidney J, Schulze Zur Wiesch J. High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients. Clin Transl Immunology 2022;11:e1410. [PMID: 35957961 DOI: 10.1002/cti2.1410] [Reference Citation Analysis]
|
| 252 |
Moody R, Sonda S, Johnston FH, Smith KJ, Stephens N, Mcpherson M, Flanagan KL, Plebanski M. Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes. Front Immunol 2022;13:945021. [DOI: 10.3389/fimmu.2022.945021] [Reference Citation Analysis]
|
| 253 |
Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, Cele S, Lustig G, Amoako D, Wolter N, Samsunder N, Sivro A, San JE, Giandhari J, Tegally H, Pillay S, Naidoo Y, Mazibuko M, Miya Y, Ngcobo N, Manickchund N, Magula N, Karim QA, von Gottberg A, Abdool Karim SS, Hanekom W, Gosnell BI, Lessells RJ, de Oliveira T, Moosa MS, Sigal A; COMMIT-KZN Team. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat Commun 2022;13:4686. [PMID: 35948557 DOI: 10.1038/s41467-022-32396-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 254 |
Kreuzberger N, Hirsch C, Andreas M, Böhm L, Bröckelmann PJ, Di Cristanziano V, Golinski M, Hausinger RI, Mellinghoff S, Lange B, Lischetzki T, Kappler V, Mikolajewska A, Monsef I, Park YS, Piechotta V, Schmaderer C, Stegemann M, Vanshylla K, Weber F, Weibel S, Stephani C, Skoetz N. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database Syst Rev 2022;8:CD015021. [PMID: 35943061 DOI: 10.1002/14651858.CD015021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 255 |
Renia L, Goh YS, Rouers A, Le Bert N, Chia WN, Chavatte JM, Fong SW, Chang ZW, Zhuo NZ, Tay MZ, Chan YH, Tan CW, Yeo NK, Amrun SN, Huang Y, Wong JXE, Hor PX, Loh CY, Wang B, Ngoh EZX, Salleh SNM, Carissimo G, Dowla S, Lim AJ, Zhang J, Lim JME, Wang CI, Ding Y, Pada S, Sun LJ, Somani J, Lee ES, Ong DLS, Leo YS, MacAry PA, Lin RTP, Wang LF, Ren EC, Lye DC, Bertoletti A, Young BE, Ng LFP; SCOPE Cohort Study Group. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nat Commun 2022;13:4615. [PMID: 35941158 DOI: 10.1038/s41467-022-32312-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 256 |
Chakraborty C, Bhattacharya M, Sharma AR, Mallik B. Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int J Biol Macromol 2022;219:980-97. [PMID: 35952818 DOI: 10.1016/j.ijbiomac.2022.07.254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 257 |
Spreco A, Dahlström Ö, Jöud A, Nordvall D, Fagerström C, Blomqvist E, Gustafsson F, Hinkula J, Schön T, Timpka T. Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021-2022: A Naturalistic Case-Control Study in Sweden. Vaccines (Basel) 2022;10. [PMID: 36016162 DOI: 10.3390/vaccines10081273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 258 |
Nanishi E, McGrath ME, O'Meara TR, Barman S, Yu J, Wan H, Dillen CA, Menon M, Seo HS, Song K, Xu AZ, Sebastian L, Brook B, Bosco AN, Borriello F, Ernst RK, Barouch DH, Dhe-Paganon S, Levy O, Frieman MB, Dowling DJ. mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant. Commun Biol 2022;5:790. [PMID: 35933439 DOI: 10.1038/s42003-022-03765-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 259 |
Magawa S, Nii M, Maki S, Enomoto N, Takakura S, Kusaka N, Maegawa Y, Osato K, Tanaka H, Kondo E, Ikeda T. Comparative study of the usefulness of risk score assessment in the early stages of COVID ‐19 affected pregnancies: Omicron variant versus previous variants. J of Obstet and Gynaecol. [DOI: 10.1111/jog.15387] [Reference Citation Analysis]
|
| 260 |
Lin Y, Zhu J, Liu Z, Li C, Guo Y, Wang Y, Chen K. Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses. Front Immunol 2022;13:864278. [DOI: 10.3389/fimmu.2022.864278] [Reference Citation Analysis]
|
| 261 |
Hauser BM, Sangesland M, Lam EC, Feldman J, Balazs AB, Lingwood D, Schmidt AG. Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. Front Immunol 2022;13:902260. [PMID: 35990628 DOI: 10.3389/fimmu.2022.902260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 262 |
Hartley GE, Edwards ES, Varese N, Boo I, Aui PM, Bornheimer SJ, Hogarth PM, Drummer HE, O’hehir RE, van Zelm MC. Double-dose mRNA vaccination to SARS-CoV-2 progressively increases recognition of variants-of-concern by Spike RBD-specific memory B cells.. [DOI: 10.1101/2022.08.03.502703] [Reference Citation Analysis]
|
| 263 |
Yang W, Shaman JL. COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron). eLife 2022;11:e78933. [DOI: 10.7554/elife.78933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 264 |
Fujio K, Sung J, Nakatani S, Yamamoto K, Iwagami M, Fujimoto K, Shokirova H, Okumura Y, Akasaki Y, Nagino K, Midorikawa-inomata A, Hirosawa K, Miura M, Huang T, Morooka Y, Kuwahara M, Murakami A, Inomata T. Characteristics and Clinical Ocular Manifestations in Patients with Acute Corneal Graft Rejection after Receiving the COVID-19 Vaccine: A Systematic Review. JCM 2022;11:4500. [DOI: 10.3390/jcm11154500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 265 |
Hung JN, Kha Vo DN, Thanh Ho HP, Tsai MH. PEDOT:PSS in Solution Form Exhibits Strong Potential in Inhibiting SARS-CoV-2 Infection of the Host Cells by Targeting Viruses and Also the Host Cells. Biomacromolecules 2022. [PMID: 35918797 DOI: 10.1021/acs.biomac.2c00271] [Reference Citation Analysis]
|
| 266 |
Yuan M, Chen X, Zhu Y, Dong X, Liu Y, Qian Z, Ye L, Liu P. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. J Virol 2022;:e0077522. [PMID: 35916510 DOI: 10.1128/jvi.00775-22] [Reference Citation Analysis]
|
| 267 |
García-Pérez J, González-Pérez M, Castillo de la Osa M, Borobia AM, Castaño L, Bertrán MJ, Campins M, Portolés A, Lora D, Bermejo M, Conde P, Hernández-Gutierrez L, Carcas A, Arana-Arri E, Tortajada M, Fuentes I, Ascaso A, García-Morales MT, Erick de la Torre-Tarazona H, Arribas JR, Imaz-Ayo N, Mellado-Pau E, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Ochando J, Belda-Iniesta C, Frías J, Alcamí J, Pérez-Olmeda M; CombiVacS study Group. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. EClinicalMedicine 2022;50:101529. [PMID: 35795713 DOI: 10.1016/j.eclinm.2022.101529] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 268 |
Joung SY, Ebinger JE, Sun N, Liu Y, Wu M, Tang AB, Prostko JC, Frias EC, Stewart JL, Sobhani K, Cheng S. Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity. JAMA Netw Open 2022;5:e2227241. [PMID: 35976645 DOI: 10.1001/jamanetworkopen.2022.27241] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 269 |
Skarbinski J, Wood MS, Chervo TC, Schapiro JM, Elkin EP, Valice E, Amsden LB, Hsiao C, Quesenberry C, Corley DA, Kushi LH. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study. Lancet Reg Health Am 2022;12:100297. [PMID: 35756977 DOI: 10.1016/j.lana.2022.100297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 270 |
Lu B, Zhu K, Cui X, Yao L, Wang X, Wang G, Duan L, Qian A, Ma M. Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.109103] [Reference Citation Analysis]
|
| 271 |
Yuan J, Zhu Y, Zhao J, Li L, Zhu C, Chen M, Zhang Y, Shang Y. Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation Studies of the Molecular Targets and Mechanisms of ChuanKeZhi in the Treatment of COVID-19. Natural Product Communications 2022;17:1934578X2211169. [DOI: 10.1177/1934578x221116977] [Reference Citation Analysis]
|
| 272 |
Li J, Wu S, Guo X, Tang R, Huang B, Chen X, Chen Y, Hou L, Liu J, Zhong J, Pan H, Shi F, Xu X, Li Z, Zhang X, Cui L, Tan W, Chen W, Zhu F, Li J, Wu S, Guo X, Tang R, Huang B, Chen X, Chen Y, Hou L, Liu J, Zhong J, Pan H, Shi F, Xu X, Li Z, Zhang X, Cui L, Tan W, Chen W, Zhu F, Huang H, Gou J, Si W, Wang X, Zhao X, Zhu T. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. The Lancet Respiratory Medicine 2022;10:739-48. [DOI: 10.1016/s2213-2600(22)00087-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 273 |
Naaber P, Tserel L, Kangro K, Punapart M, Sepp E, Jürjenson V, Kärner J, Haljasmägi L, Haljasorg U, Kuusk M, Sankovski E, Planken A, Ustav M, Žusinaite E, Gerhold JM, Kisand K, Peterson P. Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine. Cell Reports Medicine 2022;3:100716. [DOI: 10.1016/j.xcrm.2022.100716] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 274 |
Holm M, Espenhain L, Glenthøj J, Schmidt LS, Nordly SB, Hartling UB, Nygaard U. Risk and Phenotype of Multisystem Inflammatory Syndrome in Vaccinated and Unvaccinated Danish Children Before and During the Omicron Wave. JAMA Pediatr 2022;176:821-3. [PMID: 35675054 DOI: 10.1001/jamapediatrics.2022.2206] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 275 |
Sohn YJ, Shin PJ, Oh WS, Kim E, Kim Y, Kim YK. Clinical Characteristics of Patients Who Contracted the SARS-CoV-2 Omicron Variant from an Outbreak in a Single Hospital. Yonsei Med J 2022;63:790-3. [PMID: 35914762 DOI: 10.3349/ymj.2022.63.8.790] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 276 |
Almendárez-Rodriguez C, Solis-Andrade KI, Govea-Alonso DO, Comas-Garcia M, Rosales-Mendoza S. Production and characterization of chimeric SARS-CoV-2 antigens based on the capsid protein of cowpea chlorotic mottle virus. Int J Biol Macromol 2022;213:1007-17. [PMID: 35690161 DOI: 10.1016/j.ijbiomac.2022.06.021] [Reference Citation Analysis]
|
| 277 |
Shanmugaraj B, Khorattanakulchai N, Panapitakkul C, Malla A, Im-Erbsin R, Inthawong M, Sunyakumthorn P, Hunsawong T, Klungthong C, Reed MC, Kemthong T, Suttisan N, Malaivijitnond S, Srimangkornkaew P, Klinkhamhom A, Manopwisedjaroen S, Thitithanyanont A, Taychakhoonavudh S, Phoolcharoen W. Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity. Vaccine 2022;40:4440-52. [PMID: 35697573 DOI: 10.1016/j.vaccine.2022.05.087] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 278 |
Gallego-Valcarce E, Shabaka A, Leon-Poo M, Gruss E, Acedo-Sanz JM, Cordón A, Cases-Corona C, Fernandez-Juarez G. Humoral Response Following Triple Dose of mRNA Vaccines Against SARS-CoV-2 in Hemodialysis Patients: Results After 1 Year of Follow-Up. Front Med (Lausanne) 2022;9:927546. [PMID: 35903310 DOI: 10.3389/fmed.2022.927546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 279 |
Zarębska-Michaluk D, Hu C, Brzdęk M, Flisiak R, Rzymski P. COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. Vaccines (Basel) 2022;10:1223. [PMID: 36016111 DOI: 10.3390/vaccines10081223] [Reference Citation Analysis]
|
| 280 |
Wang B, Xu J, Wu S, Zhang Z, Zhao Z, Zhang J, Fu L, Zai X, Wang Y, Zhang G, Chen Z, Chen Y, Sun H, Song X, Zhang J, Zhu L, Hou L, Chen W. Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. Signal Transduct Target Ther 2022;7:257. [PMID: 35906201 DOI: 10.1038/s41392-022-01065-0] [Reference Citation Analysis]
|
| 281 |
Wang WJ, Chen Y, Su WC, Liu YY, Shen WJ, Chang WC, Huang ST, Lin CW, Wang YC, Yang CS, Hou MH, Chou YC, Wu YC, Wang SC, Hung MC. Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2. J Food Biochem 2022;:e14354. [PMID: 35894128 DOI: 10.1111/jfbc.14354] [Reference Citation Analysis]
|
| 282 |
Li T, Luo KQ. Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. Int J Biol Sci 2022;18:4642-7. [PMID: 35874950 DOI: 10.7150/ijbs.72424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 283 |
Porru S, Monaco MGL, Spiteri G, Carta A, Pezzani MD, Lippi G, Gibellini D, Tacconelli E, Dalla Vecchia I, Sala E, Sansone E, De Palma G, Bonfanti C, Lombardo M, Terlenghi L, Pira E, Mansour I, Coggiola M, Ciocan C, Godono A, Tardon A, Rodriguez-suarez M, Fernandez-tardon G, Jimeno-demuth F, Castro-delgado R, Iglesias Cabo T, Scapellato ML, Liviero F, Moretto A, Mason P, Pavanello S, Volpin A, Vimercati L, Tafuri S, De Maria L, Sponselli S, Stefanizzi P, Caputi A, Gobba F, Modenese A, Casolari L, Garavini D, D’elia C, Mariani S, Filon FL, Cegolon L, Negro C, Ronchese F, Rui F, De Michieli P, Murgia N, Dell’omo M, Muzi G, Fiordi T, Gambelunghe A, Folletti I, Mates D, Calota VC, Neamtu A, Perseca O, Staicu CA, Voinoiu A, Fabiánová E, Bérešová J, Adamčáková ZK, Nedela R, Lesňáková A, Holčíková J, Boffetta P, Abedini M, Ditano G, Asafo SS, Visci G, Violante FS, Zunarelli C, Verlato G. SARS-CoV-2 Breakthrough Infections: Incidence and Risk Factors in a Large European Multicentric Cohort of Health Workers. Vaccines 2022;10:1193. [DOI: 10.3390/vaccines10081193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 284 |
Jia L, Zhou Y, Li S, Zhang Y, Yan D, Wang W, Zhang W, Wan Y, Qiu C. Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants. Front Immunol 2022;13:897879. [PMID: 35874751 DOI: 10.3389/fimmu.2022.897879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 285 |
Chen Z, Zhang Y, Wang M, Islam MS, Liao P, Hu Y, Chen X. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. Int J Biol Sci 2022;18:4629-41. [PMID: 35874952 DOI: 10.7150/ijbs.73583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 286 |
Liu M, Li Y. Advances in COVID-19 Vaccines and New Coronavirus Variants. Front Med (Lausanne) 2022;9:888631. [PMID: 35872788 DOI: 10.3389/fmed.2022.888631] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 287 |
Kim WJ, Choi SH, Park JY, Song JS, Chung JW, Choi ST. SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. Ann Rheum Dis 2022:annrheumdis-2022-222689. [PMID: 35878999 DOI: 10.1136/ard-2022-222689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 288 |
Seidel A, Zanoni M, Groß R, Krnavek D, Erdemci-evin S, von Maltitz P, Albers DPJ, Conzelmann C, Liu S, Weil T, Mayer B, Hoffmann M, Pöhlmann S, Beil A, Kroschel J, Kirchhoff F, Münch J, Müller JA. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. Front Immunol 2022;13:882918. [DOI: 10.3389/fimmu.2022.882918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 289 |
Tong X, Mcnamara R, Avendaño M, Serrano E, García-salum T, Pardo-roa C, Levican J, Poblete E, Salina E, Muñoz A, Riquelme A, Alter G, Medina R. Waning and boosting of functional humoral immunity to SARS-CoV-2.. [DOI: 10.1101/2022.07.22.501163] [Reference Citation Analysis]
|
| 290 |
Lasagna A, Piralla A, Secondino S, Sacchi P, Baldanti F, Bruno R, Pedrazzoli P. Case report: Successful outcome of COVID-19 in the context of autologous hematopoietic stem cell transplantation: The impact of the anti-SARS-CoV-2 vaccine and early remdesivir. Front Med 2022;9. [DOI: 10.3389/fmed.2022.944855] [Reference Citation Analysis]
|
| 291 |
Planas D, Staropoli I, Porot F, Guivel-benhassine F, Handala L, Prot M, Bolland W, Puech J, Péré H, Veyer D, Sève A, Etienne-simon-lorière, Bruel T, Prazuck T, Stefic K, Hocqueloux L, Schwartz O. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection.. [DOI: 10.1101/2022.07.22.22277885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 292 |
Meijers M, Ruchnewitz D, Łuksza M, Lässig M. Vaccination shapes evolutionary trajectories of SARS-CoV-2.. [DOI: 10.1101/2022.07.19.500637] [Reference Citation Analysis]
|
| 293 |
Schuh AJ, Satheshkumar PS, Dietz S, Bull-Otterson L, Charles M, Edens C, Jones JM, Bajema KL, Clarke KEN, McDonald LC, Patel S, Cuffe K, Thornburg NJ, Schiffer J, Chun K, Bastidas M, Fernando M, Petropoulos CJ, Wrin T, Cai S, Adcock D, Sesok-Pizzini D, Letovsky S, Fry AM, Hall AJ, Gundlapalli AV. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection. Microbiol Spectr 2022;:e0124722. [PMID: 35856710 DOI: 10.1128/spectrum.01247-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 294 |
Igari H, Asano H, Murata S, Yoshida T, Kawasaki K, Kageyama T, Ikeda K, Koshikawa H, Okuda Y, Urushihara M, Chiba H, Yahaba M, Taniguchi T, Matsushita K, Yoshino I, Yokote K, Nakajima H. Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan. J Infect Chemother 2022:S1341-321X(22)00206-9. [PMID: 35870791 DOI: 10.1016/j.jiac.2022.07.010] [Reference Citation Analysis]
|
| 295 |
Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev Med Virol 2022;:e2381. [PMID: 35856385 DOI: 10.1002/rmv.2381] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 296 |
Tang J, Zeng C, Cox TM, Li C, Son YM, Cheon IS, Wu Y, Behl S, Taylor JJ, Chakraborty R, Johnson AJ, Schiavo DN, Utz JP, Reisenauer JS, Midthun DE, Mullon JJ, Edell ES, Alameh MG, Borish L, Teague WG, Kaplan MH, Weissman D, Kern R, Hu H, Vassallo R, Liu SL, Sun J. Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination. Sci Immunol 2022;:eadd4853. [PMID: 35857583 DOI: 10.1126/sciimmunol.add4853] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 297 |
Wang Z, Li S, Huang B. Alveolar macrophages: Achilles' heel of SARS-CoV-2 infection. Signal Transduct Target Ther 2022;7:242. [PMID: 35853858 DOI: 10.1038/s41392-022-01106-8] [Reference Citation Analysis]
|
| 298 |
Camacho J, Giménez E, Albert E, Zulaica J, Álvarez-rodríguez B, Torres I, Rusu L, Burgos JS, Peiró S, Vanaclocha H, Limón R, Jesús Alcaraz M, Sánchez-payá J, Díez-domingo J, Comas I, Gonzáles-candelas F, Geller R, Navarro D. Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant.. [DOI: 10.1101/2022.07.19.22277747] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 299 |
Yuan M, Zhu X, He WT, Zhou P, Kaku CI, Capozzola T, Zhu CY, Yu X, Liu H, Yu W, Hua Y, Tien H, Peng L, Song G, Cottrell CA, Schief WR, Nemazee D, Walker LM, Andrabi R, Burton DR, Wilson IA. A broad and potent neutralization epitope in SARS-related coronaviruses. Proc Natl Acad Sci U S A 2022;119:e2205784119. [PMID: 35767670 DOI: 10.1073/pnas.2205784119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 300 |
Emmelot ME, Vos M, Boer MC, Rots NY, de Wit J, van Els CACM, Kaaijk P. Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals. Viruses 2022;14:1570. [DOI: 10.3390/v14071570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 301 |
Zhang Z, He Q, Zhao W, Li Y, Yang J, Hu Z, Chen X, Peng H, Fu Y, Chen L, Lu L. A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. JCM 2022;11:4164. [DOI: 10.3390/jcm11144164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 302 |
Kedl RM. An immunological autobiography: my year as a COVID-19 vaccine trial participant. NPJ Vaccines 2022;7:80. [PMID: 35851389 DOI: 10.1038/s41541-022-00502-z] [Reference Citation Analysis]
|
| 303 |
Stufano A, Buonvino N, Trombetta CM, Pontrelli D, Marchi S, Lobefaro G, De Benedictis L, Lorusso E, Carofiglio MT, Vasinioti VI, Montomoli E, Decaro N, Lovreglio P. COVID-19 Outbreak and BNT162b2 mRNA Vaccination Coverage in a Correctional Facility during Circulation of the SARS-CoV-2 Omicron BA.1 Variant in Italy. Vaccines (Basel) 2022;10. [PMID: 35891301 DOI: 10.3390/vaccines10071137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 304 |
Bhiman JN, Richardson SI, Lambson BE, Kgagudi P, Mzindle N, Kaldine H, Crowther C, Gray G, Bekker L, Shinde V, Bennett C, Glenn GM, Madhi S, Moore PL, Novavax trial clinical lead author group. Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages.. [DOI: 10.1101/2022.07.14.500148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 305 |
Lin FJ, Altman Doss AM, Davis-adams HG, Adams LJ, Hanson CH, Vanblargan LA, Liang C, Chen RE, Monroy JM, Wedner HJ, Kulczycki A, Mantia TL, O’shaughnessy CC, Raju S, Zhao FR, Rizzi E, Rigell CJ, Dy TB, Kau AL, Ren Z, Turner J, O’halloran JA, Presti RM, Fremont DH, Kendall PL, Ellebedy AH, Mudd PA, Diamond MS, Zimmerman O, Laidlaw BJ. SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients.. [DOI: 10.1101/2022.07.14.22276948] [Reference Citation Analysis]
|
| 306 |
Klastrup V, Stærke NB, Søgaard OS. Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization. Clin Microbiol Infect 2022:S1198-743X(22)00347-0. [PMID: 35843563 DOI: 10.1016/j.cmi.2022.06.032] [Reference Citation Analysis]
|
| 307 |
Aralis Z, Comer S, Ansorg H, Palmer C, Smith J, Feinstein S, Fitzgibbons LN, Arias C. Efficient Tracing of the SARS-CoV-2 Omicron Variants in Santa Barbara County Using a Rapid Quantitative Reverse Transcription PCR Assay.. [DOI: 10.1101/2022.07.12.22277554] [Reference Citation Analysis]
|
| 308 |
Moyo-gwete T, Madzivhandila M, Mkhize NN, Kgagudi P, Ayres F, Lambson BE, Manamela NP, Richardson SI, Makhado Z, van der Mescht MA, de Beer Z, de Villiers TR, Burgers WA, Ntusi NAB, Rossouw T, Ueckermann V, Boswell MT, Moore PL, Gallagher T. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. J Virol. [DOI: 10.1128/jvi.00558-22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 309 |
Torresi J, Edeling MA, Nolan T, Godfrey DI. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. Front Immunol 2022;13:914167. [DOI: 10.3389/fimmu.2022.914167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 310 |
da Silva ES, Kohnen M, Gilson G, Staub T, Arendt V, Hilger C, Servais J, Charpentier E, Domingues O, Snoeck CJ, Ollert M, Seguin-devaux C, Perez-bercoff D. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. IJMS 2022;23:7675. [DOI: 10.3390/ijms23147675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 311 |
Gil-manso S, Carbonell D, Pérez-fernández VA, López-esteban R, Alonso R, Muñoz P, Ochando J, Sánchez-arcilla I, Bellón JM, Correa-rocha R, Pion M. Cellular and Humoral Responses Follow-up for 8 Months after Vaccination with mRNA-Based Anti-SARS-CoV-2 Vaccines. Biomedicines 2022;10:1676. [DOI: 10.3390/biomedicines10071676] [Reference Citation Analysis]
|
| 312 |
Hyun H, Choi MJ, Heo JY, Seo YB, Nham E, Yoon JG, Seong H, Noh JY, Cheong HJ, Kim WJ, Choi JY, Lee YJ, Lee HW, Kim SS, Kim B, Song JY. Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study. J Korean Med Sci 2022;37:e210. [PMID: 35818701 DOI: 10.3346/jkms.2022.37.e210] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 313 |
Choi J, Lee YJ, Ko J, Kim S, Kim H, Lee HW, Jeong H, Kim T, Jang YG, Hong H, Kim M, Lee SE, Kim YG, Chung EJ, Lim H, Jang S, Kim K, Kim SS, Ahn JY, Choi JY, Kim YC, Park YS, Peck KR, Kim B. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules. Front Cell Infect Microbiol 2022;12:948014. [DOI: 10.3389/fcimb.2022.948014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 314 |
Wu S, Zhang L, Wang W. Screened α-Helix Peptide Inhibitor toward SARS-CoV-2 by Blocking a Prion-like Domain in the Receptor Binding Domain. Anal Chem 2022. [PMID: 35816660 DOI: 10.1021/acs.analchem.2c02223] [Reference Citation Analysis]
|
| 315 |
Cuffel A, Maylin S, Le Buanec H, Delaugerre C, Minier M, Bergerat D, Merandet M, Cassius C, Peffault de Latour R, Le Goff J, Socié G, Caillat-Zucman S, Robin M, Xhaard A. Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients. Vaccine 2022:S0264-410X(22)00857-X. [PMID: 35840470 DOI: 10.1016/j.vaccine.2022.07.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 316 |
Kasuga I, Gamo S, Yokoe Y, Sugiyama T, Tokura M, Noguchi M, Okayama M, Takeda Y, Sato T, Mori M, Ohtsubo O. Antibody levels over time against the novel coronavirus and incidence of adverse reaction after vaccination. Health evaluation and promotion 2022;49:462-469. [DOI: 10.7143/jhep.49.462] [Reference Citation Analysis]
|
| 317 |
Assavavongwaikit P, Chantasrisawad N, Himananto O, Phasomsap C, Klawaja P, Cartledge S, Nadsasarn R, Jupimai T, Kawichai S, Anugulruengkitt S, Puthanakit T, On Behalf Of The Study Team. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents. Vaccines (Basel) 2022;10:1098. [PMID: 35891264 DOI: 10.3390/vaccines10071098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 318 |
Nguyen DC, Lamothe PA, Woodruff MC, Saini AS, Faliti CE, Sanz I, Lee FE. COVID-19 and plasma cells: Is there long-lived protection? Immunol Rev 2022. [PMID: 35801537 DOI: 10.1111/imr.13115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 319 |
de Oliveira Campos DM, da Silva MK, Silva de Oliveira CB, Fulco UL, Nobre Oliveira JI. Effectiveness of COVID-19 vaccines against Omicron variant. Immunotherapy 2022. [PMID: 35787018 DOI: 10.2217/imt-2022-0077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 320 |
Bekliz M, Adea K, Vetter P, Eberhardt CS, Hosszu-Fellous K, Vu DL, Puhach O, Essaidi-Laziosi M, Waldvogel-Abramowski S, Stephan C, L'Huillier AG, Siegrist CA, Didierlaurent AM, Kaiser L, Meyer B, Eckerle I. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nat Commun 2022;13:3840. [PMID: 35787633 DOI: 10.1038/s41467-022-31556-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 321 |
Ghazvini K, Karbalaei M, Keikha M. Third booster vaccination and stopping the Omicron, a new variant of concern. Vacunas 2022. [DOI: 10.1016/j.vacun.2022.05.005] [Reference Citation Analysis]
|
| 322 |
Mengist HM, Kombe Kombe JA, Jin T. Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. IDR 2022;Volume 15:4013-27. [DOI: 10.2147/idr.s366437] [Reference Citation Analysis]
|
| 323 |
Cho A, Muecksch F, Wang Z, Ben Tanfous T, DaSilva J, Raspe R, Johnson B, Bednarski E, Ramos V, Schaefer-Babajew D, Shimeliovich I, Dizon JP, Yao KH, Schmidt F, Millard KG, Turroja M, Jankovic M, Oliveira TY, Gazumyan A, Gaebler C, Caskey M, Hatziioannou T, Bieniasz PD, Nussenzweig MC. Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. J Exp Med 2022;219. [PMID: 35776090 DOI: 10.1084/jem.20220732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 324 |
Noh JY, Cheong HJ, Kim WJ, Choi J, Lee HW, Kim SS, Kim B, Song JY. Robust neutralizing antibody responses after single-dose BNT162b2 vaccination at long intervals from prior SARS-CoV-2 infection and ceiling effect with repeated vaccination. Journal of Infection 2022. [DOI: 10.1016/j.jinf.2022.07.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 325 |
Attias P, Azzaoui I, El Karoui K, de La Selle A, Sokal A, Chappert P, Grimbert P, Fernandez I, Bouvier M, Samson C, Dahmane D, Rieu P, Nizard P, Fourati S, Sakhi H, Mahévas M; Mondor NephroCov Study Group. Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2-Recovered Dialysis Patients. Clin J Am Soc Nephrol 2022:CJN. [PMID: 35764393 DOI: 10.2215/CJN.00830122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 326 |
Atyeo CG, Shook LL, Brigida S, De Guzman RM, Demidkin S, Muir C, Akinwunmi B, Baez AM, Sheehan ML, McSweeney E, Burns MD, Nayak R, Kumar MK, Patel CD, Fialkowski A, Cvrk D, Goldfarb IT, Yonker LM, Fasano A, Balazs AB, Elovitz MA, Gray KJ, Alter G, Edlow AG. Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms. Nat Commun 2022;13:3571. [PMID: 35764643 DOI: 10.1038/s41467-022-31169-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 327 |
Dangi T, Sanchez S, Lew MH, Visvabharathy L, Richner J, Koralnik IJ, Penaloza-MacMaster P. Pre-existing immunity modulates responses to mRNA boosters. bioRxiv 2022:2022. [PMID: 35794898 DOI: 10.1101/2022.06.27.497248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 328 |
Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduct Target Ther 2022;7:202. [PMID: 35764603 DOI: 10.1038/s41392-022-01039-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 329 |
Ohki Y, Kawabe M, Yamamoto I, Katsumata H, Nakada Y, Kobayashi A, Urabe F, Miki J, Yamada H, Kimura T, Matsuo N, Tanno Y, Horino T, Ohkido I, Yamamoto H, Yokoo T. Long-Term Humoral Response After a Second Dose of SARS-CoV-2 mRNA Vaccine in Japanese Kidney Transplant Recipients. Front Microbiol 2022;13:922042. [PMID: 35756063 DOI: 10.3389/fmicb.2022.922042] [Reference Citation Analysis]
|
| 330 |
Kozakai R, Suzuki S, Fukami K, Hoshi K, Izumi Y, Takahashi S. Assessment of antibody titer and side effects after third doses of COVID-19 mRNA vaccination in healthy volunteers. LaboratoriumsMedizin 2022;46:171-177. [DOI: 10.1515/labmed-2022-0057] [Reference Citation Analysis]
|
| 331 |
Meggiolaro A, Schepisi MS, Farina S, Castagna C, Mammone A, Siddu A, Stefanelli P, Boccia S, Rezza G. Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalisation: a systematic review and meta-analysis.. [DOI: 10.1101/2022.06.23.22276809] [Reference Citation Analysis]
|
| 332 |
Cheng C, Platen L, Christa C, Tellenbach M, Kappler V, Bester R, Liao B, Holzmann-littig C, Werz M, Schönhals E, Platen E, Eggerer P, Tréguer L, Küchle C, Schmaderer C, Heemann U, Renders L, Protzer U, Braunisch MC. Improved SARS-CoV-2 neutralization of Delta and Omicron variants of concern after fourth vaccination in hemodialysis patients.. [DOI: 10.1101/2022.06.22.22276787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 333 |
Yamamoto S, Matsuda K, Maeda K, Oshiro Y, Inamura N, Mizoue T, Konishi M, Takeuchi JS, Horii K, Ozeki M, Sugiyama H, Mitsuya H, Sugiura W, Ohmagari N. SARS-CoV-2 breakthrough infection during the Delta-dominant epidemic and neutralizing antibodies against Omicron in comparison with the third dose of BNT162b2: a matched analysis.. [DOI: 10.1101/2022.06.21.22276682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 334 |
Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer 2022;10. [PMID: 35732350 DOI: 10.1136/jitc-2022-004766] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 335 |
Bazargan M, Elahi R, Esmaeilzadeh A. OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. J Gene Med 2022;:e3435. [PMID: 35726542 DOI: 10.1002/jgm.3435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 336 |
Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Shinoda M, Sato T, Ishii N, Igarashi K, Ariyasu M. Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine 2022:S0264-410X(22)00781-2. [PMID: 35738968 DOI: 10.1016/j.vaccine.2022.06.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 337 |
Zipfel CM, Paul P, Gowler CD, Reddy SC, Stone ND, Jacobs Slifka K, Slayton RB. Modeling the Effectiveness of Healthcare Personnel Reactive Testing and Screening for the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant Within Nursing Homes. Clin Infect Dis 2022;75:S225-30. [PMID: 35724112 DOI: 10.1093/cid/ciac505] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 338 |
LeMaster C, Geanes ES, Fraley ER, Selvarangan R, Bradley T. Vaccination after SARS-CoV-2 infection increased antibody avidity against the Omicron variant compared to vaccination alone. J Infect Dis 2022:jiac247. [PMID: 35714328 DOI: 10.1093/infdis/jiac247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 339 |
Mauro D, Ciancio A, Di Vico C, Passariello L, Rozza G, Pasquale MD, Pantano I, Cannistrà C, Bucci L, Scriffignano S, Riccio F, Patrone M, Scalise G, Ruscitti P, Montemurro MV, Giordano A, Vietri MT, Ciccia F. Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort. Front Immunol 2022;13:901055. [DOI: 10.3389/fimmu.2022.901055] [Reference Citation Analysis]
|
| 340 |
Saberiyan M, Karimi E, Khademi Z, Movahhed P, Safi A, Mehri-Ghahfarrokhi A. SARS-CoV-2: phenotype, genotype, and characterization of different variants. Cell Mol Biol Lett 2022;27:50. [PMID: 35715738 DOI: 10.1186/s11658-022-00352-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 341 |
Poh XY, Lee IR, Lim C, Teo J, Rao S, Chia PY, Ong SWX, Lee TH, Lin RJH, Ng LFP, Ren EC, Lin RTP, Wang LF, Renia L, Lye DC, Young BE. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]. Trials 2022;23:498. [PMID: 35710572 DOI: 10.1186/s13063-022-06345-2] [Reference Citation Analysis]
|
| 342 |
Chuang C, Huang C, Huang C, Chen Y, Kung Y, Chen C, Chuang T, Liu C, Huang P, Yang S, Gu P, Shih S, Chiu C. Titers and capacity of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: a single-blinded, randomized clinical trial.. [DOI: 10.1101/2022.06.14.22276236] [Reference Citation Analysis]
|
| 343 |
Zhang Y, Tan W, Lou Z, Huang B, Zhou W, Zhao Y, Zhang J, Liang H, Li N, Zhu X, Ding L, Guo Y, He Z, He Y, Wang Z, Ma B, Ma M, Zhao S, Chang Z, Zhao X, Zheng X, Wu G, Wang H, Yang X. Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants. Vaccines (Basel) 2022;10:956. [PMID: 35746564 DOI: 10.3390/vaccines10060956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 344 |
Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, Iida S, Ainai A, Ozono S, Hemmi T, Hirata Y, Moriyama S, Kotaki R, Kinoshita H, Yamada S, Shinkai M, Fukushi S, Takahashi Y, Suzuki T. Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection.. [DOI: 10.1101/2022.06.15.22276432] [Reference Citation Analysis]
|
| 345 |
Saheli M, Khoramipour K, Vosough M, Piryaei A, Rahmati M, Suzuki K. Athletes' Mesenchymal Stem Cells Could Be the Best Choice for Cell Therapy in Omicron-Infected Patients. Cells 2022;11:1926. [PMID: 35741055 DOI: 10.3390/cells11121926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 346 |
Kolanthai E, Neal CJ, Kumar U, Fu Y, Seal S. Antiviral nanopharmaceuticals: Engineered surface interactions and virus-selective activity. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2022;:e1823. [PMID: 35697665 DOI: 10.1002/wnan.1823] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 347 |
Firinu D, Fenu G, Sanna G, Costanzo GA, Perra A, Campagna M, Littera R, Locci C, Marongiu A, Cappai R, Melis M, Orrù G, Del Giacco S, Coghe F, Manzin A, Chessa L. Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy. J Autoimmun 2022;131:102848. [PMID: 35714496 DOI: 10.1016/j.jaut.2022.102848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 348 |
Kawasuji H, Morinaga Y, Tani H, Saga Y, Kaneda M, Murai Y, Ueno A, Miyajima Y, Fukui Y, Nagaoka K, Ono C, Matsuura Y, Niimi H, Yamamoto Y. Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population. J Infect Chemother 2022:S1341-321X(22)00158-1. [PMID: 35691864 DOI: 10.1016/j.jiac.2022.05.009] [Reference Citation Analysis]
|
| 349 |
Soleimanian S, Alyasin S, Sepahi N, Ghahramani Z, Kanannejad Z, Yaghobi R, Karimi MH. An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. Front Immunol 2022;13:884879. [PMID: 35669767 DOI: 10.3389/fimmu.2022.884879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 350 |
Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, Kobiyama K, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Kuramochi J, Seki M, Fujiki R, Kaneda A, Shimada T, Nakada TA, Sakao S, Suzuki T, Ueno T, Takaori-Kondo A, Ishii KJ, Schreiber G, Sawa H, Saito A, Irie T, Tanaka S, Matsuno K, Fukuhara T, Ikeda T, Sato K; Genotype to Phenotype Japan (G2P-Japan) Consortium. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell 2022;185:2103-2115.e19. [PMID: 35568035 DOI: 10.1016/j.cell.2022.04.035] [Cited by in Crossref: 56] [Cited by in F6Publishing: 80] [Article Influence: 56.0] [Reference Citation Analysis]
|
| 351 |
Richardson SI, Madzorera VS, Spencer H, Manamela NP, van der Mescht MA, Lambson BE, Oosthuysen B, Ayres F, Makhado Z, Moyo-Gwete T, Mzindle N, Motlou T, Strydom A, Mendes A, Tegally H, de Beer Z, Roma de Villiers T, Bodenstein A, van den Berg G, Venter M, de Oliviera T, Ueckermann V, Rossouw TM, Boswell MT, Moore PL. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe 2022;30:880-886.e4. [PMID: 35436444 DOI: 10.1016/j.chom.2022.03.029] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 33.0] [Reference Citation Analysis]
|
| 352 |
Zhou H, Møhlenberg M, Thakor JC, Tuli HS, Wang P, Assaraf YG, Dhama K, Jiang S. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. Clin Microbiol Rev. [DOI: 10.1128/cmr.00014-22] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 353 |
Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Honsawek S, Poovorawan Y. Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination.. [DOI: 10.1101/2022.06.05.22276016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 354 |
Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nat Commun 2022;13:3250. [PMID: 35668119 DOI: 10.1038/s41467-022-30878-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 355 |
Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev 2022;310:6-26. [PMID: 35661178 DOI: 10.1111/imr.13091] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 356 |
Neerukonda SN, Wang R, Vassell R, Baha H, Lusvarghi S, Liu S, Wang T, Weiss CD, Wang W. Characterization of entry pathways, species-specific ACE2 residues determining entry, and antibody neutralization evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 variants.. [DOI: 10.1101/2022.06.01.494385] [Reference Citation Analysis]
|
| 357 |
Vadrevu KM, Reddy S, Jogdand H, Ganneru B, Mirza N, Tripathy VN, Singh C, Khalatkar V, Prasanth S, Rai S, Ella R, Blackwelder W, Prasad S, Ella K. Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study. The Lancet Infectious Diseases 2022. [DOI: 10.1016/s1473-3099(22)00307-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 358 |
Canaday DH, Oyebanji OA, White E, Keresztesy D, Payne M, Wilk D, Carias L, Aung H, St Denis K, Sheehan ML, Berry SD, Cameron CM, Cameron MJ, Wilson BM, Balazs AB, King CL, Gravenstein S. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents. EBioMedicine 2022;80:104066. [PMID: 35605428 DOI: 10.1016/j.ebiom.2022.104066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 359 |
Prendki V, Tiseo G, Falcone M; ESCMID Study Group for Infections in the Elderly (ESGIE). Caring for older adults during the COVID-19 pandemic. Clin Microbiol Infect 2022;28:785-91. [PMID: 35283306 DOI: 10.1016/j.cmi.2022.02.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 360 |
Li Y, Li JZ. SARS-CoV-2 Virology. Infect Dis Clin North Am 2022;36:251-65. [PMID: 35636899 DOI: 10.1016/j.idc.2022.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 361 |
Islam F, Dhawan M, Nafady MH, Emran TB, Mitra S, Choudhary OP, Akter A. Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions. Annals of Medicine and Surgery 2022;78:103737. [DOI: 10.1016/j.amsu.2022.103737] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 362 |
Alidjinou EK, Demaret J, Corroyer-simovic B, Labreuche J, Goffard A, Trauet J, Lupau D, Miczek S, Vuotto F, Dendooven A, Huvent-grelle D, Podvin J, Dreuil D, Faure K, Deplanque D, Bocket L, Duhamel A, Sobaszek A, Hober D, Hisbergues M, Puisieux F, Autran B, Yazdanpanah Y, Labalette M, Lefèvre G. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years. The Lancet Regional Health - Europe 2022;17:100385. [DOI: 10.1016/j.lanepe.2022.100385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 363 |
Chang MR, Ke H, Coherd CD, Wang Y, Mashima K, Kastrunes GM, Huang CY, Marasco WA. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants. EBioMedicine 2022;80:104025. [PMID: 35533497 DOI: 10.1016/j.ebiom.2022.104025] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 364 |
Pinato DJ, Aguilar-company J, Ferrante D, Hanbury G, Bower M, Salazar R, Mirallas O, Sureda A, Plaja A, Cucurull M, Mesia R, Townsend S, Jackson A, Dalla Pria A, Newsom-davis T, Handford J, Sita-lumsden A, Apthorp E, Vincenzi B, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Sinclair A, Bawany S, Khalique S, Rossi S, Rogers L, Murphy C, Belessiotis K, Carmona-garcía MC, Sharkey R, García-illescas D, Rizzo G, Perachino M, Saoudi-gonzalez N, Doonga K, Fox L, Roldán E, Gaidano G, Ruiz-camps I, Bruna R, Patriarca A, Martinez-vila C, Cantini L, Zambelli A, Giusti R, Mazzoni F, Caliman E, Santoro A, Grosso F, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tucci M, Libertini M, Grisanti S, Mukherjee U, Diamantis N, Fusco V, Generali D, Provenzano S, Gennari A, Tabernero J, Cortellini A, Evans JS, Swallow J, Chung C, Patel M, Dettorre G, Ottaviani D, Chowdhury A, Merry E, Chopra N, Lee AJ, Sng CC, Yu T, Shawe-taylor M, Bain HD, Wong YNS, Galazi M, Benafif S, Dileo P, Earnshaw I, Patel G, Wu A, Soosaipillai G, Cooper L, Andaleeb R, Dolly S, Apthorp E, Srikandarajah K, Jones E, Van Hemelrijck M, Moss C, Russell B, Chester J, Loizidou A, Piccart M, Cruz CA, Reyes R, Segui E, Marco-hernández J, Viladot M, Eremiev S, Fort-culillas R, Garcia I, Liñan R, Roqué Lloveras A, Harbeck N, Wuerstlein R, Henze F, Mahner S, Felip E, Pous A, D'avanzo F, Scotti L, Krengli M, Marrari A, Delfanti S, Maconi A, Betti M, Tonini G, Di Fazio GR, Tondini C, Chiudinelli L, Franchi M, Libertini M, Bertulli R, Baggi A, Tovazzi V, Ficorella C, Porzio G, Saponara M, Filetti M, Zoratto F, Paoloni F, Berardi R, Guida A, Bracarda S, Iglesias M, Sanchez de Torre A, Tagliamento M, Colomba E, Pommeret F. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00273-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 365 |
Desmecht S, Tashkeev A, El Moussaoui M, Marechal N, Perée H, Tokunaga Y, Fombellida-lopez C, Polese B, Legrand C, Wéry M, Mni M, Fouillien N, Toussaint F, Gillet L, Bureau F, Lutteri L, Hayette M, Moutschen M, Meuris C, Vermeersch P, Desmecht D, Rahmouni S, Darcis G. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Front Immunol 2022;13:863554. [DOI: 10.3389/fimmu.2022.863554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 366 |
Bonura F, Genovese D, Amodio E, Calamusa G, Sanfilippo GL, Cacioppo F, Giammanco GM, De Grazia S, Ferraro D. Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination. Vaccines 2022;10:874. [DOI: 10.3390/vaccines10060874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 367 |
Seo YB, Ko A, Shin D, Kim J, Suh YS, Na J, Ryu JI, Sung YC. Potentiating the cross-reactive IFN-γ T cell and polyfunctional T cell responses by heterologous GX-19N DNA booster in mice primed with either a COVID-19 mRNA vaccine or inactivated vaccine.. [DOI: 10.1101/2022.05.29.493923] [Reference Citation Analysis]
|
| 368 |
Kontopoulou K, Nakas CT, Papazisis G. Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece. Vaccines 2022;10:876. [DOI: 10.3390/vaccines10060876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 369 |
López-cortés GI, Palacios-pérez M, Veledíaz HF, Hernández-aguilar M, López-hernández GR, Zamudio GS, José MV. The Spike Protein of SARS-CoV-2 Is Adapting Because of Selective Pressures. Vaccines 2022;10:864. [DOI: 10.3390/vaccines10060864] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 370 |
Paschold L, Klee B, Gottschick C, Willscher E, Diexer S, Schultheiß C, Simnica D, Sedding D, Girndt M, Gekle M, Mikolajczyk R, Binder M. Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination. Front Immunol 2022;13:876306. [PMID: 35615365 DOI: 10.3389/fimmu.2022.876306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 371 |
Goel RR, Painter MM, Lundgreen KA, Apostolidis SA, Baxter AE, Giles JR, Mathew D, Pattekar A, Reynaldi A, Khoury DS, Gouma S, Hicks P, Dysinger S, Hicks A, Sharma H, Herring S, Korte S, Kc W, Oldridge DA, Erickson RI, Weirick ME, McAllister CM, Awofolaju M, Tanenbaum N, Dougherty J, Long S, D'Andrea K, Hamilton JT, McLaughlin M, Williams JC, Adamski S, Kuthuru O, Drapeau EM, Davenport MP, Hensley SE, Bates P, Greenplate AR, Wherry EJ. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell 2022;185:1875-1887.e8. [PMID: 35523182 DOI: 10.1016/j.cell.2022.04.009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 70.0] [Reference Citation Analysis]
|
| 372 |
Robinson PG, Murray A, Watson M, Close G, Kinane DF. Risk assessment and implementation of risk reduction measures is not associated with increased transmission of SARS-CoV-2 compared with standard isolation at professional golf events. BMJ Open Sport Exerc Med 2022;8:e001324. [PMID: 35601139 DOI: 10.1136/bmjsem-2022-001324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 373 |
Celik I, Abdellattif MH, Tallei TE. An Insight Based on Computational Analysis of the Interaction between the Receptor-Binding Domain of the Omicron Variants and Human Angiotensin-Converting Enzyme 2. Biology (Basel) 2022;11:797. [PMID: 35625526 DOI: 10.3390/biology11050797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 374 |
Wong G, Rowlandson M, Sabanayagam D, Ginn AN, Kable K, Sciberras F, Au E, Draper J, Arnott A, Sintchenko V, Dwyer DE, Chen SCA, Kok J. COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes. Transplantation 2022. [PMID: 35675438 DOI: 10.1097/TP.0000000000004203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 375 |
Brazete C, Pinto M, Sá L, Aguiar A, Alves F, Duarte R. Evaluation of the Real-World Effectiveness of Vaccines against COVID-19 at a Local Level: Protocol for a Test-Negative Case-Control Study. Vaccines (Basel) 2022;10:822. [PMID: 35632578 DOI: 10.3390/vaccines10050822] [Reference Citation Analysis]
|
| 376 |
Lapa D, Grousova DM, Matusali G, Meschi S, Colavita F, Bettini A, Gramigna G, Francalancia M, Garbuglia AR, Girardi E, Puro V, Antinori A, Kovyrshina AV, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Gushchin VA, Logunov DY, Naroditsky BS, Vaia F, Gintsburg AL. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. Vaccines 2022;10:817. [DOI: 10.3390/vaccines10050817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 377 |
Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, Song X. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022;7:166. [PMID: 35597779 DOI: 10.1038/s41392-022-01007-w] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 33.0] [Reference Citation Analysis]
|
| 378 |
Atyeo C, Shook LL, Nziza N, Deriso EA, Muir C, Baez AM, Lima RS, Demidkin S, Brigida S, De Guzman RM, Burns MD, Balazs AB, Fasano A, Yonker LM, Gray KJ, Alter G, Edlow AG. COVID-19 booster dose antibody response in pregnant, lactating, and nonpregnant women.. [DOI: 10.1101/2022.05.17.22275154] [Reference Citation Analysis]
|
| 379 |
Eberhardt AT, Simoncini M, Piña C, Galoppo G, Parachú-marco V, Racca A, Arce S, Viotto E, Facelli F, Valli F, Botto C, Scarpa L, Junges C, Palavecino C, Beccaria C, Sklar D, Mingo G, Genolet A, de Toro MM, Aimar H, Marignac V, Bossio JC, Armando G, Fernández H, Beldomenico PM. Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina.. [DOI: 10.1101/2022.05.18.22275138] [Reference Citation Analysis]
|
| 380 |
Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, Pannaraj PS, Irby K, Bline KE, Maddux AB, Nofziger RA, Cameron MA, Walker TC, Schwartz SP, Mack EH, Smallcomb L, Schuster JE, Hobbs CV, Kamidani S, Tarquinio KM, Bradford TT, Levy ER, Chiotos K, Bhumbra SS, Cvijanovich NZ, Heidemann SM, Cullimore ML, Gertz SJ, Coates BM, Staat MA, Zinter MS, Kong M, Chatani BM, Hume JR, Typpo KV, Maamari M, Flori HR, Tenforde MW, Zambrano LD, Campbell AP, Patel MM, Randolph AG; Overcoming Covid-19 Investigators. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. N Engl J Med 2022;386:1899-909. [PMID: 35353976 DOI: 10.1056/NEJMoa2202826] [Cited by in Crossref: 104] [Cited by in F6Publishing: 56] [Article Influence: 104.0] [Reference Citation Analysis]
|
| 381 |
Huntington KE, Carlsen L, So E, Piesche M, Liang O, El-deiry WS. Integrin/TGF-β1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity. Pharmaceuticals 2022;15:618. [DOI: 10.3390/ph15050618] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 382 |
Lee YJ, Shirkey JD, Park J, Bisht K, Cowan AJ. An Overview of Antiviral Peptides and Rational Biodesign Considerations. BioDesign Research 2022;2022:1-19. [DOI: 10.34133/2022/9898241] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 383 |
Lei H, Alu A, Yang J, Ren W, He C, Lan T, He X, Yang L, Li J, Wang Z, Song X, Wang W, Lu G, Wei X. Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants. Signal Transduct Target Ther 2022;7:159. [PMID: 35581200 DOI: 10.1038/s41392-022-01002-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 384 |
Jung MK, Jeong SD, Noh JY, Kim DU, Jung S, Song JY, Jeong HW, Park SH, Shin EC. BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality. Nat Microbiol 2022. [PMID: 35577972 DOI: 10.1038/s41564-022-01123-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 385 |
Gallian P, Amroun A, Laperche S, Le Cam S, Brisbarre N, Malard L, Nurtop E, Isnard C, Richard P, Morel P, Tiberghien P, de Lamballerie X. Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant. Vox Sang 2022. [PMID: 35577569 DOI: 10.1111/vox.13279] [Reference Citation Analysis]
|
| 386 |
Rodríguez-Mora S, Corona M, Torres M, Casado-Fernández G, García-Pérez J, Ramos-Martín F, Vigón L, Manzanares M, Mateos E, Martín-Moro F, Zurdo-Castronuño A, Murciano-Antón MA, Alcamí J, Pérez-Olmeda M, López-Jiménez J, García-Gutiérrez V, Coiras M, On Behalf Of The Multidisciplinary Group Of Study Of Covid-Mgs-Covid. Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19. J Clin Med 2022;11:2803. [PMID: 35628927 DOI: 10.3390/jcm11102803] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 387 |
Yuan M, Chen X, Zhu Y, Dong X, Liu Y, Qian Z, Ye L, Liu P. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.. [DOI: 10.1101/2022.05.11.491588] [Reference Citation Analysis]
|
| 388 |
Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H, Zhang X, Tian F, Wang C, Xiao X, Dong X, Guo L, Lu S, Yang C, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Yisimayi A, Liu S, Huang W, Cao Y, Wang Y, Zhou Z, Peng X, Wang J, Xie XS, Wei W. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 2022;185:1728-1744.e16. [PMID: 35460644 DOI: 10.1016/j.cell.2022.03.044] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 69.0] [Reference Citation Analysis]
|
| 389 |
Alcendor DJ, Matthews-juarez P, Smoot D, Hildreth JEK, Lamar K, Tabatabai M, Wilus D, Juarez PD. Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. Vaccines 2022;10:755. [DOI: 10.3390/vaccines10050755] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 390 |
Rzymski P, Sikora D, Zeyland J, Poniedziałek B, Kiedik D, Falfushynska H, Fal A. Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine. Vaccines 2022;10:754. [DOI: 10.3390/vaccines10050754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 391 |
Zhou Z, Du P, Li N, Xiong X, Tang S, Dai Q, Wang T, Yu M, Man M, Lam K, Baptista‐hon DT, Tai WH, Monteiro O, Ng WS, Lee UM, Liu Z, Zhang K, Li G. Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS‐CoV‐2 Omicron BA.1 variant. MedComm 2022;3. [DOI: 10.1002/mco2.143] [Reference Citation Analysis]
|
| 392 |
Poh XY, Tan CW, Lee IR, Chavatte JM, Fong SW, Prince T, Hartley C, Yeoh AYY, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Lim C, Teo J, Lim DRX, Chia W, Hiscox JA, Ng LFP, Ren EC, Lin RTP, Renia L, Lye DC, Wang LF, Young BE. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. Clin Infect Dis 2022;75:2088-96. [PMID: 35543372 DOI: 10.1093/cid/ciac345] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 393 |
Lindahl H, Klingström J, Da Silva Rodrigues R, Christ W, Chen P, Ljunggren HG, Buggert M, Aleman S, Smith CIE, Bergman P. Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant. J Clin Immunol 2022. [PMID: 35538387 DOI: 10.1007/s10875-022-01283-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 394 |
Waickman AT, Lu J, Chase C, Fang H, Mcdowell E, Bingham E, Bogart J, Graziano S, Thomas SJ, Gentile T. Systemic Cancer Therapy Does Not Significantly Impact Early Vaccine-Elicited SARS-CoV-2 Immunity in Patients with Solid Tumors. Vaccines 2022;10:738. [DOI: 10.3390/vaccines10050738] [Reference Citation Analysis]
|
| 395 |
Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, Li M, Cui Y, Chen Y, Qiao R, Li L, Yang L, Li Y, Hu Z, Zhang W, Wang P. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe 2022:S1931-3128(22)00243-8. [PMID: 35594867 DOI: 10.1016/j.chom.2022.05.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 33.0] [Reference Citation Analysis]
|
| 396 |
Zeng Q, Yang X, Gao Q, Lin B, Li Y, Huang G, Xu Y. Immunological findings in a group of individuals who were non-responders to standard two-dose SARS-CoV-2 vaccines.. [DOI: 10.1101/2022.05.05.490815] [Reference Citation Analysis]
|
| 397 |
Arora P, Zhang L, Krüger N, Rocha C, Sidarovich A, Schulz S, Kempf A, Graichen L, Moldenhauer AS, Cossmann A, Dopfer-Jablonka A, Behrens GMN, Jäck HM, Pöhlmann S, Hoffmann M. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host Microbe 2022:S1931-3128(22)00223-2. [PMID: 35588741 DOI: 10.1016/j.chom.2022.04.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 398 |
Zhao M, Slotkin R, Sheth AH, Pischel L, Kyriakides TC, Emu B, McNamara C, Shi Q, Delgobbo J, Xu J, Marhoffer E, Mercer-Falkoff A, Holleck J, Ardito D, Sutton RE, Gupta S. Clinical Variables Correlate with Serum Neutralizing Antibody Titers after COVID-19 mRNA Vaccination in an Adult, US-based Population. medRxiv 2022:2022. [PMID: 35411347 DOI: 10.1101/2022.04.03.22273355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 399 |
Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, Fan J, Song L, Tong Y, Fan H. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther 2022;7:146. [PMID: 35504917 DOI: 10.1038/s41392-022-00996-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 400 |
Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, Mori Y. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. JAMA Netw Open 2022;5:e2210780. [PMID: 35532938 DOI: 10.1001/jamanetworkopen.2022.10780] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 401 |
Pratama NR, Wafa IA, Budi DS, Sutanto H, Asmarawati TP, Wungu CDK. Effectiveness of Covid-19 vaccines against SARS-CoV-2 Omicron variant (B.1.1.529): A systematic review with meta-analysis and meta-regression.. [DOI: 10.1101/2022.04.29.22274454] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 402 |
Kedl RM, Hsieh E, Morrison TE, Samayoa-reyes G, Flaherty S, Jackson CL, Rochford R. Evidence for Aerosol Transfer of SARS-CoV2-specific Humoral Immunity.. [DOI: 10.1101/2022.04.28.22274443] [Reference Citation Analysis]
|
| 403 |
Quiroga B, Ortiz A, Sánchez-álvarez E, Goicoechea M, de Sequera P. SARS-CoV-2 infection evolution among nephrologists during the pandemic: clinical features and impact of vaccination. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.04.093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 404 |
Lee I, Tipoe E. Global COVID-19 vaccine inequity: Preferences for overseas vaccine donations over booster shots. Brain Behav Immun Health 2022;21:100447. [PMID: 35308083 DOI: 10.1016/j.bbih.2022.100447] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 405 |
Wang B, Zhang L, Wang Y, Dai T, Qin Z, Zhou F, Zhang L. Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions. Signal Transduct Target Ther 2022;7:143. [PMID: 35487886 DOI: 10.1038/s41392-022-00986-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 406 |
Mishra M, Zahra A, Chauhan LV, Thakkar R, Ng J, Joshi S, Spitzer ED, Marcos LA, Lipkin WI, Mishra N. A Short Series of Case Reports of COVID-19 in Immunocompromised Patients. Viruses 2022;14:934. [PMID: 35632677 DOI: 10.3390/v14050934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 407 |
Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther 2022;7:141. [PMID: 35484110 DOI: 10.1038/s41392-022-00997-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 46] [Article Influence: 36.0] [Reference Citation Analysis]
|
| 408 |
Gagne M, Moliva JI, Foulds KE, Andrew SF, Flynn BJ, Werner AP, Wagner DA, Teng IT, Lin BC, Moore C, Jean-Baptiste N, Carroll R, Foster SL, Patel M, Ellis M, Edara VV, Maldonado NV, Minai M, McCormick L, Honeycutt CC, Nagata BM, Bock KW, Dulan CNM, Cordon J, Flebbe DR, Todd JM, McCarthy E, Pessaint L, Van Ry A, Narvaez B, Valentin D, Cook A, Dodson A, Steingrebe K, Nurmukhambetova ST, Godbole S, Henry AR, Laboune F, Roberts-Torres J, Lorang CG, Amin S, Trost J, Naisan M, Basappa M, Willis J, Wang L, Shi W, Doria-Rose NA, Zhang Y, Yang ES, Leung K, O'Dell S, Schmidt SD, Olia AS, Liu C, Harris DR, Chuang GY, Stewart-Jones G, Renzi I, Lai YT, Malinowski A, Wu K, Mascola JR, Carfi A, Kwong PD, Edwards DK, Lewis MG, Andersen H, Corbett KS, Nason MC, McDermott AB, Suthar MS, Moore IN, Roederer M, Sullivan NJ, Douek DC, Seder RA. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 2022;185:1556-1571.e18. [PMID: 35447072 DOI: 10.1016/j.cell.2022.03.038] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 47.0] [Reference Citation Analysis]
|
| 409 |
Du W, Hurdiss DL, Drabek D, Mykytyn AZ, Kaiser FK, González-Hernández M, Muñoz-Santos D, Lamers MM, van Haperen R, Li W, Drulyte I, Wang C, Sola I, Armando F, Beythien G, Ciurkiewicz M, Baumgärtner W, Guilfoyle K, Smits T, van der Lee J, van Kuppeveld FJM, van Amerongen G, Haagmans BL, Enjuanes L, Osterhaus ADME, Grosveld F, Bosch BJ. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. Sci Immunol 2022;:eabp9312. [PMID: 35471062 DOI: 10.1126/sciimmunol.abp9312] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 410 |
Fisman DN, Amoako A, Tuite AR. Impact of population mixing between vaccinated and unvaccinated subpopulations on infectious disease dynamics: implications for SARS-CoV-2 transmission. CMAJ 2022;194:E573-80. [PMID: 35470204 DOI: 10.1503/cmaj.212105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 411 |
Liang LJ, Wang D, Yu H, Wang J, Zhang H, Sun BB, Yang FY, Wang Z, Xie DW, Feng RE, Xu KF, Wang GZ, Zhou GB. Transcriptional regulation and small compound targeting of ACE2 in lung epithelial cells. Acta Pharmacol Sin 2022. [PMID: 35468992 DOI: 10.1038/s41401-022-00906-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 412 |
Brüssow H. COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. Microb Biotechnol 2022. [PMID: 35443078 DOI: 10.1111/1751-7915.14064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 413 |
Jantarabenjakul W, Sodsai P, Chantasrisawad N, Jitsatja A, Ninwattana S, Thippamom N, Ruenjaiman V, Tan CW, Pradit R, Sophonphan J, Wacharapluesadee S, Wang L, Puthanakit T, Hirankarn N, Putcharoen O. Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers. Vaccines 2022;10:639. [DOI: 10.3390/vaccines10050639] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 414 |
Geahchan S, Ehrlich H, Rahman A. A Short Overview: Marine Resources as Potential Interventions for the Omicron SARS-CoV-2 Variant. COVID 2022;2:501-512. [DOI: 10.3390/covid2040037] [Reference Citation Analysis]
|
| 415 |
Petrie JG, King JP, Mcclure DL, Rolfes MA, Meece JK, Belongia EA, Mclean HQ. Effectiveness of COVID-19 mRNA vaccine booster dose relative to primary series during a period of Omicron circulation.. [DOI: 10.1101/2022.04.15.22273915] [Reference Citation Analysis]
|
| 416 |
Mader AL, Tydykov L, Glück V, Bertok M, Weidlich T, Gottwald C, Stefl A, Vogel M, Plentz A, Köstler J, Salzberger B, Wenzel JJ, Niller HH, Jantsch J, Wagner R, Schmidt B, Glück T, Gessner A, Peterhoff D. Omicron's binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals. iScience 2022;25:104076. [PMID: 35309727 DOI: 10.1016/j.isci.2022.104076] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 417 |
Lim HX, Masomian M, Khalid K, Kumar AU, Macary PA, Poh CL. Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting. IJMS 2022;23:4341. [DOI: 10.3390/ijms23084341] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 418 |
Temsah MH, Aljamaan F, Alenezi S, Alhasan K, Alrabiaah A, Assiri R, Bassrawi R, Alhaboob A, Alshahrani F, Alarabi M, Alaraj A, Alharbi NS, Halwani R, Jamal A, Al-Eyadhy A, AbdulMajeed N, Alfarra L, Almashdali W, Fayed A, Alzamil F, Barry M, Memish ZA, Al-Tawfiq JA, Alsubaie S. SARS-CoV-2 Omicron Variant: Exploring Healthcare Workers' Awareness and Perception of Vaccine Effectiveness: A National Survey During the First Week of WHO Variant Alert. Front Public Health 2022;10:878159. [PMID: 35400032 DOI: 10.3389/fpubh.2022.878159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 419 |
Shalash AO, Azuar A, Madge HYR, Modhiran N, Amarilla AA, Liang B, Khromykh AA, Hussein WM, Chappell KJ, Watterson D, Young PR, Skwarczynski M, Toth I. Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems. Pharmaceutics 2022;14:856. [DOI: 10.3390/pharmaceutics14040856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 420 |
Li M, Ren Y, Aw ZQ, Chen B, Yang Z, Lei Y, Cheng L, Liang Q, Hong J, Yang Y, Chen J, Wong YH, Shan S, Zhang S, Ge J, Wang R, Shi X, Zhang Q, Zhang Z, Chu JJH, Wang X, Zhang L. Broadly neutralizing and protective nanobodies against diverse sarbecoviruses.. [DOI: 10.1101/2022.04.12.488087] [Reference Citation Analysis]
|
| 421 |
Kuzmina A, Wattad S, Engel S, Rosenberg E, Taube R. Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity. Viruses 2022;14:803. [DOI: 10.3390/v14040803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 422 |
Machado BAS, Hodel KVS, Fonseca LMDS, Pires VC, Mascarenhas LAB, da Silva Andrade LPC, Moret MA, Badaró R. The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. Vaccines 2022;10:591. [DOI: 10.3390/vaccines10040591] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 423 |
Curlin ME, Bates TA, Guzman G, Schoen D, McBride SK, Carpenter SD, Tafesse FG. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection. medRxiv 2022:2022. [PMID: 35441177 DOI: 10.1101/2022.04.11.22273694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 424 |
Struble LR, Smith AL, Lutz WE, Grubbs G, Sagar S, Bayles KW, Radhakrishnan P, Khurana S, El‐gamal D, Borgstahl GEO. Insect cell expression and purification of recombinant SARS‐COV ‐2 spike proteins that demonstrate ACE2 binding. Protein Science 2022;31. [DOI: 10.1002/pro.4300] [Reference Citation Analysis]
|
| 425 |
Bessen C, Plaza-sirvent C, Bhat J, Marheinecke C, Urlaub D, Bonowitz P, Busse S, Schumann S, Vidal Blanco E, Skaletz-rorowski A, Brockmeyer NH, Overheu O, Reinacher-schick A, Faissner S, Watzl C, Pfaender S, Potthoff A, Schmitz I. Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV.. [DOI: 10.1101/2022.04.08.22273605] [Reference Citation Analysis]
|
| 426 |
Li Q, Zhang M, Liang Z, Zhang L, Wu X, Yang C, An Y, Tong J, Liu S, Li T, Cui Q, Nie J, Wu J, Huang W, Wang Y. Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD. MedComm 2022;3. [DOI: 10.1002/mco2.130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 427 |
van den Hoogen LL, Verheul MK, Vos ERA, van Hagen CCE, van Boven M, Wong D, Wijmenga-Monsuur AJ, Smits G, Kuijer M, van Rooijen D, Bogaard-van Maurik M, Zutt I, van Vliet J, Wolf J, van der Klis FRM, de Melker HE, van Binnendijk RS, den Hartog G. SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics. Sci Rep 2022;12:5935. [PMID: 35396570 DOI: 10.1038/s41598-022-10020-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 428 |
Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, Li M, Cui Y, Chen Y, Qiao R, Li L, Yang L, Li Y, Hu Z, Zhang W, Wang P. Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages.. [DOI: 10.1101/2022.04.07.487489] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 429 |
Gruell H, Vanshylla K, Korenkov M, Tober-lau P, Zehner M, Münn F, Janicki H, Augustin M, Schommers P, Sander LE, Kurth F, Kreer C, Klein F. Delineating antibody escape from Omicron sublineages.. [DOI: 10.1101/2022.04.06.487257] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 430 |
Winkelmann A, Loebermann M, Barnett M, Hartung HP, Zettl UK. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol 2022. [PMID: 35388213 DOI: 10.1038/s41582-022-00646-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 431 |
Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, Epsi NJ, Fries AC, Agan BK, Lindholm DA, Colombo CJ, Mody R, Ewers EC, Lalani T, Ganesan A, Goguet E, Hollis-Perry M, Coggins SA, Simons MP, Katzelnick LC, Wang G, Tribble DR, Bentley L, Eakin AE, Broder CC, Erlandson KJ, Laing ED, Burgess TH, Mitre E, Weiss CD. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies. Sci Transl Med 2022;:eabn8543. [PMID: 35380448 DOI: 10.1126/scitranslmed.abn8543] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 23.0] [Reference Citation Analysis]
|
| 432 |
Choi YJ, Acharya KP. How serious is the Omicron variant? transmissibility, genomics, and responses to COVID-19 vaccines, and ‘Stealth’ Omicron variants. Life Cycle 2022;2. [DOI: 10.54724/lc.2022.e7] [Reference Citation Analysis]
|
| 433 |
So C, Izumi S, Ishida A, Hirakawa R, Kusaba Y, Hashimoto M, Ishii S, Miyazaki H, Iikura M, Hojo M. COVID-19 mRNA vaccine-related interstitial lung disease: Two case reports and literature review. Respirol Case Rep 2022;10:e0938. [PMID: 35355663 DOI: 10.1002/rcr2.938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 434 |
Ding K, Jiang W, Xiong C, Lei M. Turning point: A new global COVID-19 wave or a signal of the beginning of the end of the global COVID-19 pandemic? Immun Inflamm Dis 2022;10:e606. [PMID: 35349754 DOI: 10.1002/iid3.606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 435 |
Davies J, Gibani MM, Portone G, Mcgregor A. Cohorting inpatients with Omicron and Delta variants of Sars-CoV-2 does not increase rates of mixed infection. Journal of Infection 2022. [DOI: 10.1016/j.jinf.2022.04.021] [Reference Citation Analysis]
|
| 436 |
Adachi E, Nagai E, Saito M, Isobe M, Konuma T, Koga M, Tsutsumi T, Nannya Y, Yotsuyanagi H. Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. Journal of Infection and Chemotherapy 2022. [DOI: 10.1016/j.jiac.2022.03.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 437 |
Madelon N, Heikkilä N, Sabater Royo I, Fontannaz P, Breville G, Lauper K, Goldstein R, Grifoni A, Sette A, Siegrist CA, Finckh A, Lalive PH, Didierlaurent AM, Eberhardt CS. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurol 2022;79:399-404. [PMID: 35212717 DOI: 10.1001/jamaneurol.2022.0245] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 28.0] [Reference Citation Analysis]
|
| 438 |
Cho A, Muecksch F, Wang Z, Tanfous TB, Dasilva J, Raspe R, Johnson B, Bednarski E, Ramos V, Schaefer-babajew D, Shimeliovich I, Dizon J, Yao K, Schmidt F, Millard KG, Turroja M, Jankovic M, Oliveira TY, Gazumyan A, Gaebler C, Caskey M, Hatziioannou T, Bieniasz PD, Nussenzweig MC. Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine.. [DOI: 10.1101/2022.03.31.486548] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 439 |
Zeng Q, Yang X, Gao Q, Lin B, Li Y, Huang G, Xu Y. Interpretation of non-responders to SARS-CoV-2 vaccines using WHO International Standard.. [DOI: 10.1101/2022.03.31.22273272] [Reference Citation Analysis]
|
| 440 |
McLean G, Kamil J, Lee B, Moore P, Schulz TF, Muik A, Sahin U, Türeci Ö, Pather S. The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. mBio 2022;:e0297921. [PMID: 35352979 DOI: 10.1128/mbio.02979-21] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 441 |
Petrone ME, Lucas C, Menasche B, Breban MI, Yildirim I, Campbell M, Omer SB, Ko AI, Grubaugh ND, Iwasak A, Wilen CB, Vogels CB, Fauver JR. Insights into the limited global spread of the immune evasive SARS-CoV-2 variant Mu.. [DOI: 10.1101/2022.03.28.22273077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 442 |
Bruel T, Pinaud L, Tondeur L, Planas D, Staropoli I, Porrot F, Guivel-benhassine F, Attia M, Pelleau S, Woudenberg T, Duru C, Koffi AD, Castelain S, Fernandes-pellerin S, Jolly N, De Facci LP, Roux E, Ungeheuer M, Van Der Werf S, White M, Schwartz O, Fontanet A. SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine.. [DOI: 10.1101/2022.03.30.22273175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 443 |
Cazzato G, Romita P, Foti C, Lobreglio D, Trilli I, Colagrande A, Ingravallo G, Resta L. Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation? Vaccines (Basel) 2022;10. [PMID: 35455281 DOI: 10.3390/vaccines10040532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 444 |
Tran TT, Vaage EB, Mehta A, Chopra A, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-due A, Medhus AW, Høivk ML, Lundin K, Karlsen RF, Dahle R, Danielsson K, Thomassen KS, Kro GB, Cox RJ, Zhou F, Langeland N, Aukrust P, Melum E, Åvitsland TL, Wiencke K, Holter JC, Munthe LA, Grødeland G, Andersen J, Vaage JT, Lund-johansen F. Titers of antibodies the receptor-binding domain (RBD) of ancestral SARS-CoV-2 are predictive for levels of neutralizing antibodies to multiple variants.. [DOI: 10.1101/2022.03.26.484261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 445 |
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S, Duncan MC, Agafitei O, Ennis S, Young L, Ali H, Ganase B, Omondi FH, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Pantophlet R, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses. medRxiv 2022:2022. [PMID: 35350205 DOI: 10.1101/2022.03.22.22272793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 446 |
Flores-Vega VR, Monroy-Molina JV, Jiménez-Hernández LE, Torres AG, Santos-Preciado JI, Rosales-Reyes R. SARS-CoV-2: Evolution and Emergence of New Viral Variants. Viruses 2022;14:653. [PMID: 35458383 DOI: 10.3390/v14040653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 447 |
Smith L, Shin JI, Koyanagi A. Vaccine strategy against COVID-19 with a focus on the Omicron and stealth Omicron variants: Life Cycle Committee Recommendations. Life Cycle 2022;2. [DOI: 10.54724/lc.2022.e5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 448 |
Yamamoto M, Tomita K, Hirayama Y, Inoue J, Kawaguchi Y, Gohda J. SARS-CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal entry pathway and reduction of cell surface entry pathways.. [DOI: 10.1101/2022.03.21.485084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 449 |
Arunachalam PS, Feng Y, Ashraf U, Hu M, Edara VV, Zarnitsyna VI, Aye PP, Golden N, Green KWM, Threeton BM, Maness NJ, Beddingfield BJ, Bohm RP, Dufour J, Russell-lodrigue K, Miranda MC, Walls AC, Rogers K, Shirreff L, Ferrell DE, Deb Adhikary NR, Fontenot J, Grifoni A, Sette A, O’hagan DT, Van Der Most R, Rappuoli R, Villinger F, Kleanthous H, Rappaport J, Suthar MS, Veesler D, Wang TT, King NP, Pulendran B. Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine.. [DOI: 10.1101/2022.03.18.484950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 450 |
Lechmere T, Snell LB, Graham C, Seow J, Shalim ZA, Charalampous T, Alcolea-Medina A, Batra R, Nebbia G, Edgeworth JD, Malim MH, Doores KJ. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. mBio 2022;:e0379821. [PMID: 35297676 DOI: 10.1128/mbio.03798-21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 451 |
Naranbhai V, Nathan A, Kaseke C, Berrios C, Khatri A, Choi S, Getz MA, Tano-Menka R, Ofoman O, Gayton A, Senjobe F, Zhao Z, St Denis KJ, Lam EC, Carrington M, Garcia-Beltran WF, Balazs AB, Walker BD, Iafrate AJ, Gaiha GD. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell 2022;185:1041-1051.e6. [PMID: 35202566 DOI: 10.1016/j.cell.2022.01.029] [Cited by in Crossref: 114] [Cited by in F6Publishing: 87] [Article Influence: 114.0] [Reference Citation Analysis]
|
| 452 |
Bowen JE, Sprouse KR, Walls AC, Mazzitelli IG, Logue JK, Franko NM, Ahmed K, Shariq A, Cameroni E, Gori A, Bandera A, Posavad CM, Dan JM, Zhang Z, Weiskopf D, Sette A, Crotty S, Iqbal NT, Corti D, Geffner J, Grifantini R, Chu HY, Veesler D. Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines. bioRxiv 2022:2022. [PMID: 35313570 DOI: 10.1101/2022.03.15.484542] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 453 |
Ao D, Lan T, He X, Liu J, Chen L, Baptista‐hon DT, Zhang K, Wei X. SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development. MedComm 2022;3. [DOI: 10.1002/mco2.126] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 37.0] [Reference Citation Analysis]
|
| 454 |
Cinkilic O, Anft M, Blazquez-Navarro A, Meister TL, Roch T, Stervbo U, Pfaender S, Westhoff TH, Babel N. Inferior humoral and sustained cellular immunity against wild type and omicron VOC in hemodialysis patients immunized with three SARS-CoV-2 vaccine doses compared to four doses. Kidney Int 2022:S0085-2538(22)00204-6. [PMID: 35301007 DOI: 10.1016/j.kint.2022.03.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 455 |
Yuan M, Zhu X, He WT, Zhou P, Kaku CI, Capozzola T, Zhu CY, Yu X, Liu H, Yu W, Hua Y, Tien H, Peng L, Song G, Cottrell CA, Schief WR, Nemazee D, Walker LM, Andrabi R, Burton DR, Wilson IA. A broad and potent neutralization epitope in SARS-related coronaviruses. bioRxiv 2022:2022. [PMID: 35313576 DOI: 10.1101/2022.03.13.484037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 456 |
Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I, Guivel-benhassine F, Porrot F, Bolland W, Nguyen Y, Casadevall M, Charre C, Péré H, Veyer D, Prot M, Baidaliuk A, Cuypers L, Planchais C, Mouquet H, Baele G, Mouthon L, Hocqueloux L, Simon-loriere E, André E, Terrier B, Prazuck T, Schwartz O. Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies.. [DOI: 10.1101/2022.03.09.22272066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 457 |
Edwards AM, Baric RS, Saphire EO, Ulmer JB. Stopping pandemics before they start: Lessons learned from SARS-CoV-2. Science 2022;375:1133-9. [PMID: 35271333 DOI: 10.1126/science.abn1900] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 458 |
Vo GV, Bagyinszky E, An SSA. COVID-19 Genetic Variants and Their Potential Impact in Vaccine Development. Microorganisms 2022;10:598. [DOI: 10.3390/microorganisms10030598] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 459 |
van der Velden YU, Grobben M, Caniels TG, Burger JA, Poniman M, Oomen M, Rijnstra ES, Tejjani K, Guerra D, Kempers R, Stegmann T, van Gils MJ, Sanders RW. A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. Sci Rep 2022;12:3884. [PMID: 35273217 DOI: 10.1038/s41598-022-07590-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 460 |
Zhang Z, Wu S, Liu Y, Li K, Fan P, Song X, Wang Y, Zhao Z, Zhang X, Shang J, Zhang J, Xu J, Li Y, Li Y, Zhang J, Fu K, Wang B, Hao M, Zhang G, Long P, Qiu Z, Zhu T, Liu S, Zhang Y, Shao F, Lv P, Yang Y, Zhao X, Sun Y, Hou L, Chen W. Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming.. [DOI: 10.1101/2022.03.08.22271816] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 461 |
Wan J, Cazer CL, Clarkberg ME, Henderson SG, Lee SE, Meredith G, Osman M, Shmoys DB, Frazier PI. Boosters protect against SARS-CoV-2 infections in young adults during an Omicron-predominant period.. [DOI: 10.1101/2022.03.08.22272056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 462 |
Peng H, Fu YX. Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine. Cell Res 2022. [PMID: 35260791 DOI: 10.1038/s41422-022-00634-w] [Reference Citation Analysis]
|
| 463 |
Gu Y, Shunmuganathan BD, Qian X, Gupta R, Tan RS, Kozma M, Purushotorman K, Murali TM, Tan NY, Preiser PR, Lescar J, Nasir H, Somani J, Tambyah PA, Smith KG, Renia L, Ng LF, Lye DC, Young BE, Macary PA, SCOPE Cohort Study Group. Defining Factors that Influence vaccine-induced, cross-variant neutralizing antibodies for SARS-CoV-2 in Asians.. [DOI: 10.1101/2022.03.06.22271809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 464 |
Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Kärner J, Haljasmägi L, Haljasorg U, Kuusk M, Gerhold JM, Planken A, Ustav M, Kisand K, Peterson P. Protective antibodies and T cell responses to Omicron variant three months after the booster dose of BNT162b2 vaccine.. [DOI: 10.1101/2022.03.04.22271890] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 465 |
Zhou P, Song G, He WT, Beutler N, Tse LV, Martinez DR, Schäfer A, Anzanello F, Yong P, Peng L, Dueker K, Musharrafieh R, Callaghan S, Capozzola T, Yuan M, Liu H, Limbo O, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Jardine JG, Wilson IA, Safonova Y, Rogers TF, Baric RS, Gralinski LE, Burton DR, Andrabi R. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease. bioRxiv 2022:2022. [PMID: 35291291 DOI: 10.1101/2022.03.04.479488] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 466 |
Shinkai M, Sonoyama T, Kamitani A, Shibata R, Seki N, Omoto S, Shinoda M, Sato T, Ishii N, Igarashi K, Ariyasu M. Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study.. [DOI: 10.1101/2022.03.03.22271827] [Reference Citation Analysis]
|
| 467 |
Niyomnaitham S, Toh ZQ, Wongprompitak P, Jansarikit L, Srisutthisamphan K, Sapsutthipas S, Jantraphakorn Y, Mingngamsup N, Licciardi PV, Chokephaibulkit K. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.. [DOI: 10.1101/2022.03.03.22271601] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 468 |
Ibáñez AJ. How Is Mass Spectrometry Tackling the COVID-19 Pandemic? Front Anal Sci 2022;2. [DOI: 10.3389/frans.2022.846102] [Reference Citation Analysis]
|
| 469 |
Chu D, Vu Thi H, Nguyen Thi YV, Nguyen M, Bui N, Hoang VT, Hoang Nam D, Do D, than VT, Al-tawfiq JA. Willingness to receive COVID-19 vaccine booster doses for adults and their children in Vietnam. Journal of Human Behavior in the Social Environment. [DOI: 10.1080/10911359.2022.2046235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 470 |
Sharma M, Vanam HP, Panda NK, Patro SK, Arora R, Bhadada SK, Rudramurthy SM, Singh MP, Koppula PR. Deciphering the Neurosensory Olfactory Pathway and Associated Neo-Immunometabolic Vulnerabilities Implicated in COVID-Associated Mucormycosis (CAM) and COVID-19 in a Diabetes Backdrop—A Novel Perspective. Diabetology 2022;3:193-235. [DOI: 10.3390/diabetology3010013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 471 |
Swart M, de Wilde A, Schmit-tillemans S, Verspuij J, Daal C, Choi Y, Perkasa A, Kourkouta E, Tahiri I, Mulders M, Gil AI, Muchene L, Juraszek J, Vellinga J, Custers J, Bos R, Schuitemaker H, Wegmann F, Roozendaal R, Kuipers H, Zahn R. Immunogenicity of an Ad26-based SARS-CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters.. [DOI: 10.1101/2022.03.04.482636] [Reference Citation Analysis]
|
| 472 |
Walls AC, Sprouse KR, Bowen JE, Joshi A, Franko N, Navarro MJ, Stewart C, Cameroni E, McCallum M, Goecker EA, Degli-Angeli EJ, Logue J, Greninger A, Corti D, Chu HY, Veesler D. SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell 2022;185:872-880.e3. [PMID: 35123650 DOI: 10.1016/j.cell.2022.01.011] [Cited by in Crossref: 107] [Cited by in F6Publishing: 101] [Article Influence: 107.0] [Reference Citation Analysis]
|
| 473 |
Seaman MS, Siedner MJ, Boucau J, Lavine CL, Ghantous F, Liew MY, Mathews J, Singh A, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, Chen G, Stuckwisch AM, Lipiner T, Kittilson A, Melberg M, Gilbert RF, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Goldberg MB, Luban J, Li JZ, Barczak AK, Lemieux JE. Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses. medRxiv 2022:2022. [PMID: 35262094 DOI: 10.1101/2022.03.02.22271731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 474 |
Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, Bloom NI, Goodwin B, Phillips E, Mallal S, Sidney J, Filaci G, Weiskopf D, da Silva Antunes R, Crotty S, Grifoni A, Sette A. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 2022;185:847-859.e11. [PMID: 35139340 DOI: 10.1016/j.cell.2022.01.015] [Cited by in Crossref: 321] [Cited by in F6Publishing: 307] [Article Influence: 321.0] [Reference Citation Analysis]
|
| 475 |
Paschold L, Klee B, Gottschick C, Willscher E, Diexer S, Schultheiß C, Simnica D, Sedding D, Girndt M, Gekle M, Mikolajczyk R, Binder M. Rapid hypermutation B cell trajectory recruits previously primed B cells upon third SARS-CoV-2 mRNA vaccination.. [DOI: 10.1101/2022.03.01.482462] [Reference Citation Analysis]
|
| 476 |
Rayati Damavandi A, Dowran R, Al Sharif S, Kashanchi F, Jafari R. Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. Med Microbiol Immunol 2022. [PMID: 35235048 DOI: 10.1007/s00430-022-00729-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 477 |
Vandergaast R, Carey T, Suksanpaisan L, Lathrum C, Narjari R, Haselton M, Schnebeck L, Wijesekara A, Duncan A, Russell L, Naik S, Peng K, Lech P, Russell SJ. Longitudinal monitoring of SARS-CoV-2 neutralizing antibody titers and its impact on employee personal wellness decisions.. [DOI: 10.1101/2022.03.01.22271202] [Reference Citation Analysis]
|
| 478 |
Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Mongkolsapaya J, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y. Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine.. [DOI: 10.1101/2022.03.01.22271735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 479 |
Norddahl GL, Melsted P, Gunnarsdottir K, Halldorsson GH, Olafsdottir TA, Gylfason A, Kristjansson M, Magnusson OT, Sulem P, Gudbjartsson DF, Thorsteinsdottir U, Jonsdottir I, Stefansson K. Effect of booster vaccination against Delta and Omicron variants in Iceland.. [DOI: 10.1101/2022.02.26.22271509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 480 |
Wu Y, Shen Y, Wu N, Zhang X, Chen S, Yang C, Zhou J, Wu Y, Chen D, Wang L, Wang Y, Xu J, Liu K, Wang C, Zhang H, Xia N, Chiu S, Wang Y. Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates.. [DOI: 10.1101/2022.03.01.481391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 481 |
Pozdnyakova V, Weber B, Cheng S, Ebinger JE. Review of Immunologic Manifestations of COVID-19 Infection and Vaccination. Cardiology Clinics 2022. [DOI: 10.1016/j.ccl.2022.03.006] [Reference Citation Analysis]
|
| 482 |
He X, Zeng XX. Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19? DDDT 2022;Volume 16:951-972. [DOI: 10.2147/dddt.s347297] [Reference Citation Analysis]
|
| 483 |
Tsai TI, Khalili JS, Gilchrist M, Waight AB, Cohen D, Zhuo S, Zhang Y, Ding M, Zhu H, Nga-Sze Mak A, Zhu Y, Goulet DR. ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern. Antiviral Res 2022;:105271. [PMID: 35240221 DOI: 10.1016/j.antiviral.2022.105271] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 484 |
Kurahashi Y, Furukawa K, Sutandhio S, Tjan LH, Iwata S, Sano S, Tohma Y, Ohkita H, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y. Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination.. [DOI: 10.1101/2022.02.24.22271262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 485 |
Kawasuji H, Morinaga Y, Tani H, Saga Y, Kaneda M, Murai Y, Ueno A, Miyajima Y, Fukui Y, Nagaoka K, Ono C, Matsuura Y, Niimi H, Yamamoto Y. Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population.. [DOI: 10.1101/2022.02.23.22271433] [Reference Citation Analysis]
|
| 486 |
Jia L, Zhou Y, Li S, Zhang Y, Yan D, Wang W, Zhang W, Wan Y, Qiu C. Omicron booster in ancestral strain vaccinated mice augments protective immunities against both the Delta and Omicron variants.. [DOI: 10.1101/2022.02.19.481110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 487 |
Goel RR, Painter MM, Lundgreen KA, Apostolidis SA, Baxter AE, Giles JR, Mathew D, Pattekar A, Reynaldi A, Khoury DS, Gouma S, Hicks P, Dysinger S, Hicks A, Sharma H, Herring S, Korte S, Kc W, Oldridge DA, Erickson RI, Weirick ME, McAllister CM, Awofolaju M, Tanenbaum N, Dougherty J, Long S, D'Andrea K, Hamilton JT, McLaughlin M, Williams JC, Adamski S, Kuthuru O, Drapeau EM, Davenport MP, Hensley SE, Bates P, Greenplate AR, Wherry EJ. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. bioRxiv 2022:2022. [PMID: 35233575 DOI: 10.1101/2022.02.20.481163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 488 |
Housset P, Kubab S, Pardon A, Vittoz N, Bozman DF, Hanafi L, Caudwell V, Faucon AL. Waning but persistent humoral response 6 months after the third dose of the mRNA BNT162b2 vaccine in hemodialysis and peritoneal dialysis patients. J Nephrol 2022. [PMID: 35192157 DOI: 10.1007/s40620-022-01276-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 489 |
Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Datwani S, Omondi FH, Burns L, Young L, Leung V, Agafitei O, Ennis S, Dong W, Basra S, Lim LY, Ng K, Pantophlet R, Brumme CJ, Montaner JSG, Prystajecky N, Lowe CF, DeMarco ML, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA. Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose. medRxiv 2022:2022. [PMID: 35018381 DOI: 10.1101/2022.01.06.22268745] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 490 |
Wang J, Deng C, Liu M, Liu Y, Li L, Huang Z, Shang L, Jiang J, Li Y, Mo R, Zhang H, Liu M, Peng S, Xiao H. Four doses of the inactivated SARS-CoV-2 vaccine redistribute humoral immune responses away from the Receptor Binding Domain.. [DOI: 10.1101/2022.02.19.22271215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 491 |
Zheng J, Wang Z, Li J, Zhang Y, Jiang L, Fu Y, Jin Y, Cheng H, Li J, Chen Z, Tang F, Lu B, Li L, Zhang X. High amounts of SARS-CoV-2 in aerosols exhaled by patients with Omicron variant infection. J Infect 2022:S0163-4453(22)00075-5. [PMID: 35183607 DOI: 10.1016/j.jinf.2022.02.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 492 |
Du W, Hurdiss DL, Drabek D, Mykytyn AZ, Kaiser FK, González-hernandez M, Muñoz-santos D, Lamers MM, van Haperen R, Li W, Drulyte I, Wang C, Sola I, Armando F, Beythien G, Ciurkiewicz M, Baumgärtner W, Guilfoyle K, Smits T, van der Lee J, van Kuppeveld FJ, van Amerongen G, Haagmans BL, Enjuanes L, Osterhaus AD, Grosveld F, Bosch B. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants.. [DOI: 10.1101/2022.02.17.480751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 493 |
Lu H. More effective vaccines and oral antivirals: Keys for the battle against Omicron. Biosci Trends 2022. [PMID: 35173108 DOI: 10.5582/bst.2022.01062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 494 |
Dönges P, Wagner J, Contreras S, Iftekhar EN, Bauer S, Mohr SB, Dehning J, Calero Valdez A, Kretzschmar M, Mäs M, Nagel K, Priesemann V. Interplay Between Risk Perception, Behavior, and COVID-19 Spread. Front Phys 2022;10:842180. [DOI: 10.3389/fphy.2022.842180] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 495 |
Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, Gumina RJ, Liu SL. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med 2022;:eabn8057. [PMID: 35166573 DOI: 10.1126/scitranslmed.abn8057] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 49.0] [Reference Citation Analysis]
|
| 496 |
Fang Z, Peng L, Filler R, Suzuki K, Mcnamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.. [DOI: 10.1101/2022.02.14.480449] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 497 |
Richardson SI, Madzorera VS, Spencer H, Manamela NP, van der Mescht M, Lambson BE, Oosthuysen B, Ayres F, Makhado Z, Moyo-gwete T, Mzindle N, Motlou T, Strydom A, Mendes A, Tegally H, de Beer Z, de Villiers TR, Bodenstein A, van den Berg G, Venter M, de Oliviera T, Ueckermann V, Rossouw TM, Boswell MT, Moore PL. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated individuals.. [DOI: 10.1101/2022.02.10.22270789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 498 |
Etemadifar M, Nouri H, Pitzalis M, Idda ML, Salari M, Baratian M, Mahdavi S, Abhari AP, Sedaghat N. Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: A practical review and meta-analysis.. [DOI: 10.1101/2022.02.12.22270883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 499 |
Loconsole D, Bisceglia L, Centrone F, Sallustio A, Accogli M, Dalfino L, Brienza N, Chironna M. Autochthonous Outbreak of SARS-CoV-2 Omicron Variant in Booster-Vaccinated (3 Doses) Healthcare Workers in Southern Italy: Just the Tip of the Iceberg? Vaccines 2022;10:283. [DOI: 10.3390/vaccines10020283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 500 |
Tiecco G, Storti S, Degli Antoni M, Focà E, Castelli F, Quiros-Roldan E. Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. Int J Mol Sci 2022;23:1987. [PMID: 35216104 DOI: 10.3390/ijms23041987] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 33.0] [Reference Citation Analysis]
|
| 501 |
Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, Bartolini S, Kho N, Noble PW, Isonaka S, Chen P. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep 2022;71:217-23. [PMID: 35143466 DOI: 10.15585/mmwr.mm7106e2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 41.0] [Reference Citation Analysis]
|
| 502 |
Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, Bartolini S, Kho N, Noble PW, Isonaka S, Chen P. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep 2022;71:217-23. [PMID: 35143466 DOI: 10.15585/mmwr.mm7106e2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 503 |
Ai L, Li Y, Zhou L, Yao W, Zhang H, Hu Z, Han J, Wu J, Wang W, Xu P, Wang R, Li Z, Li Z, Wei C, Chen H, Liang J, Guo M, Huang Z, Wang X, Zhang Z, Xiang W, Xu L, Lv B, Peng P, Zhang S, Ji X, Luo H, Chen N, Chen J, Lan K, Hu Y. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2.. [DOI: 10.1101/2022.02.10.479867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 504 |
Wagner CE, Saad-Roy CM, Grenfell BT. Modelling vaccination strategies for COVID-19. Nat Rev Immunol 2022. [PMID: 35145245 DOI: 10.1038/s41577-022-00687-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 505 |
Hong H, Noh JY, Lee H, Choi S, Choi B, Kim JK, Shin E. Increasing viral transmission paradoxically reduces progression rates to severe COVID-19 during endemic transition.. [DOI: 10.1101/2022.02.09.22270633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 506 |
Rizzo A, Palmiotti G. SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate. Future Oncol 2022. [PMID: 35109688 DOI: 10.2217/fon-2022-0024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 507 |
Kotaki R, Adachi Y, Moriyama S, Onodera T, Fukushi S, Nagakura T, Tonouchi K, Terahara K, Sun L, Takano T, Nishiyama A, Shinkai M, Oba K, Nakamura-Uchiyama F, Shimizu H, Suzuki T, Matsumura T, Isogawa M, Takahashi Y. SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine. Sci Immunol 2022;:eabn8590. [PMID: 35113654 DOI: 10.1126/sciimmunol.abn8590] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 36.0] [Reference Citation Analysis]
|
| 508 |
Bellos I, Karageorgiou V, Viskin D. Myocarditis following mRNA Covid-19 vaccination: a pooled analysis. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.02.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 509 |
Minka S, Minka F. A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant. Immunology Letters 2022. [DOI: 10.1016/j.imlet.2022.02.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 510 |
Wang Y, Zhang X, Liu J, Wang Y, Zhan W, Liu M, Zhang M, Wang Q, Liu Q, Zhu T, Wen Y, Chen Z, Zhao J, Wu F, Sun L, Huang J. Combating the SARS-CoV-2 Omicron variant with non-Omicron neutralizing antibodies.. [DOI: 10.1101/2022.01.30.478305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 511 |
Hardt K, Vandebosch A, Sadoff J, Gars ML, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F, the ENSEMBLE2 Study Group. Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19.. [DOI: 10.1101/2022.01.28.22270043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 512 |
Grabowski F, Kochańczyk M, Lipniacki T. The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0–3.3 Days Can Be Explained by Immune Evasion. Viruses 2022;14:294. [DOI: 10.3390/v14020294] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 43.0] [Reference Citation Analysis]
|
| 513 |
Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck B, Schepers R, van Gageldonk-Lafeber AB, van den Hof S, Reusken CB, Knol MJ. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro Surveill 2022;27. [PMID: 35086609 DOI: 10.2807/1560-7917.ES.2022.27.4.2101196] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 38.0] [Reference Citation Analysis]
|
| 514 |
Desmecht S, Tashkeev A, Marechal N, Perée H, Tokunaga Y, Lopez CF, Polese B, Legrand C, Wéry M, Mni M, Fouillien N, Toussaint F, Gillet L, Bureau F, Lutteri L, Hayette M, Moutschen M, Meuris C, Desmecht D, Rahmouni S, Darcis G. Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjects.. [DOI: 10.1101/2022.01.17.22269278] [Reference Citation Analysis]
|
| 515 |
Wu Y, Wang S, Zhang Y, Yuan L, Zheng Q, Wei M, Shi Y, Wang Z, Ma J, Wang K, Nie M, Xiao J, Huang Z, Chen P, Guo H, Lan M, Xu J, Hou W, Hong Y, Chen D, Sun H, Xiong H, Zhou M, Liu C, Guo W, Guo H, Gao J, Li Z, Zhang H, Wang X, Li S, Cheng T, Zhao Q, Chen Y, Wu T, Zhang T, Zhang J, Cao H, Zhu H, Yuan Q, Guan Y, Xia N. Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine.. [DOI: 10.1101/2022.01.25.477789] [Reference Citation Analysis]
|
| 516 |
Chaguza C, Coppi A, Earnest R, Ferguson D, Kerantzas N, Warner F, Young HP, Breban MI, Billig K, Koch RT, Pham K, Kalinich CC, Ott IM, Fauver JR, Hahn AM, Tikhonova IR, Castaldi C, De Kumar B, Pettker CM, Warren JL, Weinberger DM, Landry ML, Peaper DR, Schulz W, Vogels CB, Grubaugh ND. Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons.. [DOI: 10.1101/2022.01.22.22269660] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 517 |
Seki Y, Yoshihara Y, Nojima K, Momose H, Fukushi S, Moriyama S, Wagatsuma A, Numata N, Sasaki K, Kuzuoka T, Yato Y, Takahashi Y, Maeda K, Suzuki T, Mizukami T, Hamaguchi I. Safety and immunogenicity of Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine against SARS-CoV-2 Omicron variant in Japanese healthcare workers.. [DOI: 10.1101/2022.01.20.22269587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 518 |
Puya-dehgani-mobaraki, Wang C, Floridi A, Floridi E, Zaidi AK. Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response.. [DOI: 10.1101/2022.01.18.22269349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 519 |
Lamers MM, Mykytyn AZ, Breugem TI, Groen N, Knoops K, Schipper D, van Acker R, van den Doel PB, Bestebroer T, Koopman CD, Reusken C, Muraro MJ, Geurtsvankessel CH, van Royen ME, Peters PJ, Zhang J, Haagmans BL. SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium.. [DOI: 10.1101/2022.01.19.476898] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 520 |
Lapa D, Grousova D, Matusali G, Meschi S, Colavita F, Bettini A, Gramigna G, Francalancia M, Garbuglia A, Girardi E, Puro V, Antinori A, Kovyrshina A, Dolzhikova I, Shcheblyakov D, Tukhvatulin A, Zubkova O, Logunov D, Naroditsky B, Vaia F, Gintsburg A. Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals.. [DOI: 10.1101/2022.01.15.22269335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 521 |
Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, Bruxvoort KJ, Tubert JE, Florea A, Ku JH, Lee GS, Choi SK, Takhar HS, Aragones M, Qian L. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants.. [DOI: 10.1101/2022.01.07.22268919] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 37.0] [Reference Citation Analysis]
|
| 522 |
Sohan M, Hossain MJ, Islam MR. The SARS-CoV-2 Omicron (B.1.1.529) variant and effectiveness of existing vaccines: What we know so far. J Med Virol 2022. [PMID: 34989403 DOI: 10.1002/jmv.27574] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 523 |
Willett BJ, Grove J, Maclean OA, Wilkie C, Logan N, Lorenzo GD, Furnon W, Scott S, Manali M, Szemiel A, Ashraf S, Vink E, Harvey WT, Davis C, Orton R, Hughes J, Holland P, Silva V, Pascall D, Puxty K, da Silva Filipe A, Yebra G, Shaaban S, Holden MTG, Pinto RM, Gunson R, Templeton K, Murcia PR, Patel AH, Haughney J, Robertson DL, Palmarini M, Ray S, Thomson EC, The COVID-19 Genomics UK (COG-UK) Consortium. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism.. [DOI: 10.1101/2022.01.03.21268111] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 64.0] [Reference Citation Analysis]
|
| 524 |
Zhu J, Li Y, Liang J, Mubareka S, Slutsky AS, Zhang H. The Potential Protective Role of GS-441524, a Metabolite of the Prodrug Remdesivir, in Vaccine Breakthrough SARS-CoV-2 Infections. Intensive Care Res 2022;2:49-60. [PMID: 36407474 DOI: 10.1007/s44231-022-00021-4] [Reference Citation Analysis]
|
| 525 |
Brewer-smyth K. COVID-19 Trauma: The New Complex Adverse Childhood Experience. Adverse Childhood Experiences 2022. [DOI: 10.1007/978-3-031-08801-8_7] [Reference Citation Analysis]
|
| 526 |
Mullender C, da Costa KAS, Alrubayyi A, Pett SL, Peppa D. SARS-CoV-2 immunity and vaccine strategies in people with HIV. Oxf Open Immunol 2022;3:iqac005. [PMID: 36846557 DOI: 10.1093/oxfimm/iqac005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 527 |
Nashwan A, Yassin M, Soliman A, De Sanctis V, Ibrahim M. mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks and Coverage. Acta Biomed 2022;93:e2022236. [PMID: 35775753 DOI: 10.23750/abm.v93i3.13103] [Reference Citation Analysis]
|
| 528 |
Yang CY, Chen YH, Liu PJ, Hu WC, Lu KC, Tsai KW. The emerging role of miRNAs in the pathogenesis of COVID-19: Protective effects of nutraceutical polyphenolic compounds against SARS-CoV-2 infection. Int J Med Sci 2022;19:1340-56. [PMID: 35928726 DOI: 10.7150/ijms.76168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 529 |
Gu B, Yao L, Zhu XY, Zou T, Feng YJ, Yan JY, Zhang JP, Tang PJ, Chen C. Comparison of initial clinic characteristics of hospitalized patients in Suzhou City during the COVID-19 Omicron wave with ancestral variant wave. Ther Adv Respir Dis 2022;16:17534666221110346. [PMID: 35796535 DOI: 10.1177/17534666221110346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 530 |
Taytard J, Prevost B, Schnuriger A, Aubertin G, Berdah L, Bitton L, Dupond-Athenor A, Thouvenin G, Nathan N, Corvol H. SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant. Front Pediatr 2022;10:932170. [PMID: 35832582 DOI: 10.3389/fped.2022.932170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 531 |
Errico JM, Adams LJ, Fremont DH. Antibody-mediated immunity to SARS-CoV-2 spike. Adv Immunol 2022;154:1-69. [PMID: 36038194 DOI: 10.1016/bs.ai.2022.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 532 |
Hong H, Noh JY, Lee H, Choi S, Choi B, Kim JK, Shin E. Modeling Incorporating the Severity-Reducing Long-term Immunity: Higher Viral Transmission Paradoxically Reduces Severe COVID-19 During Endemic Transition. Immune Netw 2022;22:e23. [DOI: 10.4110/in.2022.22.e23] [Reference Citation Analysis]
|
| 533 |
Setiabudi D, Sribudiani Y, Hermawan K, Andriyoko B, Nataprawira HM. The Omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children. Front Pediatr 2022;10:898463. [PMID: 35983081 DOI: 10.3389/fped.2022.898463] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 534 |
Kaku N, Nakagama Y, Nitahara Y, Kido Y. Antibody testing as the guide to our living with COVID-19. Nihon Kessen Shiketsu Gakkaishi 2022;33:338-346. [DOI: 10.2491/jjsth.33.338] [Reference Citation Analysis]
|
| 535 |
Kang H, Kim D, Min K, Park M, Kim S, Sohn E, Choi B, Hwang I. Recombinant proteins of spike protein of SARS-CoV-2 with the Omicron receptor-binding domain induce production of highly Omicron-specific neutralizing antibodies. Clin Exp Vaccine Res 2022;11:285. [DOI: 10.7774/cevr.2022.11.3.285] [Reference Citation Analysis]
|
| 536 |
Temsah M, Aljamaan F, Alenezi S, Alhasan K, Alrabiaah A, Assiri R, Bassrawi R, Alhaboob A, Alshahrani F, Alarabi M, Alaraj A, Alharbi NS, Halwani R, Jamal A, Al-eyadhy A, Abdulmajeed N, Alfarra L, Almashdali W, Al-zamil F, Barry M, Memish ZA, Al-tawfiq JA, Alsubaie S. SARS-CoV-2 Omicron variant: exploring healthcare workers’ awareness and perception of vaccine effectiveness: a national survey during the first week of WHO variant alert.. [DOI: 10.1101/2021.12.27.21268431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 537 |
Grabowski F, Kochańczyk M, Lipniacki T. The spread of SARS-CoV-2 variant Omicron with the doubling time of 2.0–3.3 days can be explained by immune evasion.. [DOI: 10.1101/2021.12.08.21267494] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 538 |
Gobeil P, Pillet S, Boulay I, Charland N, Lorin A, Cheng MP, Vinh DC, Boutet P, Van Der Most R, Roman F, Angeles Ceregido M, Landry N, D’aoust M, Ward BJ. Durability and Cross-Reactivity of Immune Responses Induced by an AS03-Adjuvanted Plant-Based Recombinant Virus-Like Particle Vaccine for COVID-19.. [DOI: 10.1101/2021.08.04.21261507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
